CAR-T cell assay for specificity testing of novel antigen binding modules
Through the method of reporting T cells in contact with target cells with chimeric antigen receptor expression, the problem that the prior art cannot comprehensively evaluate the specificity and functionality of antibodies is solved, and efficient screening and characterization of antibodies is achieved, which reduces health Side effects of tissue.
Patent Information
- Application Number
- CN201880081668.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2017-12-21
- Filing Date
- 2018-12-20
- Publication Date
- 2024-11-01
- Estimated Expiration
- 2039-02-23
AI Technical Summary
Existing protein-protein interaction assays cannot fully reproduce the situation in vivo, especially during antibody treatment, which makes it difficult to effectively evaluate the binding specificity and functionality of antibodies to targets, resulting in difficulty in reducing side effects on healthy tissues.
T cell activation was determined to evaluate the specificity of the antigen binding module by transferring the target antigen-binding module into the CAR vector system and contacting the reporter CAR-T cells with the target cells. , the results are read using fluorescence or luminescent signals.
A high-throughput, comprehensive and specific approach is provided to evaluate antibody binding to targets, helping to screen out the optimal candidates in the early stages of drug development and reducing side effects on healthy tissues.
Smart Images

Figure BDA0002544159270000521 
Figure BDA0002544159270000531 
Figure BDA0002544159270000532
Abstract
Description
Field of the Invention
[0001] The present invention generally relates to specific assays using cell culture, in particular, chimeric antigen receptor (CAR) expression reporter T (CAR-T cell) assays for testing different types of antigen binding moieties. Furthermore, the present invention relates to the use of CAR-T cells transfected / transduced with engineered chimeric antigen receptor (CAR) containing a target antigen binding moiety that is capable of specifically binding to a target antigen, such as a tumor-associated antigen. Background of the Invention
[0003] Chemotherapy remains one of the most commonly used treatments for cancer. Furthermore, antibody-based therapies have advanced over the past 15 years and now represent a valuable combination or alternative to chemotherapy in the treatment of hematological malignancies and solid tumors. Unlike chemotherapy, antibody therapies target specific antigens on cancer cells, allowing for more targeted treatment and reducing side effects on healthy tissue. The development of antibody-based therapeutic agents requires a variety of assays to identify the best candidates, advance them into clinical trials, and ultimately bring them to market. In the first, early preclinical phase, antibodies, particularly their antigen-binding moieties, must be generated and analyzed for their target specificity and affinity.
[0004] Binding properties can be analyzed using various protein-protein interaction assays, such as FRET-based methods, surface plasmon resonance (SPR), or fluorescence-activated cell sorting (FACS). However, available assay formats may not always fully and comprehensively recapitulate the in vivo situation. For example, targeting cancer cells with a therapeutic antibody that binds to a cell-surface receptor can have effects at multiple levels, such as intracellular signaling via binding and cross-linking of surface molecules and marking tumor cells for engagement with immune cells. Furthermore, the recognition cascade from antigen binding to the establishment of effector functions (e.g., T cell cytotoxicity) requires a series of carefully orchestrated cell-surface interactions, of which the binding affinity of the antigen-binding moiety is one of several factors. Therefore, while these assays are valuable tools for early candidate development, simple protein-protein affinity interaction assays may not yield a complete picture.
[0005] In summary, there remains a need to develop binding assays that more closely mimic the in vivo situation in a more comprehensive setting, minimizing nonspecific effects on target-antibody binding as much as possible. Furthermore, it would be greatly beneficial to design combined assays that allow for the assessment of binding and functionality at an early stage in the development process of antibody therapeutic molecules.
[0006] The inventors of the present invention have developed a novel assay that is applicable to a wide variety of different cancer cell types to assess the binding of antibodies to their targets. This innovative assay, which includes modified T cells as reporter cells, combines a straightforward readout with comprehensive and inclusive results.
[0007] Furthermore, the present invention provides assays for combining the assessment of binding and functionality of antibodies and antibody-like constructs (e.g., ligands). This novel assay is useful, for example, for the screening or characterization of therapeutic antibody drug candidates, e.g., in a high-throughput format.
[0008] This new assay represents a valuable tool for early and late stage screening and characterization of antibodies that bind to their natural targets and to assess functionality, allowing identification of the best binders at an early stage in the development of drug candidates. SUMMARY OF THE INVENTION
[0010] The present invention generally relates to a method for selecting novel antigen binding moieties, particularly in drug development, and combining the assessment of binding to a target antigen (e.g. on a tumor cell) with the activation of T cells in response to antibody-target binding.
[0011] Thus, provided herein is a method for assessing the specificity of an antigen binding moiety comprising the following steps:
[0012] a. Providing an antigen binding module specific for the target antigen;
[0013] b. Generate chimeric antigen receptor (CAR)-expressing reporter T (CAR-T) cells by:
[0014] i. transferring the antigen binding moiety into a CAR carrier system operably coupled to a response element; and
[0015] ii. transferring the CAR vector system into reporter T cells comprising a reporter gene under the control of the response element;
[0016] c. contacting the reporter CAR-T cell with a target cell comprising the target antigen on its surface, particularly wherein the target cell is a cancer cell; and
[0017] d. Assaying T cell activation by measuring expression of the reporter gene to establish the specificity of the antigen binding moiety.
[0018] In one embodiment, the antigen binding moiety is a Fab fragment, in particular a Fab fragment derived from phage display library screening.
[0019] In one embodiment, the antigen binding moiety comprises a variable heavy chain domain (VH) and a variable light chain domain (VL). In one embodiment, the VH and VL domains of the antigen binding moiety are transferred to the CAR.
[0020] In one embodiment, the CAR vector system encodes a CAR comprising a Fab or crossover Fab fragment, an anchoring transmembrane domain and at least one intracellular signaling and / or co-signaling domain.
[0021] In one embodiment, binding of the target antigen to the reporter CAR-T cell results in activation of the intracellular signaling and / or co-signaling domain.
[0022] In one embodiment, activation of the intracellular signaling domain results in activation of the response element.
[0023] In one embodiment, the response element controls expression of the reporter gene.
[0024] In one embodiment, activation of the response element results in expression of the reporter gene.
[0025] In one embodiment, the response element is part of the NFAT pathway, the NF-κB pathway, or the AP-1 pathway.
[0026] In one embodiment, the reporter gene encodes a luminescent protein, particularly a fluorescent protein.
[0027] In one embodiment, the reporter gene encodes green fluorescent protein (GFP) or luciferase.
[0028] In one embodiment, the target antigen is a cell surface receptor.
[0029] In one embodiment, the target antigen is a peptide that binds to a molecule of the human major histocompatibility complex (MHC).
[0030] In one embodiment, the antigen binding moiety is a T cell receptor-like (TCRL) antigen binding moiety.
[0031] In one embodiment, the method further comprises the steps of:
[0032] e. Compare the level of expression of the reporter gene to a reference.
[0033] In one embodiment, the reference is expression of the reporter gene in the absence of the target cell.
[0034] In one embodiment, expression of the reporter gene is at least 2-fold, 3-fold, 4-fold, 5-fold, 10-fold, 100-fold, 1000-fold, or 10,000-fold greater than expression of the reporter gene in the absence of the target cell.
[0035] In one embodiment, the method further comprises the steps of:
[0036] f. If the level of expression of the reporter gene in the presence of the target cell is higher than a predetermined threshold relative to the expression of the reporter gene in the absence of the target cell, selecting the novel antigen binding moiety.
[0037] In one embodiment, the threshold is 2, 3, 4, 5, 10, 100, 1000, or 10000.
[0038] In one embodiment, high levels of expression of the reporter gene in the presence of the target cell and low levels of expression of the reporter gene in the absence of the target cell indicate high specificity of the antigen binding moiety, in particular high specificity of the T cell bispecific (TCB) antibody comprising the antigen binding moiety.
[0039] In one embodiment, the method is an in vitro method
[0040] In one embodiment, provided is a method for generating a TCB antibody, wherein the TCB antibody format comprises a first antigen binding moiety specific for a target antigen and a second antigen binding moiety capable of specifically binding to a T cell activating receptor, wherein the first antigen binding moiety is selected according to the method as described herein.
[0041] In one embodiment, the T cell activating receptor is CD3. BRIEF DESCRIPTION OF THE DRAWINGS
[0043] Figure 1 Schematic diagram showing the Jurkat NFAT reporter CAR-T cell assay. Tumor-associated antigens (TAAs) are recognized by Jurkat NFAT reporter CAR-T cells expressing anti-TAA antigen-binding receptors. This recognition leads to cell activation, which can be detected by measuring luminescence (cps).
[0044] FIG2 depicts the configuration of different CAR formats used in the present invention. Figure 2A The structure of a Fab format is shown. Depicted is the extracellular domain, which comprises an antigen-binding module composed of an Ig heavy chain fragment and an Ig light chain. Attached to the heavy chain, a linker connects the antigen-recognition domain to the anchor transmembrane domain (ATD), which is fused to the intracellular costimulatory signaling domain (CSD), which in turn is fused to the stimulatory signaling domain (SSD). Figure 2BThe architecture of a Fab format with heavy and light chain exchange is shown. Depicted is the extracellular domain comprising an antigen-binding module composed of an Ig heavy chain fragment and an Ig light chain. Attached to the light chain constant domain, a linker connects the antigen-recognition domain to the anchor transmembrane domain (ATD), which is fused to the intracellular costimulatory signaling domain (CSD), which in turn is fused to the stimulatory signaling domain (SSD). Figure 2C The architecture of the scFab format is shown. Depicted is the extracellular domain comprising an antigen-binding module composed of an Ig heavy chain fragment and an Ig light chain connected by a linker. Attached to the heavy chain, the linker connects the antigen-recognition domain to the anchor transmembrane domain (ATD), which is fused to the intracellular costimulatory signaling domain (CSD), which in turn is fused to the stimulatory signaling domain (SSD). Figure 2D The structure of a crossover Fab format with VH-VL exchange is shown. Depicted is the extracellular domain comprising an antigen-binding module composed of an Ig heavy chain fragment and an Ig light chain (in which the VH and VL domains are exchanged). Attached to the heavy chain constant domain, a linker connects the antigen recognition domain to the anchor transmembrane domain (ATD), which is fused to the intracellular costimulatory signaling domain (CSD), which in turn is fused to the stimulatory signaling domain (SSD). Figure 2E The architecture of a crossover Fab format with CH-CL exchange is shown. Depicted is the extracellular domain comprising an antigen-binding moiety composed of an Ig heavy chain fragment and an Ig light chain (in which the CH and CL domains are exchanged). Attached to the light chain constant domain, a linker connects the antigen recognition domain to the anchor transmembrane domain (ATD), which is fused to the intracellular costimulatory signaling domain (CSD), which in turn is fused to the stimulatory signaling domain (SSD). Figure 2F The architecture of a classic scFv format is shown, with an extracellular antigen recognition domain consisting of a variable heavy and variable light chain connected by a linker. Attached to the variable light chain, the linker connects the antigen recognition domain to the anchor transmembrane domain (ATD), which is fused to the intracellular costimulatory signaling domain (CSD), which in turn is fused to the stimulatory signaling domain (SSD).
[0045] Figure 3 depicts a schematic diagram illustrating the modular composition of an exemplary expression construct encoding a CAR for use in accordance with the present invention. Figure 3A and Figure 3B Exemplary Fab formats are depicted. Figure 3C Exemplary scFab formats are depicted. Figure 3D and Figure 3E Exemplary crossover Fab formats are depicted. Figure 3F Depicts the classic scFv format.
[0046] Figure 4Depicts a Jurkat NFAT reporter CAR-T cell assay using CD20-expressing SUDHDL4 tumor cells as target cells. A monoclonal anti-CD20-Fab-CD28ATD-CD28CSD-CD3zSSD-expressing Jurkat NFAT reporter CAR-T cell was used as a reporter cell.
[0047] Figure 5 Depicts a Jurkat NFAT reporter CAR-T cell assay using CD20-expressing SUDHDL4 tumor cells as target cells. A collection of anti-CD20-Fab-CD28ATD-CD28CSD-CD3zSSD or anti-CD20-crossFab-CD28ATD-CD28CSD-CD3zSSD-expressing Jurkat NFAT reporter CAR-T cells was used as reporter cells.
[0048] Figure 6 Depicts a Jurkat NFAT reporter CAR-T cell assay using CD20-expressing SUDHDL4 tumor cells as target cells. A collection of anti-CD20-scFab-CD28ATD-CD28CSD-CD3zSSD-expressing Jurkat NFAT reporter CAR-T cells was used as reporter cells.
[0049] Figure 7 Depicts a Jurkat NFAT reporter CAR-T cell reporter assay using CD20-expressing SUDHDL4 tumor cells as target cells. A collection of anti-CD20-Fab-CD28ATD-CD28CSD-CD3zSSD or anti-CD20-scFv-CD28ATD-CD28CSD-CD3zSSD-expressing Jurkat NFAT reporter CAR-T cells was used as reporter cells.
[0050] Figure 8A and Figure 8B Depicted are the assessment of the specificity of WT1 / HLA binders 5E11 and 33H09 by FACS using T2 cells pulsed with RMF peptide or VLD peptide.
[0051] Figure 9 Figure 3. Activation of CAR-NFAT signaling in Jurkat NFAT reporter anti-WT1 / HLA-Fab-CAR-T cell pools following co-incubation with T2 cells pulsed with RMF or VLD peptides. Comparison of the signal on RMF peptide (target) versus VLD peptide (off-target) helps assess the specificity of activation.
[0052] Figure 10Depicts activation of CAR-NFAT signaling in Jurkat NFAT reporter anti-WT1 / HLA-Fab-CAR-T cell pools after co-incubation with T2 cells pulsed with RMF or VLD peptides. Comparison of the signal on RMF peptide (target) versus VLD peptide (off-target) helps assess the specificity of activation. The signal of the NFAR reporter CAR-T cell pool incubated in the absence of target cells illustrates the low background of the assay.
[0053] Figure 11 Figure 2 depicts activation of CAR-NFAT signaling in Jurkat NFAT Fab-CAR-T cell pools expressing CAR-binding agents against different peptide / HLA targets. Jurkat NFAT CAR-T cell pools F06, F29, and F30 bind to blinded peptide / HLA targets with irrelevant peptides. Detailed Description of the Invention
[0055] definition
[0056] Unless otherwise defined below, terms are used herein as commonly used in the art.
[0057] An "activating Fc receptor" is an Fc receptor that, upon engagement by the Fc domain of an antibody, triggers signaling events that stimulate cells bearing the receptor to carry out effector functions. Human activating Fc receptors include FcγRIIIa (CD16a), FcγRI (CD64), FcγRIIa (CD32), and FcαRI (CD89).
[0058] An "effective amount" of an agent is that amount necessary to effect a physiological change in the cell or tissue to which it is administered.
[0059] "Affinity" refers to the strength of the sum of non-covalent interactions between a single binding site of a molecule (e.g., a receptor) and its binding partner (e.g., a ligand). Unless otherwise indicated, as used herein, "binding affinity" refers to the intrinsic binding affinity that reflects a 1:1 interaction between members of a binding pair (e.g., an antigen binding moiety and an antigen and / or a receptor and its ligand). The affinity of a molecule X for its partner Y can generally be expressed in terms of the dissociation constant (K D ) are expressed as the dissociation and association rate constants (K 解离 and K 结合 ). Thus, equal affinities may include different rate constants, as long as the ratio of the rate constants remains the same. Affinity can be measured by established methods known in the art, including those described herein. A preferred method for measuring affinity is surface plasmon resonance (SPR), and the preferred temperature for measurement is 25°C.
[0060] The term "amino acid" refers to naturally occurring and synthetic amino acids, as well as amino acid analogs and amino acid mimetics that function in a manner similar to naturally occurring amino acids. Naturally occurring amino acids are those encoded by the genetic code, as well as those that are later modified, such as hydroxyproline, γ-carboxyglutamate, and O-phosphoserine. Amino acid analogs are compounds that have the same basic chemical structure as naturally occurring amino acids (i.e., a hydrogen atom, a carboxyl group, an amino group, and an α-carbon bonded to the R group), such as homoserine, norleucine, methionine sulfoxide, and methionine methylsulfonium. Such analogs have modified R groups (e.g., norleucine) or modified peptide backbones but retain the same basic chemical structure as naturally occurring amino acids. Amino acid mimetics are chemical compounds that have a structure that differs from the general chemical structure of an amino acid but functions in a manner similar to a naturally occurring amino acid. Amino acids may be referred to herein by their commonly known three-letter symbols or one-letter symbols recommended by the IUPAC-IUB Biochemical Nomenclature Commission.
[0061] As used herein, the term "amino acid mutation" is intended to encompass amino acid substitutions, deletions, insertions, and modifications. Any combination of substitutions, deletions, insertions, and modifications can be performed to achieve the final construct, as long as the final construct possesses the desired properties. Amino acid sequence deletions and insertions include amino- and / or carboxyl-terminal deletions and amino acid insertions. A specific amino acid mutation is an amino acid substitution. To alter, for example, the binding characteristics of an antigen-binding moiety, non-conservative amino acid substitutions are particularly preferred, i.e., replacing one amino acid with another having different structural and / or chemical properties. Amino acid substitutions include replacement with non-naturally occurring amino acids or with naturally occurring amino acid derivatives of the 20 standard amino acids (e.g., 4-hydroxyproline, 3-methylhistidine, ornithine, homoserine, 5-hydroxylysine). Amino acid mutations can be generated using genetic or chemical methods known in the art. Genetic methods can include site-directed mutagenesis, PCR, gene synthesis, and the like. Methods that alter amino acid side chain groups by methods other than genetic engineering, such as chemical modification, are also contemplated. Various names may be used herein to refer to the same amino acid mutation.
[0062] The term "antibody" is used herein in the broadest sense and encompasses various antibody structures, including but not limited to monoclonal antibodies, polyclonal antibodies, and antibody fragments, so long as they exhibit the desired antigen-binding activity. Thus, in the context of the present invention, the term antibody refers to intact immunoglobulin molecules as well as portions of such immunoglobulin molecules. Furthermore, as discussed herein, the term also refers to modified and / or altered antibody molecules, particularly mutant antibody molecules. The term also refers to recombinantly or synthetically produced / synthesized antibodies. In the context of the present invention, the term antibody is used interchangeably with the term immunoglobulin.
[0063] "Antibody fragment" refers to a molecule other than an intact antibody that contains a portion of an intact antibody that binds to the antigen to which the intact antibody binds. Examples of antibody fragments include, but are not limited to, Fv, Fab, Fab', Fab'-SH, F(ab')2, diabodies, linear antibodies, single-chain antibody molecules (e.g., scFv), and single-domain antibodies. For a review of certain antibody fragments, see Hudson et al., Nat Med 9, 129-134 (2003). For a review of scFv fragments, see, for example, Plückthun, in The Pharmacology of Monoclonal Antibodies, vol. 113, Rosenburg and Moore, eds., Springer-Verlag, New York, pp. 269-315 (1994); see also WO 93 / 16185; and U.S. Patent Nos. 5,571,894 and 5,587,458. Diabodies are antibody fragments with two antigen-binding sites that can be bivalent or bispecific. See, e.g., EP 404,097; WO 1993 / 01161; Hudson et al., Nat Med 9, 129-134 (2003); and Hollinger et al., Proc Natl Acad Sci USA 90, 6444-6448 (1993). Triabodies and tetrabodies are also described in Hudson et al., Nat Med 9, 129-134 (2003). Single-domain antibodies are antibody fragments that contain all or part of the heavy chain variable domain, or all or part of the light chain variable domain of an antibody (Domantis, Inc., Waltham, MA; see, e.g., U.S. Patent No. 6,248,516 B1). Antibody fragments can be prepared by various techniques, including but not limited to proteolytic digestion of intact antibodies and production by recombinant host cells (e.g., E. coli or phage), as described herein.
[0064] As used herein, the term "antigen binding molecule" in its broadest sense refers to a molecule that specifically binds to an antigenic determinant. Examples of antigen binding molecules are immunoglobulins and their derivatives, such as fragments thereof, and antigen binding receptors, such as CARs, and their derivatives.
[0065] As used herein, the term "antigen binding moiety" refers to a polypeptide molecule that specifically binds to an antigenic determinant. In one embodiment, the antigen binding moiety is capable of directing an entity attached thereto (e.g., an immunoglobulin or CAR) to a target site, such as a specific type of tumor cell or a tumor stroma carrying the antigenic determinant. In another embodiment, the antigen binding moiety is capable of activating signal transduction via its target antigen, such as upon binding of the antigenic determinant to a CAR on a T cell. In the context of the present invention, the antigen binding moiety may be included in antibodies and fragments thereof, as well as CARs and fragments thereof, as further defined herein. The antigen binding moiety includes an antigen binding domain comprising an immunoglobulin heavy chain variable region and an immunoglobulin light chain variable region. In certain embodiments, the antigen binding moiety may comprise an immunoglobulin constant region as further defined herein and known in the art. Useful heavy chain constant regions include any of five isotypes: α, δ, ε, γ, or μ. Useful light chain constant regions include any of two isotypes: κ and λ.
[0066] In the context of the present invention, the term "antigen-binding receptor" refers to an antigen-binding molecule comprising an anchoring transmembrane domain and an extracellular domain comprising at least one antigen-binding moiety. An antigen-binding receptor (e.g., CAR) can be composed of polypeptide portions derived from different sources. Thus, it can also be understood as a "fusion protein" and / or a "chimeric protein." Typically, a fusion protein is a protein created by linking two or more genes (or preferably cDNAs) that originally encoded separate proteins. Translation of such a fusion gene (or fusion cDNA) produces a single polypeptide, preferably with functional properties derived from each of the original proteins. Recombinant fusion proteins are artificially created using recombinant DNA technology for use in biological research or therapy. In the context of the present invention, a CAR (chimeric antigen receptor) is understood to be an antigen-binding receptor comprising an extracellular portion comprising an antigen-binding moiety, fused to an anchoring transmembrane domain via a spacer sequence, and the anchoring transmembrane domain itself fused to the intracellular signaling domains of CD3z and CD28.
[0067] "Antigen binding site" refers to the site on an antigen-binding molecule that interacts with an antigen, i.e., one or more amino acid residues. For example, the antigen-binding site of an antibody or CAR comprises amino acid residues from the complementarity-determining region (CDR). Natural immunoglobulin molecules typically have two antigen-binding sites, while Fab or scFv molecules typically have a single antigen-binding site.
[0068] The term "antigen binding domain" refers to the portion of an antibody or antigen binding receptor (e.g., CAR) that contains a region that specifically binds to a portion or all of an antigen and is complementary to it. The antigen binding domain can be provided, for example, by one or more immunoglobulin variable domains (also referred to as variable regions). Specifically, the antigen binding domain comprises an immunoglobulin light chain variable region (VL) and an immunoglobulin heavy chain variable region (VH).
[0069] The term "variable region" or "variable domain" refers to the domain of an immunoglobulin heavy or light chain involved in binding to an antigen. The variable domains of the heavy and light chains of native antibodies (VH and VL, respectively) generally have similar structures, with each domain comprising four conserved framework regions (FRs) and three hypervariable regions (HVRs). See, for example, Kindt et al., Kuby Immunology, 6th ed., WH Freeman and Co., p. 91 (2007). A single VH or VL domain is generally sufficient to confer antigen-binding specificity.
[0070] As used herein, the term "ATD" refers to an "anchoring transmembrane domain," which defines a polypeptide segment capable of integrating into the cell membrane. The ATD can be fused to additional extracellular and / or intracellular polypeptide domains, where these extracellular and / or intracellular polypeptide domains are also bound to the cell membrane. In the context of an antigen-binding receptor as used in the present invention, the ATD confers membrane attachment and binding to the antigen-binding receptor, such as the CAR used in accordance with the present invention.
[0071] As used in the context of antigen-binding receptors (e.g., CARs) used in accordance with the present invention, the term "binding" defines the binding (interaction) of an "antigen interaction site" and an antigen with one another. The term "antigen interaction site" defines a motif in a polypeptide that exhibits the ability to specifically interact with one or a group of specific antigens. Such binding / interaction is also understood to define "specific recognition." The term "specific recognition" according to this invention means that the antigen-binding receptor is able to specifically interact and / or bind to a tumor-associated antigen (TAA) molecule as defined herein. The antigen-binding moiety of an antigen-binding receptor (e.g., CAR) can recognize, interact, and / or bind to different epitopes on the same molecule. This term refers to the specificity of the antigen-binding receptor, i.e., its ability to discriminate between specific regions of a molecule as defined herein. The specific interaction of the antigen-interaction site with its specific antigen can lead to the initiation of a signal, for example, by inducing a conformational change in the antigen-containing polypeptide, oligomerization of the antigen-containing polypeptide, oligomerization of the antigen-binding receptor, etc. Thus, the antigen-interaction site and specific motifs in the amino acid sequence of the antigen bind to one another as a result of their primary, secondary, or tertiary structure, as well as secondary modifications of said structure. Thus, the term binding refers not only to linear epitopes but also to conformational epitopes, structural epitopes, or discontinuous epitopes consisting of two regions of a target molecule or a portion thereof. In the context of this invention, a conformational epitope is defined by two or more discrete amino acid sequences separated in the primary sequence that come together on the surface of the molecule when the polypeptide folds into a native protein (Sela, Science 166 (1969), 1365 and Laver, Cell 61 (1990), 553-536). Furthermore, the term "binding" is used interchangeably with the term "interacting" in the context of this invention. The ability of the antigen binding moiety (e.g., Fab or scFv domain) of a CAR or antibody to bind to a specific target antigenic determinant can be measured via enzyme-linked immunosorbent assay (ELISA) or other techniques familiar to those skilled in the art, such as surface plasmon resonance (SPR) technology (analyzed on a BIAcore instrument) (Liljeblad et al., Glyco J 17, 323-329 (2000)) and traditional binding assays (Heeley, Endocr Res 28, 217-229 (2002)). In one embodiment, the extent to which the antigen binding moiety binds to an unrelated protein is less than about 10% of the binding of the antigen binding moiety to the target antigen, as measured, in particular, by SPR. In certain embodiments, the antigen binding moiety that binds to the target antigen has a binding affinity of ≤1 μM, ≤100 nM, ≤10 nM, ≤1 nM, ≤0.1 nM, ≤0.01 nM, or ≤0.001 nM (e.g., 10 -8 M or smaller, such as 10 -8 M to 10-13 M, for example 10 -9 M to 10 -13 The dissociation constant (K D ). As used in accordance with the present invention, the term "specifically binds" means that the molecules used in the present invention do not cross-react or substantially cross-react with (poly)peptides of similar structure. A panel of constructs under investigation can be tested for cross-reactivity, for example by evaluating the binding of a panel of antigen binding moieties to the antigen of interest as well as to unrelated antigens under conventional conditions (see, for example, Harlow and Lane, Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory Press, (1988) and Using Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory Press, (1999)). Only those constructs (i.e., Fab fragments, scFv, etc.) that bind to the antigen of interest but do not, or do not substantially, bind to unrelated antigens are considered specific for the antigen of interest and are selected for further studies according to the methods provided herein. These methods may inter alia include binding studies, blocking and competition studies with structurally and / or functionally closely related polypeptides. Binding studies also include FACS analysis, surface plasmon resonance (SPR, e.g., using ), analytical ultracentrifugation, isothermal titration calorimetry, fluorescence anisotropy, fluorescence spectroscopy, or radiolabeled ligand binding assays.
[0072] As used herein, the term "CDR" refers to a "complementarity determining region," which is well known in the art. A CDR is the portion of an immunoglobulin or antigen-binding receptor (e.g., CAR) that determines the specificity of the molecule and contacts a specific ligand. CDRs are the most variable portion of the molecule and contribute to the antigen-binding diversity of these molecules. There are three CDR regions in each V domain, CDR1, CDR2, and CDR3. CDR-H depicts the CDR region of the variable heavy chain, while CDR-L relates to the CDR region of the variable light chain. VH means variable heavy chain and VL means variable light chain. The CDR regions of the Ig-derived region can be determined as described in "Kabat" (Sequences of Proteins of Immunological Interest", 5th edit. NIH Publication no. 91-3242 U.S. Department of Health and Human Services (1991); Chothia J. Mol. Biol. 196 (1987), 901-917) or "Chothia" (Nature 342 (1989), 877-883).
[0073] The term "CD3z" refers to the T-cell surface glycoprotein CD3 zeta (ζ) chain, also known as the "T-cell receptor T3 zeta chain" and "CD247."
[0074] The term "chimeric antigen receptor" or "chimeric receptor" or "CAR" refers to an antigen binding receptor composed of the extracellular portion of an antigen binding moiety (e.g., scFv or Fab) fused to an intracellular signaling domain (e.g., CD3z and CD28) via a spacer sequence. The term "CAR" is understood in its broadest form and includes antigen binding receptors composed of the extracellular portion of an antigen binding moiety fused to CD3z and its fragments and CD28 and its fragments, optionally via one or more peptide linkers.
[0075] The "class" of an antibody or immunoglobulin refers to the type of constant domain or region possessed by its heavy chain. There are five major classes of antibodies: IgA, IgD, IgE, IgG, and IgM, and several of these can be further divided into subclasses (isotypes), such as IgG1, IgG2, IgG3, IgG4, IgA1, and IgA2. The heavy chain constant domains corresponding to the different immunoglobulin classes are called α, δ, ε, γ, and μ, respectively.
[0076] A "crossover" Fab molecule (also referred to as a "crossover Fab" or "crossover Fab fragment") refers to a Fab molecule in which the variable or constant regions of the Fab heavy and light chains are exchanged. That is, the crossover Fab fragment comprises a peptide chain consisting of a light chain variable region and a heavy chain constant region, and a peptide chain consisting of a heavy chain variable region and a light chain constant region. For clarity, in a crossover Fab fragment in which the variable regions of the Fab light chain and the Fab heavy chain are exchanged, the peptide chain comprising the heavy chain constant region is referred to herein as the heavy chain of the crossover Fab molecule. Conversely, in a crossover Fab fragment in which the constant regions of the Fab light chain and the Fab heavy chain are exchanged, the peptide chain comprising the heavy chain variable region is referred to herein as the heavy chain of the crossover Fab fragment. Thus, a crossover Fab fragment comprises a heavy or light chain (VH-CL) consisting of a heavy chain variable region and a light chain constant region, and a heavy or light chain (VL-CH1) consisting of a light chain variable region and a heavy chain constant region.
[0077] In contrast, a "Fab" or "conventional Fab" molecule refers to a Fab molecule in its natural form, i.e., comprising a heavy chain (VH-CH1) consisting of the heavy chain variable and constant regions, and a light chain (VL-CL) consisting of the light chain variable and constant regions.
[0078] As used herein, the term "CSD" refers to costimulatory signaling domain.
[0079] The term "effector function" refers to those biological activities attributable to the Fc region of an antibody and which vary with the antibody isotype. Examples of antibody effector functions include: C1q binding and complement-dependent cytotoxicity (CDC), Fc receptor binding, antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), cytokine secretion, immune complex-mediated antigen uptake by antigen-presenting cells, downregulation of cell surface receptors (e.g., B cell receptor), and B cell activation.
[0080] As used herein, the terms "engineering" or "modification" are considered to include any manipulation of the peptide backbone or post-translational modification of a naturally occurring or recombinant polypeptide or fragment thereof. Engineering or modification includes modifications to the amino acid sequence, glycosylation pattern, or individual amino acid side chain groups, as well as combinations of these approaches.
[0081] The term "expression cassette" refers to a recombinantly or synthetically generated polynucleotide containing a series of defined nucleic acid elements that allow transcription of a specific nucleic acid in target cells. Recombinant expression cassettes can be incorporated into plasmids, chromosomes, mitochondrial DNA, plastid DNA, viruses, or nucleic acid fragments. Typically, the recombinant expression cassette portion of an expression vector contains the nucleic acid sequence to be transcribed and sequences such as a promoter.
[0082] "Fab molecule" refers to a protein composed of the heavy chain VH and CH1 domains ("Fab heavy chain") and the light chain VL and CL domains ("Fab light chain") of an antigen binding molecule.
[0083] The term "Fc domain" or "Fc region" is used herein to define the C-terminal region of an immunoglobulin heavy chain that contains at least a portion of the constant region. This term includes native sequence Fc regions and variant Fc regions. Although the boundaries of the Fc region of an IgG heavy chain can vary slightly, the human IgG heavy chain Fc region is generally defined as extending from Cys226 or Pro230 to the carboxyl terminus of the heavy chain. However, the C-terminal lysine (Lys447) of the Fc region may or may not be present. Unless otherwise specified herein, the numbering of amino acid residues in the Fc region or constant region follows the "EU numbering system," also known as the EU index, as described in Kabat et al., Sequences of Proteins of Immunological Interest, 5th ed. Public Health Service, National Institutes of Health, Bethesda, MD, 1991. As used herein, a subunit of an Fc domain refers to one of the two polypeptides that form a dimeric Fc domain, i.e., the polypeptide comprising the C-terminal constant region of an immunoglobulin heavy chain that is capable of stable self-association. For example, the subunit of the IgG Fc domain contains the IgG CH2 and IgG CH3 constant domains.
[0084] "Framework" or "FR" refers to variable domain residues excluding hypervariable region (HVR) residues. The variable domain FR generally consists of four FR domains: FR1, FR2, FR3, and FR4. Thus, HVR and FR sequences generally appear in the following order in VH (or VL): FR1-H1(L1)-FR2-H2(L2)-FR3-H3(L3)-FR4.
[0085] The term "full-length antibody" refers to an antibody composed of two full-length antibody heavy chains and two full-length antibody light chains. A "full-length antibody heavy chain" is a polypeptide consisting, in the N-terminal to C-terminal direction, of an antibody heavy chain variable domain (VH), an antibody constant heavy chain domain 1 (CH1), an antibody hinge region (HR), an antibody heavy chain constant domain 2 (CH2), and an antibody heavy chain constant domain 3 (CH3) (abbreviated as VH-CH1-HR-CH2-CH3); and, in the case of antibodies of the IgE subclass, an optional antibody heavy chain constant domain 4 (CH4). Preferably, a "full-length antibody heavy chain" is a polypeptide consisting, in the N-terminal to C-terminal direction, of VH, CH1, HR, CH2, and CH3. A "full-length antibody light chain" is a polypeptide consisting, in the N-terminal to C-terminal direction, of an antibody light chain variable domain (VL) and an antibody light chain constant domain (CL) (abbreviated as VL-CL). The antibody light chain constant domain (CL) can be either kappa (kappa) or lambda (lambda). The two full-length antibody chains are linked together via inter-polypeptide disulfide bonds between the CL and CH1 domains and between the hinge regions of the full-length antibody heavy chains. Typical examples of full-length antibodies are natural antibodies, such as IgG (e.g., IgG1 and IgG2), IgM, IgA, IgD, and IgE).
[0086] "Fusion" means that the components (eg, Fab and transmembrane domain) are linked by a peptide bond, either directly or via one or more peptide linkers.
[0087] The terms "host cell," "host cell line," and "host cell culture" are used interchangeably to refer to cells into which exogenous nucleic acid has been introduced, including the progeny of such cells. Host cells include "transformants" and "transformed cells," which include the initially transformed cell and progeny derived therefrom (regardless of the number of passages). Progeny may not be completely identical to the parent cell in terms of nucleic acid content but may contain mutations. Mutant progeny that have the same function or biological activity as screened or selected for in the originally transformed cell are included herein. Host cells include cultured cells, such as cultured mammalian cells such as CHO cells, BHK cells, NSO cells, SP2 / 0 cells, YO myeloma cells, P3X63 mouse myeloma cells, PER cells, PER.C6 cells, or hybridoma cells, yeast cells, insect cells, and plant cells, among others, and also include cells contained in transgenic animals, transgenic plants, or cultured plant or animal tissues.
[0088] As used herein, the term "hypervariable region" or "HVR" refers to each of the regions of an antibody variable domain that are highly variable in sequence and / or form structurally defined loops ("hypervariable loops"). Typically, native four-chain antibodies contain six HVRs: three in VH (H1, H2, H3) and three in VL (L1, L2, L3). HVRs generally comprise amino acid residues from the hypervariable loops and / or from the complementarity determining regions (CDRs), the latter of which have the highest sequence variability and / or are involved in antigen recognition. With the exception of CDR1 in VH, CDRs generally comprise amino acid residues that form the hypervariable loops. Hypervariable regions (HVRs) are also called complementarity determining regions (CDRs), and these terms are used interchangeably herein to refer to the portions of the variable domains that form the antigen-binding region. This specific region has been described by Kabat et al., U. S. Pat. of Health and Human Services, Sequences of Proteins of Immunological Interest (1983) and by Chothia et al., J Mol Biol 196:901-917 (1987), where the definitions include overlapping or subsets of amino acid residues when compared to each other. However, the application of any one definition to refer to the CDRs of antibodies and / or antigen-binding receptors or variants thereof is intended to be within the scope of the term as defined and used herein. Suitable amino acid residues encompassing the CDRs as defined by each of the references cited above are listed in Table 1 below for comparison. The exact number of residues encompassing a particular CDR will vary with the sequence and size of the CDR. Given the variable region amino acid sequence of an antibody, one skilled in the art can routinely determine which residues constitute a particular CDR.
[0089] Table 1: CDR definitions 1
[0090] CDR Kabat Chothia <![CDATA[AbM 2 ]]> <![CDATA[V H CDR1]]> 31-35 26-32 26-35 <![CDATA[V H CDR2]]> 50-65 52-58 50-58 <![CDATA[V H CDR3]]> 95-102 95-102 95-102 <![CDATA[V L CDR1]]> 24-34 26-32 24-34 <![CDATA[V L CDR2]]> 50-56 50-52 50-56 <![CDATA[V L CDR3]]> 89-97 91-96 89-97
[0091] 1 The numbering of all CDR definitions in Table 1 follows the numbering convention proposed by Kabat et al. (see below).
[0092] 2 "AbM" with a lowercase "b" as used in Table 1 refers to CDRs defined by Oxford Molecular's "AbM" antibody modeling software.
[0093] Kabat et al. also defined a numbering system for variable region sequences that can be applied to any antibody. A person skilled in the art can unambiguously assign this Kabat numbering system to any variable region sequence, independent of any experimental data beyond the sequence itself. As used herein, "Kabat numbering" refers to the numbering system proposed by Kabat et al., U.S. Department of Health and Human Services, "Sequences of Proteins of Immunological Interest" (1983). Unless otherwise stated, references to specific amino acid residue positions in the variable region of an antigen-binding moiety are numbered according to the Kabat numbering system. The polypeptide sequences in the Sequence Listing are not numbered according to the Kabat numbering system. However, a person skilled in the art is fully capable of converting the sequence numbering system in the Sequence Listing to the Kabat numbering system.
[0094] An "individual" or "subject" is a mammal. Mammals include, but are not limited to, domesticated animals (e.g., cattle, sheep, cats, dogs, and horses), primates (e.g., humans and non-human primates such as monkeys), rabbits, and rodents (e.g., mice and rats). Specifically, the individual or subject is a human.
[0095] An "isolated nucleic acid" molecule or polynucleotide means a nucleic acid molecule, DNA or RNA, that has been removed from its natural environment. For example, a recombinant polynucleotide encoding a polypeptide contained in a vector is considered isolated for the purposes of the present invention. Other examples of isolated polynucleotides include recombinant polynucleotides maintained in heterologous host cells or purified (partially or substantially) polynucleotides in solution. An isolated polynucleotide includes a polynucleotide molecule contained in a cell that normally contains the polynucleotide molecule, but the polynucleotide molecule is present extrachromosomally or at a chromosomal location that is different from its natural chromosomal location. Isolated RNA molecules include in vivo or in vitro RNA transcripts of the present invention, as well as positive and negative strand forms, and double-stranded forms. Isolated polynucleotides or nucleic acids according to the present invention also include such molecules produced synthetically. Additionally, a polynucleotide or nucleic acid may be or may include regulatory elements such as a promoter, a ribosome binding site, or a transcription terminator.
[0096] A nucleic acid or polynucleotide having a nucleotide sequence that is at least, for example, 95% "identical" to a reference nucleotide sequence of the present invention means that the nucleotide sequence of the polynucleotide is identical to the reference sequence, except that the polynucleotide sequence may contain up to 5 point mutations per every 100 nucleotides of the reference nucleotide sequence. In other words, to obtain a polynucleotide having a nucleotide sequence that is at least 95% identical to a reference nucleotide sequence, up to 5% of the nucleotides in the reference sequence may be deleted or substituted with another nucleotide, or up to 5% of the total nucleotides in the reference sequence may be inserted into the reference sequence. These alterations in the reference sequence may occur at or anywhere between the 5' or 3' terminal positions of the reference nucleotide sequence, interspersed individually among residues in the reference sequence, or in one or more contiguous groups within the reference sequence. As a practical matter, whether any particular polynucleotide sequence is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to a nucleotide sequence of the present invention can be routinely determined using known computer programs, such as those discussed below for polypeptides (e.g., ALIGN-2).
[0097] An "isolated polypeptide," or variant or derivative thereof, is intended to be a polypeptide that is not in its native environment. No particular level of purification is required. For example, an isolated polypeptide can be removed from its native or natural environment. For the purposes of the present invention, recombinantly produced polypeptides and proteins expressed in host cells are considered isolated, as are native or recombinant polypeptides that have been separated, fractionated, or partially or substantially purified by any suitable technique.
[0098] "Percent (%) amino acid sequence identity" with respect to a reference polypeptide sequence is defined as the percentage of amino acid residues in a candidate sequence that are identical with the amino acid residues in the reference polypeptide sequence, after aligning the sequences and introducing gaps, if necessary, to achieve maximum percent sequence identity, and not considering any conservative substitutions as part of the sequence identity. Alignment for the purpose of determining percent amino acid sequence identity can be performed in a variety of ways that are within the skill in the art, for example, using publicly available computer software such as BLAST, BLAST-2, ALIGN, or Megalign (DNASTAR) software. Those skilled in the art can determine appropriate parameters for aligning sequences, including any algorithms needed to achieve maximal alignment over the full length of the compared sequences. However, for purposes herein, the sequence comparison computer program ALIGN-2 is used to generate % amino acid sequence identity values. The ALIGN-2 sequence comparison computer program was created by Genentech, Inc., and the source code has been filed with user documentation in the U.S. Copyright Office, Washington, DC, 20559, where it is registered under U.S. Copyright Registration No. TXU510087. The ALIGN-2 program is publicly available from Genentech, Inc., South San Francisco, California, or can be compiled from source code. The ALIGN-2 program should be compiled for UNIX operating systems, including digital UNIX V4.0D. All sequence comparison parameters are set by the ALIGN-2 program and do not change. When ALIGN-2 is used for amino acid sequence comparison, the % amino acid sequence identity of a given amino acid sequence A to / with / relative to a given amino acid sequence B (or which can be phrased as a given amino acid sequence A having or comprising a specific % amino acid sequence identity to / with / relative to a given amino acid sequence B) is calculated as follows:
[0099] 100 times the fraction X / Y
[0100] where X is the number of amino acid residues scored as identical matches by the sequence alignment program ALIGN-2 in that program's alignment of A and B, and where Y is the total number of amino acid residues in B. It will be appreciated that when the length of amino acid sequence A is not equal to the length of amino acid sequence B, the % amino acid sequence identity of A to B will not equal the % amino acid sequence identity of B to A. Unless expressly stated otherwise, all % amino acid sequence identity values used herein are obtained using the ALIGN-2 computer program as described in the immediately preceding paragraph.
[0101] The term "nucleic acid molecule" refers to a base sequence comprising purine and pyrimidine bases contained within a polynucleotide, whereby these bases represent the primary structure of a nucleic acid molecule. As used herein, the term nucleic acid molecule includes DNA, cDNA, genomic DNA, RNA, synthetic forms of DNA, and mixed polymers comprising two or more of these molecules. Furthermore, the term nucleic acid molecule includes both sense and antisense strands. Furthermore, the nucleic acid molecules described herein may contain non-natural or derivatized nucleotide bases, as will be readily appreciated by those skilled in the art.
[0102] As used herein, "NFAT" refers to "nuclear factor of activated T cells" and is a family of transcription factors expressed in most immune cells. Activation of NFAT family transcription factors depends on calcium signaling. For example, T cell activation via the T cell synapse leads to calcium influx. Elevated intracellular calcium levels activate the calcium-sensitive phosphatase, calcineurin, which rapidly dephosphorylates the serine-rich region (SRR) and SP repeats in the amino terminus of NFAT proteins. This results in a conformational change that exposes a nuclear localization signal, promoting NFAT nuclear import and target gene activation.
[0103] As used herein, "NFAT pathway" refers to stimulation that results in regulation of the activity of members of the NFAT transcription factor family. NFAT DNA elements are known in the art and are also referred to herein as "NFAT pathway response elements." Thus, a "NFAT pathway receptor" refers to a receptor that can trigger regulation of NFAT activity. Examples of "NFAT pathway receptors" are, for example, T cell receptors and B cell receptors.
[0104] As used herein, "NF-κB" refers to "nuclear factor kappa-light-chain-enhancer of activated B cells" and is a transcription factor involved in regulating numerous genes encoding mediators of apoptosis, viral replication, tumorigenesis, various autoimmune diseases, and inflammatory responses. NFκB is present in nearly all eukaryotic cells. Normally, it resides in the cytosol in an inactive state, where it forms a complex with inhibitory κB (IκB) proteins. IκB kinase (IKK) is activated by ligand binding to integral membrane receptors (also known as "receptors of the NF-κB pathway"). IKK is an enzyme complex composed of two kinases and a regulatory subunit. This complex phosphorylates IκB proteins, leading to their ubiquitination and subsequent proteasomal degradation. Finally, free NFκB assumes an active state, translocates to the nucleus, binds to κB DNA elements, and induces target gene transcription.
[0105] As used herein, the "NF-κB pathway" refers to a stimulus that leads to the regulation of NF-κB activity. For example, activation of Toll-like receptor signaling, TNF receptor signaling, T cell receptor signaling, and B cell receptor signaling via ligand or antibody binding leads to the activation of NF-κB. Subsequently, phosphorylated NF-κB dimers bind to κB DNA elements and induce target gene transcription. κB DNA elements are known in the art and are also referred to herein as "NF-κB pathway response elements." Therefore, a "NF-κB pathway receptor" refers to a receptor that can trigger the regulation of NF-κB activity. Examples of "NF-κB pathway receptors" are Toll-like receptors, TNF receptors, T cell receptors, and B cell receptors.
[0106] As used herein, "AP-1" refers to "activator protein 1" and is a transcription factor involved in several cellular processes, including differentiation, proliferation, and apoptosis. AP-1 function depends on specific Fos and Jun subunits that contribute to the AP-1 dimer. AP-1 binds to a palindromic DNA motif (5'-TGA G / C TCA-3') to regulate gene expression.
[0107] The term "pharmaceutical composition" refers to a preparation that is in a form that permits the biological activity of the active ingredient contained therein to be effective, and does not contain additional ingredients that are unacceptably toxic to a subject to which the formulation would be administered. Pharmaceutical compositions typically contain one or more pharmaceutically acceptable carriers.
[0108] "Pharmaceutically acceptable carrier" refers to a component other than the active ingredient in a pharmaceutical composition that is non-toxic to the subject. Pharmaceutically acceptable carriers include, but are not limited to, buffers, excipients, stabilizers, or preservatives.
[0109] As used herein, the term "polypeptide" refers to a molecule composed of monomers (amino acids) linearly linked by amide bonds (also known as peptide bonds). The term polypeptide refers to any chain of two or more amino acids and does not refer to a specific length of the product. Thus, peptide, dipeptide, tripeptide, oligopeptide, protein, amino acid chain, or any other term used to refer to a chain of two or more amino acids are included within the definition of polypeptide, and the term polypeptide may be used in place of or interchangeably with any of these terms. The term polypeptide is also intended to refer to products of post-expression modifications of the polypeptide, including, but not limited to, glycosylation, acetylation, phosphorylation, acylation, derivatization with known protective / blocking groups, proteolytic cleavage, or modification with non-naturally occurring amino acids. A polypeptide can be derived from a natural biological source or produced by recombinant technology, but is not necessarily translated from a designated nucleic acid sequence. It can be produced by any means, including chemical synthesis. The polypeptides of the present invention can be about 3 or more, 5 or more, 10 or more, 20 or more, 25 or more, 50 or more, 75 or more, 100 or more, 200 or more, 500 or more, 1,000 or more, or 2,000 or more amino acids in size. Polypeptides can have a defined three-dimensional structure, although they do not necessarily have such a structure. Polypeptides with a defined three-dimensional structure are referred to as folded, while polypeptides that do not have a defined three-dimensional structure and can adopt a large number of different conformations are referred to as unfolded.
[0110] The term "polynucleotide" refers to an isolated nucleic acid molecule or construct, such as messenger RNA (mRNA), virally derived RNA, or plasmid DNA (pDNA). A polynucleotide can contain conventional phosphodiester bonds or unconventional bonds (e.g., amide bonds, as found in peptide nucleic acids (PNA)). The term nucleic acid molecule refers to any one or more nucleic acid segments, such as DNA or RNA fragments, present in a polynucleotide.
[0111] The term "intrinsically fluorescent protein" refers to proteins that are capable of forming a highly fluorescent, intrinsic chromophore through cyclization and oxidation of internal amino acids within the protein or through enzymatic addition of fluorescent cofactors. The term "intrinsically fluorescent protein" includes wild-type fluorescent proteins and mutants that exhibit altered spectral or physical properties. The term does not include proteins that exhibit weak fluorescence solely due to the fluorescent contribution of unmodified tyrosine, tryptophan, histidine, and phenylalanine groups within the protein. Proteins with intrinsic fluorescence are known in the art, such as green fluorescent protein (GFP), red fluorescent protein (RFP), blue fluorescent protein (BFP, Heim et al. 1994, 1996), a cyan fluorescent variant called CFP (Heim et al. 1996; Tsien 1998); a yellow fluorescent variant called YFP (Ormo et al. 1996; Wachter et al. 1998); a violet excitable green fluorescent variant called Sapphire (Tsien 1998; Zapata-Hommer et al. 2003); and a cyan excitable green fluorescent variant called enhanced green fluorescent protein or EGFP (Yang et al. 1996), and can be measured, for example, by live cell imaging (e.g., Incucyte) or fluorescence spectrophotometry.
[0112] "Decreased binding" refers to a decrease in the affinity of the corresponding interaction, as measured, for example, by SPR. For the sake of clarity, the term also includes a decrease in affinity to zero (or below the detection limit of the analytical method), i.e., complete abolition of the interaction. Conversely, "increased binding" refers to an increase in the binding affinity of the corresponding interaction.
[0113] The term "regulatory sequence" refers to DNA sequences that are necessary to achieve expression of coding sequences to which they are linked. The nature of such control sequences varies among organisms. In prokaryotes, control sequences generally include promoters, ribosome binding sites, and terminators. In eukaryotes, control sequences generally include promoters, terminators, and in some cases, enhancers, transactivators, or transcription factors. The term "control sequence" is intended to include, at a minimum, all components whose presence is necessary for expression, but may also include additional advantageous components.
[0114] As used herein, "reporter gene" means a gene whose expression can be measured. In a preferred embodiment, a "reporter gene" is a gene encoding a protein whose production and detection are used as a surrogate to indirectly detect the activity of the antibody or ligand to be tested. The reporter protein is the protein encoded by the reporter gene. Preferably, the reporter gene encodes an enzyme whose catalytic activity can be detected by a simple assay method or a protein having properties such as intrinsic fluorescence or luminescence, so that the expression of the reporter gene can be detected in a simple and rapid assay that requires minimal sample preparation. Non-limiting examples of enzymes whose catalytic activity can be detected are luciferase, β-galactosidase, alkaline phosphatase. Luciferase is a monomeric enzyme with a molecular weight (MW) of 61 kDa. It acts as a catalyst and is able to convert adenosine triphosphate (ATP) and Mg into luciferase. 2+ In the presence of luciferin, D-luciferin is converted to luciferin adenylate. In addition, pyrophosphate (PPi) and adenosine monophosphate (AMP) are produced as byproducts. The intermediate luciferin adenylate is then oxidized to oxyluciferin, carbon dioxide (CO2), and light. Oxyluciferin is a bioluminescent product that can be quantitatively measured in a luminometer by the light released from the reaction. Luciferase reporter assays are commercially available and known in the art, such as the Luciferase 1000 Assay System and the ONE-Glo TM Luciferase assay system.
[0115] "Response element" refers to a specific transcription factor binding element, or cis-acting element, that can activate or silence a transcription factor upon binding. In one embodiment, the response element is a cis-acting enhancer element located upstream of a minimal promoter (e.g., a TATA box promoter) that drives reporter gene expression upon transcription factor binding.
[0116] As used herein, the term "single-chain" refers to a molecule comprised of amino acid monomers linearly linked by peptide bonds. In certain embodiments, one of the antigen-binding moieties is a scFv fragment, i.e., a VH domain and a VL domain connected by a peptide linker. In certain embodiments, one of the antigen-binding moieties is a single-chain Fab molecule, i.e., a Fab molecule in which a Fab light chain and a Fab heavy chain are connected by a peptide linker to form a single peptide chain. In a specific such embodiment, in the single-chain Fab molecule, the C-terminus of the Fab light chain is linked to the N-terminus of the Fab heavy chain.
[0117] As used herein, the term "SSD" refers to stimulatory signaling domain.
[0118] As used herein, "treatment" (and grammatical variations thereof) refers to an attempt to alter the natural course of a disease in a treated individual and can be a clinical intervention performed for prevention or during the course of clinical pathology. Desirable effects of treatment include, but are not limited to, preventing the occurrence or recurrence of the disease, alleviating symptoms, reducing any direct or indirect pathological consequences of the disease, preventing metastasis, slowing the rate of disease progression, ameliorating or palliating the disease state, and regression or improved prognosis.
[0119] As used herein, the term "target antigenic determinant" is synonymous with "target antigen," "target epitope," "tumor-associated antigen," and "target cell antigen," and refers to the site on a polypeptide macromolecule (e.g., a continuous stretch of amino acids or a conformational configuration consisting of distinct regions of discontinuous amino acids) that binds to an antibody, thereby forming an antigen-binding moiety-antigen complex. Useful antigenic determinants can be found, for example, on the surface of tumor cells, on the surface of virus-infected cells, on the surface of other diseased cells, on the surface of immune cells, free in blood serum, and / or in the extracellular matrix (ECM). Unless otherwise indicated, proteins referred to herein as antigens (e.g., CD20, CEA, FAP, TNC) can be any native form of the protein from any vertebrate source, including mammals such as primates (e.g., humans) and rodents (e.g., mice and rats). In a specific embodiment, the target antigen is a human protein. When reference is made to a specific target protein herein, the term encompasses the "full-length," unprocessed target protein as well as any form of the target protein that results from processing in the target cell. The term also encompasses naturally occurring variants of the target protein, such as splice variants or allelic variants. Exemplary human target proteins that can be used as antigens include, but are not limited to: CD20, CEA, FAP, TNC, MSLN, FolR1, HER1, and HER2. The ability of an antigen-binding receptor (e.g., CAR) to bind to a specific target antigenic determinant can be measured via enzyme-linked immunosorbent assay (ELISA) or other techniques familiar to those skilled in the art, such as surface plasmon resonance (SPR) technology (analyzed on a BIAcore instrument) (Liljeblad et al., Glyco J 17, 323-329 (2000)) and traditional binding assays (Heeley, Endocr Res 28, 217-229 (2002)). In one embodiment, the extent to which the antigen-binding receptor binds to an unrelated protein is less than about 10% of the binding of the antibody to the target antigen, as measured, for example, by SPR. In certain embodiments, the antigen binding receptor that binds to the target antigen has a specific activity of ≤1 μM, ≤100 nM, ≤10 nM, ≤1 nM, ≤0.1 nM, ≤0.01 nM, or ≤0.001 nM (e.g., 10 -8 M or smaller, such as 10 -8 M to 10 -13M, for example 10 -9 M to 10 -13 The affinity dissociation constant (K D ).
[0120] As used herein, "T cell activation" refers to one or more cellular responses of T lymphocytes, particularly cytotoxic T lymphocytes, selected from the group consisting of proliferation, differentiation, cytokine secretion, cytotoxic effector molecule release, cytotoxic activity, and expression of activation markers. Suitable assays for measuring T cell activation are known in the art described herein.
[0121] According to the present invention, the term "T cell receptor" or "TCR" is generally known in the art. In particular, the term "T cell receptor" herein refers to any T cell receptor that meets the following three criteria: (i) tumor specificity, (ii) recognition of (most) tumor cells, meaning that the antigen or target should be expressed on (most) tumor cells, and (iii) the TCR matches the HLA type of the subject to be treated. In this context, suitable T cell receptors that meet the above three criteria are known in the art, such as receptors that recognize NY-ESO-1 (sequence information see, for example, PCT / GB2005 / 001924) and / or HER2neu (sequence information see WO-A1 2011 / 0280894).
[0122] A "therapeutically effective amount" of an agent, such as a pharmaceutical composition, is an amount effective (at the necessary dosage and for the necessary period of time) to achieve the desired therapeutic or preventive result. A therapeutically effective amount of an agent, for example, eliminates, reduces, delays, minimizes, or prevents the adverse effects of a disease.
[0123] The term "vector" or "expression vector" is synonymous with "expression construct" and refers to a DNA molecule used to introduce a specific gene into a target cell and direct its expression in operative association with the gene. The term encompasses vectors that are autonomously replicating nucleic acid structures as well as vectors that are incorporated into the genome of a host cell into which they have been introduced. The expression vectors of the present invention comprise an expression cassette. Expression vectors allow for the transcription of large amounts of stable mRNA. Once within the target cell, the cellular transcription and / or translation machinery produces the ribonucleic acid molecule or protein encoded by the gene. In one embodiment, the expression vector of the present invention comprises an expression cassette comprising a polynucleotide sequence encoding an antigen-binding receptor of the present invention or a fragment thereof.
[0124] Provided herein are methods for selecting novel antigen binding moieties for further development based on their specificity, particularly with respect to activation of reporter cells (e.g., T cells) upon contact with target cells. In this context, the novel antigen binding moieties mediate contact between target cells (particularly cancer cells) and reporter cells (particularly T cells). In one embodiment, provided are methods for evaluating the specificity of antigen binding moieties comprising the following steps:
[0125] a) providing an antigen binding moiety specific for the target antigen;
[0126] b) Generation of chimeric antigen receptor (CAR)-expressing reporter T (CAR-T) cells by:
[0127] i. transferring the antigen binding moiety into a CAR carrier system operably coupled to a response element; and
[0128] ii. transferring the CAR vector system into reporter T cells comprising a reporter gene under the control of the response element;
[0129] c) contacting the reporter CAR-T cell with a target cell comprising the target antigen on its surface, particularly wherein the target cell is a cancer cell; and
[0130] d) determining T cell activation by measuring expression of the reporter gene to establish the specificity of the antigen binding moiety.
[0131] Immunoglobulins typically include variable and constant domains capable of stable folding, wherein the variable domains confer specificity to the immunoglobulin molecule for the target antigen. The specificity of the candidate antigen binding module (e.g., for the target antigen on tumor cells) can be transferred to different antigen binding molecules (e.g., CAR) by transferring the variable domains of the candidate antigen binding module. Such transfer is known in the art and can be performed, for example, by subcloning the coding region of the candidate antigen binding module into different DNA vector systems (e.g., CAR vector systems as described herein). For this purpose, suitable recombinant DNA technology is widely used in the art, and it is straightforward to transfer from one vector system to another. However, it may be appropriate to transfer the variable domains (particularly VH and VL domains) of an antigen binding compound (e.g., immunoglobulin) into an antigen binding module (e.g., Fab to Fab, cross Fab, or scFab) of an antigen binding receptor containing a similar antigen binding pattern to retain binding characteristics and generate a meaningful assay system. Thus, provided herein is a method using different CAR types (e.g., scFv, Fab, cross Fab, and scFab; scFv to scFv), which can be selected according to the type of the source immunoglobulin. After the VH and VL domains are transferred into the CAR vector system, cells transfected or transduced with the CAR vector system become reactive against a target antigen, such as a target antigen on a tumor cell. Activation of the CAR vector system upon binding of the antigen-binding moiety of the CAR to the target antigen on the tumor cell results in activation of a reporter gene, which can be measured.
[0132] This approach has significant advantages over conventional binding assays because, without being bound by theory, the T cell-based system described herein more closely resembles the in vivo situation encountered by, for example, T cell-engaging therapeutic antibodies (e.g., T cell bispecific antibodies).
[0133] Thus, the present invention provides a universal screening platform in which an engineered CAR comprising an antigen binding module can be used to identify novel antigen binding modules for target cells (e.g., tumor cells). After binding to a target antigen (e.g., a tumor-associated antigen) on the surface of a tumor cell, the T cell becomes activated, where activation can be measured, for example, by reading out a fluorescent or luminescent signal. By allowing the use of a variety of newly developed target antigen binding modules, the platform has flexibility and specificity.
[0134] In the context of the present invention, CARs comprise an extracellular domain that does not naturally occur in or on T cells. Thus, according to the methods described herein for evaluating the binding and functionality of novel antigen-binding moieties, CARs can provide tailored binding specificity to a recognition domain, such as a target antigen of a tumor cell. Cells (e.g., T cells) transduced with CARs and used in accordance with the present invention become capable of specifically binding to a target antigen, i.e., specificity for the target antigen domain is provided by the antigen-binding moiety of the extracellular domain of the CAR.
[0135] In this context, an antigen binding receptor, such as a CAR, is provided that comprises an anchored transmembrane domain and an extracellular domain comprising an antigen binding moiety, wherein the antigen binding moiety is a Fab, cross-Fab or scFab fragment.
[0136] In certain embodiments, the antigen binding moiety is a Fab fragment, in particular a Fab fragment derived from a phage display library. In this context, the antigen binding moiety of the CAR carrier system is preferably also a Fab fragment. In such embodiments, preferably, the CAR comprises an antigen binding moiety, in particular wherein the antigen binding moiety of the CAR is a Fab fragment. In one embodiment, the antigen binding moiety comprises a variable heavy chain domain (VH) and a variable light chain domain (VL). In one embodiment, the VH and VL domains of the antigen binding moiety are transferred to the CAR.
[0137] Thus, in one embodiment, at least one antigen-binding moiety is a conventional Fab fragment, i.e., a Fab molecule composed of a Fab light chain and a Fab heavy chain. In one embodiment, at least one antigen-binding moiety is a crossover Fab fragment, i.e., a Fab molecule composed of a Fab light chain and a Fab heavy chain, in which the variable or constant regions of the Fab heavy and light chains are swapped. In one embodiment, at least one antigen-binding moiety is an scFv fragment. In a specific embodiment, in the scFv molecule, the C-terminus of the variable heavy chain (VH) is linked to the N-terminus of the variable light chain (VL), optionally via a peptide linker. In certain embodiments, at least one antigen-binding moiety is a single-chain Fab molecule, i.e., a Fab molecule in which the Fab light chain and the Fab heavy chain are linked by a peptide linker to form a single peptide chain. In a specific such embodiment, in the single-chain Fab molecule, the C-terminus of the Fab light chain is linked to the N-terminus of the Fab heavy chain, optionally via a peptide linker.
[0138] Antigen binding moieties that can specifically bind to a target antigen, such as a tumor-associated antigen, can be generated, for example, by immunization of the mammalian immune system. Such methods are known in the art and are described, for example, in Burns, Methods in Molecular Biology 295: 1-12 (2005). Alternatively, the antigen binding moieties of the present invention can be isolated by screening combinatorial libraries for antibodies having one or more desired activities. Methods for screening combinatorial libraries are reviewed, for example, in Lerner et al., Nature Reviews 16: 498-508 (2016). For example, a variety of methods are known in the art for generating phage display libraries and screening such libraries for antigen binding moieties having desired binding characteristics. Such methods are reviewed, for example, in Frenzel et al., mAbs 8: 1177-1194 (2016); Bazan et al., Human Vaccines and Immunotherapeutics 8: 1817-1828 (2012) and Zhao et al., Critical Reviews in Biotechnology 36: 276-289 (2016) and Hoogenboom et al., Methods in Molecular Biology 178: 1-37 (O'Brien et al., ed., Human Press, Totowa, NJ, 2001) and further described, for example, in McCafferty et al., Nature 348: 552-554; Clackson et al., Nature 352: 624-628 (1991); Marks et al., Nature 353: 626-628 (1992); al., J. Mol. Biol. 222: 581-597 (1992) and Marks and Bradbury in Methods in Molecular Biology 248: 161-175 (Lo, ed., Human Press, Totowa, NJ, 2003); Sidhu et al. al., J.Mol.Biol.338(2):299-310(2004); Lee et al., J.Mol.Biol.340(5):1073-1093(2004); Fellouse, Proc.Natl.Acad.Sci.USA 101(34):12467-12472(2004); and Lee et al., J. Immunol. Methods 284(1-2):119-132(2004).In certain phage display methods, repertoires of VH and VL genes are cloned separately by polymerase chain reaction (PCR) and randomly recombined in phage libraries, which can then be screened for antigen-binding phage, as described in Winter et al., Annual Review of Immunology 12:433-455 (1994). Phage typically display antibody fragments as either single-chain Fv (scFv) fragments or Fab fragments. Libraries from immunized sources provide high-affinity antigen-binding modules for the immunogen without the need for hybridoma construction. Alternatively, non-immunized repertoires can be cloned (e.g., from humans) to provide a single source of antigen-binding modules for a wide range of non-self, as well as self, antigens, without the need for any immunization, as described in Griffiths et al., EMBO Journal 12:725-734 (1993). Finally, unimmunized libraries can also be generated synthetically by cloning unrearranged V gene segments from stem cells and using PCR primers containing random sequences to encode highly variable CDR3 regions and achieve in vitro rearrangement, as described in Hoogenboom and Winter, Journal of Molecular Biology 227:381-388 (1992). Patent publications describing human antibody phage libraries include, for example, U.S. Patent Nos. 5,750,373; 7,985,840; 7,785,903 and 8,679,490 and U.S. Patent Publication Nos. 2005 / 0079574, 2007 / 0117126, 2007 / 0237764 and 2007 / 0292936, and 2009 / 0002360. Other examples of methods known in the art for screening combinatorial libraries for antigen-binding modules with one or more desired activities include ribosome and mRNA display, and methods for antibody display and selection on bacteria, mammalian cells, insect cells, or yeast cells. Methods for yeast surface display are reviewed in, for example, Scholler et al., Methods in Molecular Biology 503: 135-56 (2012) and Cherf et al., Methods in Molecular biology 1319: 155-175 (2015) and Zhao et al., Methods in Molecular Biology 889: 73-84 (2012). Methods for ribosome display are described in, for example, He et al., Nucleic Acids Research 25: 5132-5134 (1997) and Hanes et al., PNAS 94: 4937-4942 (1997).A particular advantage of the methods of the present invention is the straightforward integration and characterization of library-derived antigen-binding moieties without the need to change format, for example, Fab antigen binders derived from screened phage display libraries can be included in Fab and / or cross-Fab formats as described herein. Thus, antigen-binding moieties derived from Fab display phage libraries can be included in antigen-binding receptors described herein, such as CARs, without the need to change format to, for example, scFv format, which may affect the binding properties of the library-derived binders.
[0139] In the context of the present invention, provided herein are CARs comprising an antigen binding moiety that can specifically bind to a target antigen, i.e., a tumor-associated antigen. Thus, transduced cells, i.e., T cells, expressing a CAR as described herein can specifically bind to tumor cells.
[0140] In an exemplary embodiment of the present invention, as a proof of concept, a CAR capable of specifically binding to CD20 and a reporter cell expressing the antigen-binding receptor are provided. The target cell is a cell type that expresses the CD20 polypeptide and specifically expresses or overexpresses the CD20 polypeptide. The cell can be a cancerous or normal cell of a specific cell type. The cell can be a normal B cell involved in autoimmunity. In one embodiment, the cell is a cancer cell, preferably a malignant B cell. Other tumor-associated antigens can be targeted using the CAR described herein.
[0141] Thus, in a specific embodiment, the extracellular domain of the CAR comprises an antigen binding moiety capable of specifically binding to CD20, wherein the antigen binding moiety comprises:
[0142] (i) a heavy chain variable region (VH), comprising
[0143] (a) heavy chain complementarity determining region (CDR H) 1 amino acid sequence YSWIN (SEQ ID NO: 1);
[0144] (b) CDR H2 amino acid sequence RIFPGDGDTDYNGKFKG (SEQ ID NO: 2); and
[0145] (c) CDR H3 amino acid sequence NVFDGYWLVY (SEQ ID NO: 3); and
[0146] (ii) a light chain variable region (VL), which comprises
[0147] (d) light chain complementarity determining region (CDR L) 1 amino acid sequence RSSKSLLHSNGITYLY (SEQ ID NO: 4);
[0148] (e) CDR L2 amino acid sequence QMSNLVS (SEQ ID NO: 5); and
[0149] (f) CDR L3 amino acid sequence AQNLELPYT (SEQ ID NO: 6).
[0150] In one embodiment, the extracellular domain of the CAR comprises an antigen binding moiety capable of specifically binding to CD20, wherein the antigen binding moiety comprises a heavy chain variable region (VH) comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: 12 and a light chain variable region (VL) comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: 10.
[0151] In one embodiment, the extracellular domain of the CAR comprises an antigen binding moiety capable of specifically binding to CD20, wherein the antigen binding moiety comprises a heavy chain variable region (VH) of SEQ ID NO: 12 and a light chain variable region (VL) of SEQ ID NO: 10.
[0152] In one embodiment, the antigen binding moiety is a Fab, crossover Fab or scFab fragment.
[0153] In a preferred embodiment, the extracellular domain of the CAR comprises an antigen binding moiety capable of specifically binding to CD20, wherein the antigen binding moiety is a Fab fragment.
[0154] In one embodiment, the extracellular domain of the CAR comprises an antigen binding moiety capable of specifically binding to CD20, wherein the Fab fragment comprises a heavy chain of SEQ ID NO: 8 and a light chain of SEQ ID NO: 9.
[0155] In one embodiment, the antigen binding moiety of the CAR is a scFv fragment, which is a polypeptide consisting of a heavy chain variable domain (VH), a light chain variable domain (VL) and a linker, wherein the variable domain and the linker have one of the following structures in the N-terminal to C-terminal direction: a) VH-linker-VL or b) VL-linker-VH. In a preferred embodiment, the scFv fragment has the structure VH-linker-VL.
[0156] In certain embodiments, the CAR as used herein comprises an extracellular domain comprising an antigen binding moiety capable of specifically binding to a target antigen, an anchoring transmembrane domain, and at least one intracellular signaling and / or at least one co-stimulatory signaling domain. Thus, in one embodiment, the CAR vector system used in accordance with the present invention encodes a CAR comprising an antigen binding moiety, an anchoring transmembrane domain, and at least one intracellular signaling and / or co-signaling domain. The anchoring transmembrane domain of the CAR may be characterized in that it does not have a cleavage site for a mammalian protease. A protease refers to a proteolytic enzyme capable of hydrolyzing the amino acid sequence of a transmembrane domain comprising a cleavage site for a protease. The term protease includes both endopeptidases and exopeptidases. In the context of the present invention, any anchoring transmembrane domain of a transmembrane protein as defined by the CD nomenclature, etc., can be used to generate a CAR used in accordance with the present invention, which activates T cells, preferably CD8+ T cells, after binding to an antigen as defined herein.
[0157] Thus, in the context of the present invention, the anchoring transmembrane domain may comprise a portion of a murine / mouse or preferably human transmembrane domain. An example of such an anchoring transmembrane domain is the transmembrane domain of CD28, for example having an amino acid sequence as shown herein in SEQ ID NO: 14 (as encoded by the DNA sequence as shown in SEQ ID NO: 29). In the context of the present invention, the transmembrane domain of a CAR may comprise / consist of an amino acid sequence as shown in SEQ ID NO: 14 (as encoded by the DNA sequence as shown in SEQ ID NO: 29).
[0158] In an exemplary embodiment of the present invention, as a proof of concept, a CAR is provided comprising the amino acid sequence of SEQ ID NO: 7 (as encoded by the DNA sequence shown in SEQ ID NO: 22) and comprising a fragment / polypeptide portion of CD28 as shown herein as SEQ ID NO: 73 (as encoded by the DNA sequence shown in SEQ ID NO: 72) (the Uniprot entry number for human CD28 is P10747 (version number 173 and version 1 of the sequence)). Alternatively, any protein having a transmembrane domain as provided by CD nomenclature, etc., can be used as the anchor transmembrane domain of the antigen-binding receptor protein of the present invention. As described above, the CAR provided herein can comprise the anchor transmembrane domain of CD28, which is located at the human full-length CD28 protein as shown in SEQ ID NO: 69 (as encoded by the DNA sequence shown in SEQ ID NO: 72). 179, 170 to 179, 171 to 179, 172 to 179, 173 to 179, 174 to 179, 175 to 179, 176 to 179, 177 to 179 or 178 to 179 of the present invention. Thus, in the context of the present invention, the anchor transmembrane domain may comprise or consist of the amino acid sequence as shown in SEQ ID NO: 14 (as encoded by the DNA sequence shown in SEQ ID NO: 29).
[0159] As described herein, the CAR used in accordance with the present invention comprises at least one stimulatory signaling domain and / or at least one co-stimulatory signaling domain to transduce the binding of the CAR's antigen binding moiety to the target antigen into an intracellular signal in the CAR-T cell. Thus, the CAR described herein preferably comprises a stimulatory signaling domain that provides T cell activation. The CAR described herein may comprise a stimulatory signaling domain that is a fragment / polypeptide portion of murine / mouse or human CD3z (UniProt entry for human CD3z is P20963 (version number 177 and sequence number 2; UniProt entry for murine / mouse CD3z is P24161 (primary citable accession number) or Q9D3G3 (secondary citable accession number) version number 143 and sequence number 1)), FCGR3A (UniProt entry for human FCGR3A is P08637 (version number 178 and sequence number 2)), or NKG2D (UniProt entry for human NKG2D is P26718 (version number 151 and sequence number 1); UniProt entry for murine / mouse NKG2D is O54709 (version number 132 and sequence number 2)).
[0160] Thus, the stimulatory signaling domain included in the CARs described herein can be a fragment / polypeptide portion of full-length CD3z, FCGR3A, or NKG2D. The amino acid sequence of murine / mouse full-length CD3z is shown herein as SEQ ID NO:70 (murine / mouse, as encoded by the DNA sequence shown in SEQ ID NO:71). The amino acid sequence of human full-length CD3z is shown herein as SEQ ID NO:68 (human, as encoded by the DNA sequence shown in SEQ ID NO:69). CARs used in accordance with the present invention may include a fragment of CD3z, FCGR3A, or NKG2D as a stimulatory domain, provided that it includes at least one signaling domain. In particular, any portion / fragment of CD3z, FCGR3A, or NKG2D is suitable as a stimulatory domain, as long as it includes at least one signaling motif. However, more preferably, the CARs of the present invention include a polypeptide derived from human origin. Preferably, the CARs described herein include the amino acid sequence shown herein as SEQ ID NO:68 (CD3z) (human, as encoded by the DNA sequence shown in SEQ ID NO:69). For example, a fragment / polypeptide portion of human CD3 zeta that can be included in a CAR for use according to the present invention can comprise or consist of the amino acid sequence shown in SEQ ID NO: 16 (e.g., encoded by the DNA sequence shown in SEQ ID NO: 31). Thus, in one embodiment, the CAR comprises a sequence as shown in SEQ ID NO: 16 or a sequence having up to 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 23, 24, 25, 26, 27, 28, 29 or 30 substitutions, deletions or insertions compared to SEQ ID NO: 16 and characterized in that it has stimulatory signaling activity. Specific configurations of CARs comprising a stimulatory signaling domain (SSD) are provided herein below and in the Examples and Figures. Stimulatory signaling activity can be measured; for example, by enhanced cytokine release (as measured by ELISA (IL-2, IFNγ, TNFα)), enhanced proliferative activity (as measured by increased cell number), or enhanced lytic activity (as measured by LDH release assay).
[0161] The CAR used in accordance with the present invention preferably comprises at least one co-stimulatory signaling domain that provides additional activity to T cells. The CAR described herein may comprise a co-stimulatory signaling domain that is mouse or human CD28 (the UniProt entry for human CD28 is P10747 (version number 173 and sequence number 1); the UniProt entry for mouse / mouse CD28 is P31041 (version number 134 and sequence number 2)), CD137 (the UniProt entry for human CD137 is Q07011 (version number 145 and sequence number 1); the UniProt entry for mouse / mouse CD137 is P20334 (version number 139 and sequence number 1)), OX40 (UniProt entry for human OX40 is P23510 (version 138 and sequence number 1); UniProt entry for rat / mouse OX40 is P43488 (version 119 and sequence number 1)), ICOS (UniProt entry for human ICOS is Q9Y6W8 (version 126 and sequence number 1)); UniProt entry for rat / mouse ICOS is Q9WV40 (primary citable accession number) or Q9JL17 (secondary citable accession number) version 102 and sequence number 2)), CD27 (human The UniProt entry for CD27 is P26842 (version 160 and sequence number 2); the UniProt entry for mouse / mouse CD27 is P41272 (version 137 and sequence version 1)), 4-1-BB (the UniProt entry for mouse / mouse 4-1-BB is P20334 (version 140 and sequence version 1); the UniProt entry for human 4-1-BB is Q07011 (version 146 and sequence version)), DAP10 (the UniProt entry for human DAP10 is Q9UBJ5 (version No. 25 and SEQ ID NO: 1); the UniProt entry for murine / mouse DAP10 is Q9QUJ0 (primary citable accession number) or Q9R1E7 (secondary citable accession number) version 101 and SEQ ID NO: 1) or DAP12 (the UniProt entry for human DAP12 is O43914 (version 146 and SEQ ID NO: 1); the UniProt entry for murine / mouse DAP12 is O054885 (primary citable accession number) or Q9R1E7 (secondary citable accession number) version 123 and a fragment / polypeptide portion of said sequence number 1). In certain embodiments of the present invention, the CAR used in accordance with the present invention may comprise one or more, i.e., 1, 2, 3, 4, 5, 6, or 7, costimulatory signaling domains as defined herein.Thus, in the context of the present invention, the CAR may comprise a fragment / polypeptide portion of murine / mouse or preferably human CD28 as the first costimulatory signaling domain and the second costimulatory signaling domain may be selected from the group consisting of murine / mouse or preferably human CD27, CD28, CD137, OX40, ICOS, DAP10 and DAP12, or fragments thereof. Preferably, the CAR used in accordance with the present invention comprises a costimulatory signaling domain derived from human origin. Thus, more preferably, the costimulatory signaling domain comprised in the CAR may comprise or consist of the amino acid sequence shown in SEQ ID NO: 15 (as encoded by the DNA sequence shown in SEQ ID NO: 30).
[0162] Thus, the costimulatory signaling domain that can optionally be included in the CARs described herein is a fragment / polypeptide portion of full-length CD27, CD28, CD137, OX40, ICOS, DAP10, and DAP12. The amino acid sequence of murine / mouse full-length CD28 is shown herein as SEQ ID NO: 75 (murine / mouse, as encoded by the DNA sequence shown in SEQ ID NO: 74). However, because human sequences are most preferred in the context of the present invention, the costimulatory signaling domain that can optionally be included in the CARs described herein is a fragment / polypeptide portion of human full-length CD27, CD28, CD137, OX40, ICOS, DAP10, or DAP12. The amino acid sequence of human full-length CD28 is shown herein as SEQ ID NO: 73 (human, as encoded by the DNA sequence shown in SEQ ID NO: 72).
[0163] In a preferred embodiment, the CAR comprises CD28 or a fragment thereof as a co-stimulatory signaling domain. The CAR described herein may comprise a fragment of CD28 as a co-stimulatory signaling domain, provided that it comprises at least one signaling domain of CD28. In particular, any part / fragment of CD28 is suitable for the CAR as described herein, as long as it comprises at least one signaling motif of CD28. For example, the CD28 polypeptide contained in the CAR used in accordance with the present invention may comprise or consist of the amino acid sequence shown in SEQ ID NO: 15 (such as encoded by the DNA sequence shown in SEQ ID NO: 30). The intracellular domain of CD28 that functions as a co-stimulatory signaling domain may comprise a sequence derived from the intracellular domain of the CD28 polypeptide having the sequence YMNM (SEQ ID NO: 76) and / or PYAP (SEQ ID NO: 77). Preferably, the CAR comprises a polypeptide derived from human origin. For example, the fragment / polypeptide portion of human CD28 that can be included in the CAR can include or consist of the amino acid sequence shown in SEQ ID NO: 15 (e.g., encoded by the DNA sequence shown in SEQ ID NO: 30). Thus, in one embodiment, the CAR comprises a sequence as shown in SEQ ID NO: 15 or a sequence having up to 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 substitutions, deletions, or insertions compared to SEQ ID NO: 15 and characterized by having costimulatory signaling activity. Specific configurations of CARs comprising a costimulatory signaling domain (CSD) are provided herein below and in the Examples and Figures. Costimulatory signaling activity can be measured; for example, by enhanced cytokine release (e.g., as measured by ELISA (IL-2, IFNγ, TNFα)), enhanced proliferation activity (e.g., as measured by increased cell number), or enhanced lytic activity (e.g., as measured by LDH release assay).
[0164] As mentioned above, in one embodiment of the present invention, the co-stimulatory signaling domain of the CAR can be derived from the human CD28 gene (UniProt entry number: P10747 (accession number and entry version of this sequence: 173 and version 1)) and provide CD28 activity, defined as the cytokine production, proliferation and lytic activity of the transduced cells described herein, like the transduced T cells. CD28 activity can be measured by cytokine release by ELISA or flow cytometry of cytokines such as interferon gamma (IFN-γ) or interleukin 2 (IL-2), proliferation of T cells, for example, by ki67 measurement, cell quantification by flow cytometry, or lytic activity, as assessed by real-time impedance measurement of target cells (by using, for example, an ICELLligence instrument, as described in, for example, Thakur et al., Biosens Bioelectron. 35(1) (2012), 503-506; Krutzik et al., Methods Mol Biol. 699 (2011), 179-202; Ekkens et al., Infect Immun. 75(5) (2007), 2291-2296; Ge et al., Proc Natl Acad Sci US A. 99(5) (2002), 2983-2988; Düwell et al., Cell Death Differ.21(12)(2014), 1825-1837; Erratum, Cell Death Differ.21(12)(2014), 161). The co-stimulatory signaling domains PYAP and YMNM are beneficial to the function of the CD28 polypeptide and the functional effects listed above. The amino acid sequence of the YMNM domain is shown in SEQ ID NO:76; the amino acid sequence of the PYAP domain is shown in SEQ ID NO:77. Thus, in the antigen-binding receptor of the present invention, the CD28 polypeptide preferably comprises a sequence derived from the intracellular domain of the CD28 polypeptide having the sequence YMNM (SEQ ID NO:76) and / or PYAP (SEQ ID NO:77). These signaling motifs can be present at any site within the intracellular domain of the described CAR.
[0165] Moreover, the CAR described herein may comprise at least one linker (or "spacer"). A linker is typically a peptide having a length of up to 20 amino acids. Thus, in the context of the present invention, a linker may have a length of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 amino acids. For example, the CAR described herein may comprise a linker between an extracellular domain comprising an antigen binding moiety, an anchoring transmembrane domain, a costimulatory signaling domain and / or a stimulatory signaling domain. Such linkers have the advantage that they increase the probability that the different polypeptides of the CAR (i.e., the extracellular domain, the anchoring transmembrane domain, the costimulatory signaling domain and / or the stimulatory signaling domain) fold independently and behave as expected. Thus, in the context of the present invention, an extracellular domain comprising at least one antigen binding moiety, an anchoring transmembrane domain that does not have a cleavage site for a mammalian protease, a costimulatory signaling domain and a stimulatory signaling domain may be contained in a single multifunctional polypeptide chain. The fusion construct may, for example, be composed of one or more polypeptides comprising one or more extracellular domains comprising at least one antigen binding moiety, one or more anchoring transmembrane domains, one or more costimulatory signaling domains and / or one or more stimulatory signaling domains. In a preferred embodiment, the CAR comprises an antigen binding moiety that is not a single-chain construct, i.e., the antigen binding moiety is a Fab or cross-Fab fragment. Preferably, such a construct will comprise a single-chain heavy or light chain fusion polypeptide in combination with an immunoglobulin light or heavy chain as described herein, for example, a heavy chain fusion polypeptide comprising one or more immunoglobulin heavy chains, one or more anchoring transmembrane domains, one or more costimulatory signaling domains and / or one or more stimulatory signaling domains and in combination with one or more immunoglobulin light chains, or a light chain fusion polypeptide comprising one or more immunoglobulin light chains, one or more anchoring transmembrane domains, one or more costimulatory signaling domains and / or one or more stimulatory signaling domains and in combination with one or more immunoglobulin heavy chains. Thus, the antigen binding moiety, the anchoring transmembrane domain, the costimulatory signaling domain and the stimulatory signaling domain may be connected by one or more identical or different peptide linkers as described herein. For example, in the CAR described herein, the linker between the extracellular domain comprising the antigen binding moiety and the anchoring transmembrane domain may comprise or consist of an amino acid sequence as shown in SEQ ID NO: 20. Thus, the anchoring transmembrane domain, the costimulatory signaling domain and / or the stimulatory domain may be connected to each other via a peptide linker or by direct fusion of the domains.
[0166] In some embodiments, the antigen-binding moiety contained in the extracellular domain is a single-chain variable fragment (scFv), which is a fusion protein of the variable regions of the heavy (VH) and light (VL) chains of an antibody connected by a short linker peptide of 10 to about 25 amino acids. The linker is typically rich in glycine (for flexibility) and serine or threonine (for solubility) and can connect the N-terminus of the VH to the C-terminus of the VL, or vice versa. For example, the linker can have the amino acid sequence shown in SEQ ID NO: 19.
[0167] In some embodiments according to the present invention, the antigen binding moiety contained in the extracellular domain is a single-chain Fab fragment or scFab, which is a polypeptide consisting of a heavy chain variable domain (VH), an antibody constant domain 1 (CH1), an antibody light chain variable domain (VL), an antibody light chain constant domain (CL), and a linker, wherein the antibody domain and the linker have one of the following orders in the N-terminal to C-terminal direction: a) VH-CH1-linker-VL-CL, b) VL-CL-linker-VH-CH1, c) VH-CL-linker-VL-CH1, or d) VL-CH1-linker-VH-CL; and wherein the linker is a polypeptide of at least 30 amino acids, preferably between 32 and 50 amino acids. The single-chain Fab fragment is stabilized by a native disulfide bond between the CL domain and the CH1 domain.
[0168] In some embodiments, the antigen binding moiety contained in the extracellular domain is a crossover single-chain Fab fragment, which is a polypeptide consisting of an antibody heavy chain variable domain (VH), an antibody constant domain 1 (CH1), an antibody light chain variable domain (VL), an antibody light chain constant domain (CL) and a linker, wherein the antibody domain and the linker have one of the following orders in the N-terminal to C-terminal direction: a) VH-CL-linker-VL-CH1 and b) VL-CH1-linker-VH-CL; wherein VH and VL together form an antigen binding site that specifically binds to an antigen and wherein the linker is a polypeptide of at least 30 amino acids.
[0169] The CAR described herein or a portion thereof may include a signal peptide. Such a signal peptide brings the protein to the surface of the T cell membrane. For example, in the CAR described herein, the signal peptide may have an amino acid sequence as shown in SEQ ID NO: 78 (as encoded by the DNA sequence shown in SEQ ID NO: 79).
[0170] The components of the CAR as described herein can be fused to each other in a variety of configurations to generate a T cell activating CAR.
[0171] In some embodiments, CAR comprises an extracellular domain consisting of a heavy chain variable domain (VH) and a light chain variable domain (VL) connected to an anchor transmembrane domain. In some embodiments, the VH domain is fused to the N-terminus of the VL domain at the C-terminus, optionally via a peptide linker. In other embodiments, CAR further comprises a stimulatory signaling domain and / or a costimulatory signaling domain. In a specific embodiment of this type, CAR is essentially composed of a VH domain and a VL domain connected by one or more peptide linkers, an anchor transmembrane domain, and an optional stimulatory signaling domain, wherein the VH domain is fused to the N-terminus of the VL domain at the C-terminus, and the VL domain is fused to the N-terminus of the anchor transmembrane domain at the C-terminus, wherein the anchor transmembrane domain is fused to the N-terminus of the stimulatory signaling domain at the C-terminus. Optionally, CAR further comprises a costimulatory signaling domain. In one such specific embodiment, the antigen-binding receptor consists essentially of a VH domain and a VL domain connected by one or more peptide linkers, an anchor transmembrane domain, a stimulatory signaling domain, and a costimulatory signaling domain, wherein the VH domain is fused at the C-terminus to the N-terminus of the VL domain, and the VL domain is fused at the C-terminus to the N-terminus of the anchor transmembrane domain, wherein the anchor transmembrane domain is fused at the C-terminus to the N-terminus of the stimulatory signaling domain, and wherein the stimulatory signaling domain is fused at the C-terminus to the N-terminus of the costimulatory signaling domain. In an alternative embodiment, the costimulatory signaling domain is connected to the anchor transmembrane domain in place of the stimulatory signaling domain. In a preferred embodiment, the CAR consists essentially of a VH domain and a VL domain connected by one or more peptide linkers, an anchor transmembrane domain, a costimulatory signaling domain, and a stimulatory signaling domain, wherein the VH domain is fused at the C-terminus to the N-terminus of the VL domain, and the VL domain is fused at the C-terminus to the N-terminus of the anchor transmembrane domain, wherein the anchor transmembrane domain is fused at the C-terminus to the N-terminus of the costimulatory signaling domain, and wherein the costimulatory signaling domain is fused at the C-terminus to the N-terminus of the stimulatory signaling domain.
[0172] In a preferred embodiment, the antigen binding moiety is a Fab fragment or a cross Fab fragment. In a preferred embodiment, the antigen binding moiety is fused to the N-terminus of the anchor transmembrane domain at the C-terminus of the Fab or cross Fab heavy chain, optionally via a peptide linker. In an alternative embodiment, the antigen binding moiety is fused to the N-terminus of the anchor transmembrane domain at the C-terminus of the Fab or cross Fab light chain, optionally via a peptide linker. In other embodiments, the CAR further comprises a stimulatory signaling domain and / or a costimulatory signaling domain. In a specific embodiment of this type, the CAR is essentially composed of a Fab or cross Fab fragment connected by one or more peptide linkers, an anchor transmembrane domain, and optionally a stimulatory signaling domain, wherein the Fab or cross Fab fragment is fused to the N-terminus of the anchor transmembrane domain at the C-terminus of the heavy or light chain, wherein the anchor transmembrane domain is fused to the N-terminus of the stimulatory signaling domain at the C-terminus. Preferably, the CAR further comprises a costimulatory signaling domain. In one such embodiment, the CAR consists essentially of a Fab or crossover Fab fragment, an anchor transmembrane domain, a stimulatory signaling domain, and a costimulatory signaling domain connected by one or more peptide linkers, wherein the Fab or crossover Fab fragment is fused at the C-terminus of the heavy or light chain to the N-terminus of the anchor transmembrane domain, wherein the stimulatory signaling domain is fused at the C-terminus to the N-terminus of the costimulatory signaling domain. In a preferred embodiment, the costimulatory signaling domain is connected to the anchor transmembrane domain instead of the stimulatory signaling domain. In a most preferred embodiment, the CAR consists essentially of a Fab or crossover Fab fragment, an anchor transmembrane domain, a costimulatory signaling domain, and a stimulatory signaling domain, wherein the Fab or crossover Fab fragment is fused at the C-terminus of the heavy chain to the N-terminus of the anchor transmembrane domain via a peptide linker, wherein the anchor transmembrane domain is fused at the C-terminus to the N-terminus of the costimulatory signaling domain, wherein the costimulatory signaling domain is fused at the C-terminus to the N-terminus of the stimulatory signaling domain.
[0173] As described herein, the CAR used in accordance with the present invention comprises an extracellular domain comprising an antigen binding moiety. A CAR having an antigen binding moiety capable of specifically binding to a target cell antigen is useful and preferred, particularly in situations where high expression of the CAR is desired. In such cases, the presence of more than one antigen binding moiety specific for a target cell antigen may limit the expression efficiency of the CAR. However, in other cases, it may be advantageous to have a CAR comprising two or more antigen binding moieties specific for a target cell antigen, for example, in order to optimize targeting to a target site or to allow cross-linking of a target cell antigen.
[0174] In a specific embodiment, the antigen binding moiety is a Fab fragment capable of specific binding to CD20, wherein the antigen binding receptor comprises a heavy chain fusion polypeptide comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: 7 and a light chain polypeptide comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: 9.
[0175] In a specific embodiment, the antigen binding moiety is a Fab fragment capable of specific binding to CD20, wherein the antigen binding receptor comprises a light chain fusion polypeptide comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: 50 and a heavy chain polypeptide comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: 8.
[0176] In a preferred embodiment, the antigen binding moiety is a Fab fragment capable of specifically binding to CD20, wherein the antigen binding receptor comprises a light chain fusion polypeptide comprising the amino acid sequence of SEQ ID NO: 7 and a heavy chain polypeptide comprising the amino acid sequence of SEQ ID NO: 9.
[0177] In the context of the present invention, binding of a target antigen to a T cell, such as a reporter CAR-T cell, results in activation of intracellular signaling and / or a co-signaling domain. As described herein, in one embodiment, activation of intracellular signaling and / or a co-signaling domain results in activation of a response element as described herein. In a preferred embodiment, the response element controls expression of a reporter gene. In this context, upon or after the antigen binding moiety of the CAR binds to the target antigen, the response element activates expression of a reporter gene as described herein. Thus, when a CAR comprising a candidate antigen binding moiety binds to the target antigen, the reporter gene is expressed in the reporter cell (e.g., a CAR-T reporter cell). In one embodiment, expression of the reporter gene indicates binding of the antigen binding moiety to the target antigen. In this context, binding of the target antigen to the CAR triggers a cellular response that results in regulation of the activity of the response element, either directly or via a cascade of cell signaling. A response element is a DNA element that can be silenced or activated by a transcription factor or the like. Response elements are known in the art and commercially available, for example, in reporter vectors. Typically, the response element comprises a DNA repeat element and is a cis-acting enhancer element located upstream of a minimal promoter that drives expression of the reporter gene upon transcription factor binding.
[0178] The binding of CAR to a target antigen, such as a tumor-associated antigen, activates the response element. In one embodiment, the response element is a nuclear response element located in the cell nucleus. In another embodiment, the response element is located on a plasmid in the reporter cell. In one embodiment, the assay comprises a preliminary step of transfecting the reporter cell (e.g., CAR-T cell) with an expression vector comprising a DNA sequence encoding a reporter gene under the control of the response element. In addition, the reporter cell can be transfected with an expression vector comprising a DNA sequence encoding a CAR. The reporter cell can be transfected with an expression vector comprising all elements of the signal transduction cascade (e.g., CAR, response element, and reporter gene) or with different vectors expressing different components. In one embodiment, the reporter cell comprises a DNA sequence encoding a reporter gene under the control of the response element and a DNA sequence encoding a CAR.
[0179] Thus, as described herein, the CAR is functionally linked to a response element. In one embodiment, the response element controls expression of a reporter gene. In one embodiment, activation of the response element results in expression of the reporter gene. In one embodiment, the response element is part of the NFAT pathway, the NF-κB pathway, or the AP-1 pathway. In a preferred embodiment, the response element is part of the NFAT pathway.
[0180] In one embodiment, the reporter gene is selected from a gene encoding a fluorescent protein or a gene encoding an enzyme whose catalytic activity can be detected. In one embodiment, the reporter gene encodes a fluorescent or luminescent protein. In one embodiment, the reporter gene encodes green fluorescent protein (GFP) or luciferase. In yet another embodiment, the fluorescent protein is selected from the group consisting of green fluorescent protein (GFP), yellow fluorescent protein (YFP), red fluorescent protein (RFP), blue fluorescent protein (BFP, Heim et al. 1994, 1996), a cyan fluorescent variant called CFP (Heim et al. 1996; Tsien 1998); a yellow fluorescent variant called YFP (Ormo et al. 1996; Wachter et al. 1998); a violet excitable green fluorescent variant called Sapphire (Tsien 1998; Zapata-Hommer et al. 2003); and a cyan excitable green fluorescent variant called enhanced green fluorescent protein or EGFP (Yang et al. 1996) Enhanced green fluorescent protein (EGFP) and can be measured, for example, by live cell imaging (e.g., Incucyte) or fluorescence spectrophotometry. In one embodiment, the enzyme whose catalytic activity can be detected is selected from the group consisting of luciferase, β-galactosidase, and alkaline phosphatase. In one embodiment, the reporter gene encodes GFP. In a preferred embodiment, the reporter gene encodes luciferase. Detection of the luciferase activity can be performed using commercially available assays, such as the Luciferase 1000 Assay System or the ONE-Glo TM Luciferase activity is detected using a luciferase assay system (both from Promega). In addition to luciferin as a substrate, the Luciferase 1000 assay system contains coenzyme A (CoA), resulting in a strong light intensity that lasts for at least one minute. To measure intracellular luciferase, cells must be lysed before detection. Light generated as a byproduct of the reaction is collected across the entire visible spectrum by a luminometer. In the examples presented herein, the signal is proportional to the amount of luciferase generated and, therefore, proportional to the intensity of activation of the NFAT promoter used. In another embodiment, a luciferase assay is used in which luciferase is secreted from cells; therefore, the assay can also be performed without lysing the cells.
[0181] Further described herein are transduced T cells capable of expressing a CAR as described herein, i.e., reporter CAR-T cells. A CAR is a molecule not naturally contained within and / or on the surface of a T cell and not expressed (endogenously) in or on normal (non-transduced) T cells. Thus, a CAR as described herein is artificially introduced into and / or on a T cell. Thus, the CAR as described herein, artificially introduced and subsequently presented on and / or on the surface of the T cell, e.g., a reporter CAR-T cell, comprises a domain comprising one or more antigen-binding moieties accessible (in vitro or in vivo) to an antigen presented on the surface of a target cell, particularly a tumor cell. Additionally, the T cell comprises or is transfected with an expression vector comprising a DNA sequence encoding a reporter gene under the control of a response element, e.g., for generating a reporter CAR-T cell as described herein. T cells can be transfected with an expression vector comprising all elements of the signaling cascade (e.g., a CAR, a response element, and a reporter gene), or with separate vectors expressing different components. In this context, the reporter cell comprises a DNA sequence encoding a reporter gene under the control of a response element and a DNA sequence encoding a CAR. Thus, after transduction, T cells as described herein, such as reporter CAR-T cells, can be activated by the target antigen, in particular by the target antigen of the antigen binding moiety. Also described herein are transduced T cells expressing a CAR encoded by one or more nucleic acid molecules encoding a CAR as described herein. Thus, in the context of the present invention, the transduced cells may comprise nucleic acid molecules encoding a CAR and / or a response element and a reporter gene as described herein.
[0182] In the context of the present invention, the term "transduced T cell" refers to a genetically modified T cell (i.e., a T cell into which a nucleic acid molecule has been intentionally introduced). In particular, a nucleic acid molecule encoding a CAR, a response element, and a reporter gene as described herein can be stably integrated into the genome of a T cell using retroviral or lentiviral transduction. The extracellular domain of the CAR can comprise the entire extracellular domain of an antigen binding moiety as described herein, but can also be a portion thereof. The minimum size required is the antigen binding site of the antigen binding moiety in the CAR. The extracellular portion of the CAR can be detected on the cell surface, while the intracellular portion (i.e., the costimulatory signaling domain and the stimulatory signaling domain) is not detected on the cell surface. The extracellular domain of the CAR can be detected by using an antibody that specifically binds to this extracellular domain or by using a recognition domain to which the antigen binding moiety can bind, such as a target antigen. These antibodies or antigens can be used to detect the extracellular domain by flow cytometry or microscopy.
[0183] The transduced cells can be any immune cells. These include, but are not limited to, B cells, T cells, natural killer (NK) cells, natural killer (NK) T cells, γδ T cells, innate lymphoid cells, macrophages, monocytes, dendritic cells, or neutrophils and immortalized cell lines thereof. Preferably, the immune cells are lymphocytes, preferably NK or T cells. The T cells include CD4+ T cells and CD8+ T cells. Triggering the CAR on the surface of the leukocytes will make the cells responsive to the target cells, regardless of the lineage of the cell origin. Activation will occur regardless of the stimulatory signaling domain or co-stimulatory signaling domain selected for the CAR and is independent of the exogenous supply of additional cytokines.
[0184] In the Examples and as proof of concept for the inventive concepts of the present invention, an activation assay based on Jurkat NFAT reporter CAR-T cells is described. In one embodiment, the reporter cells are Jurkat NFAT cells. Jurkat cells are an immortalized human T lymphocyte cell line. The Jurkat NFAT cell line is known in the art and contains the firefly luciferase gene under the control of an NFAT response element stably integrated into the cells. In accordance with the inventive concepts described herein and as proof of concept, Jurkat NFAT cells are transduced with a CAR as described herein and in the accompanying Examples to generate Jurkat NFAT reporter CAR-T cells as described herein and used in accordance with the present invention. Thus, in a preferred embodiment, the Jurkat NFAT cells further comprise a CAR as described herein, i.e., these cells are referred to as Jurkat NFAT reporter CAR-T cells.
[0185] In this context, cells can be co-transduced with additional nucleic acid molecules, e.g., nucleic acid molecules encoding a CAR and / or a response element and / or a reporter gene as described herein.
[0186] Specifically, the present invention relates to a method for generating reporter CAR-T cells expressing one or more CARs and one or more response elements and a reporter gene, comprising the steps of transducing T cells with one or several vectors as described herein and culturing the transduced T cells under conditions that allow expression of an antigen binding receptor in or on the transduced cells.
[0187] Methods for transducing cells (e.g., T cells) are known in the art and include, but are not limited to (in the case of transducing nucleic acids or recombinant nucleic acids) electroporation methods, calcium phosphate methods, cationic lipid methods, or liposome methods. The nucleic acid to be transduced can be routinely and highly efficiently transduced using commercially available transfection reagents, such as Lipofectamine (manufactured by Invitrogen, catalog number: 11668027). In the case of using a vector, the vector can be transduced in the same manner as the nucleic acid described above, as long as the vector is a plasmid vector (i.e., a vector that is not a viral vector).
[0188] Preferably, the transduced T cells are grown under controlled conditions outside of their natural environment. In particular, the term "culture" means cells (e.g., transduced cells) in vitro. Culturing cells is a laboratory technique for keeping cells alive that are separated from their original tissue source. In this article, the transduced cells of the present invention are cultured under conditions that allow CAR to be expressed in or on the transduced cells. Conditions that allow expression or transgenesis (i.e., CAR and / or reporter gene) are commonly known in the art.
[0189] As described herein, reporter gene expression can be directly correlated with the functionality of the antigen-binding moiety being tested and the resulting T cells, such as reporter CAR-T cell activation. For example, when a gene encoding a fluorescent protein or a gene encoding luciferase is used as a reporter gene, the amount of light detected from the cells can be directly correlated with the target antigen binding and specificity of the antibody being tested.
[0190] In one embodiment, the target antigen is a cell surface receptor. In one embodiment, the target antigen is a tumor-associated antigen. In one embodiment, the tumor-associated antigen is selected from the group consisting of CEA, Her2, TYRP, EGFR, MCSP, STEAP1, WT1, and FolR1.
[0191] Target antigens are not limited to proteins located on the cell surface but can also be derived from polypeptides or proteins that are temporarily or permanently located within the cell. In such cases, target antigens derived from intracellular polypeptides or proteins can be presented on the cell surface by one or more molecules of the major histocompatibility complex (MHC). In one embodiment, the target antigen is a peptide bound by an MHC molecule. In one embodiment, the MHC is human MHC. In one embodiment, the peptide bound by the MHC molecule has an overall length of between 8 and 100 amino acids, preferably between 8 and 30, and more preferably between 8 and 16 amino acids. In one embodiment, the target antigen is derived from a protein expressed exclusively or predominantly in tumor tissue. In one embodiment, the protein is an intracellular protein and the peptide is produced via the MHC-I or MHC-II pathway and presented by an MHC class I or MHC class II complex. In one embodiment, the peptide is produced via the MHC-I pathway and presented by an MHC class I complex. Major histocompatibility complex (MHC) class I molecules present peptides from endogenous antigens to CD8+ cytotoxic T cells, and therefore, MHC-peptide complexes are suitable targets for immunotherapy approaches. MHC-peptide complexes can be targeted via recombinant T cell receptors (TCRs). However, most TCRs may have an affinity that is too low for immunotherapy, and high-affinity binding modules with TCR-specificity would be beneficial. To this end, high-affinity soluble antibody molecules with TCR-like specificity can be generated, for example, by generating phage display libraries (e.g., combinatorial libraries) and screening such libraries, as further described herein. These soluble antigen-binding modules (e.g., scFv or Fab) with TCR-like specificity are referred to herein as "T cell receptor-like antigen-binding modules" or "TCRL antigen-binding modules." In one embodiment, the antigen-binding module is a T cell receptor-like (TCRL) antigen-binding module. TCRL antigen-binding modules are capable of specifically binding to peptide antigens expressed exclusively or predominantly in tumor tissue, where the peptide antigen binds to MHC molecules located on the surface of cells, particularly cancer cells. In this context, the methods of the invention are suitable for evaluating the specificity of established or novel TCRL antigen binding moieties in a high-throughput assay format.
[0192] Binding of an antigen-binding moiety to a target antigen can be measured qualitatively or quantitatively, i.e., by the presence or absence of reporter gene expression; the absence of any fluorescence or luminescence indicates the absence of binding. For quantitative measurements of binding and activation, the amount of reporter gene activation can be compared to a reference. Thus, methods as described herein may further comprise a step of comparing the level of reporter gene expression to a reference. Suitable references typically include negative controls, which are substantially identical to the reference assay, omitting an essential component of the assay or method. For the methods of the present invention, the omitted component can, for example, be the omission of the addition of target cells. Alternatively, reporter CAR-T cells that bind to a different target antigen not present in the assay can be used. Thus, in one embodiment, the reference is reporter gene expression in the absence of the target antigen. In a preferred embodiment, the reference is reporter gene expression in the absence of target cells. In specific embodiments, reporter gene expression is at least 2-fold, 3-fold, 4-fold, 5-fold, 10-fold, 100-fold, 1000-fold, or 10,000-fold greater than reporter gene expression in the absence of target cells.
[0193] Alternatively, the absence of reporter gene expression can be defined by a threshold, i.e., after deducting the background signal. Background signal is typically determined by performing an assay with all reagents except the target antigen of the antigen binding moiety to be tested or in the absence of target cells containing the target antigen. Novel antigen binding moieties can be selected, for example, according to the methods of the present invention, by defining a threshold for baseline activation of reporter gene expression and selecting novel antigen binding moieties if the level of expression of the reporter gene in the presence of target cells is higher than a predetermined threshold relative to the expression of the reporter gene in the absence of target cells. Thus, the methods as described herein may further comprise the step of selecting novel antigen binding moieties if the level of expression of the reporter gene in the presence of target cells is higher than a predetermined threshold relative to the expression of the reporter gene in the absence of target cells. In specific embodiments, the threshold is 2, 3, 4, 5, 10, 100, 1000, or 10,000.
[0194] The novel assays described herein are robust, suitable for use in a high-throughput format, and efficient in terms of the hands-on time required to complete the assay. Furthermore, the assays of the present invention tolerate the presence of dead cells in the sample being analyzed. This is in contrast to cellular assays, such as killing assays, in which the binding and functionality of antibodies are determined by measuring cell viability or cell death.
[0195] Another advantage of the novel assay described herein is that no washing step is required. Reporter cells can be added to target cells, such as tumor cells, in any order. In one embodiment, a tumor sample is added to cell culture medium containing reporter CAR-T cells in a suitable cell culture format, such as in the wells of a 24-well plate, in the wells of a 96-well plate, or in the wells of a 384-well plate. Preferably, the assay medium is one that provides conditions for the cells to survive for up to 48 hours. A suitable medium is, for example, Jurkat medium, as outlined in the Examples. In one embodiment, the assay is performed in a microtiter plate. In one embodiment, microtiter plates are suitable for high-throughput screening. The assay of the present invention can be performed in any format that allows for rapid preparation, processing, and analysis of multiple reactions. This can be, for example, in a multi-well assay plate (e.g., 24-well, 96-well, or 386-well). Stock solutions of various agents can be generated manually or robotically, and all subsequent pipetting, dilution, mixing, dispensing, washing, incubation, sample readout, data collection, and analysis can be performed robotically using commercially available analysis software, robots, and detection instruments capable of detecting fluorescent and / or luminescent signals.
[0196] In one embodiment, in step 1.c), approximately 100,000 to approximately 1,000,000 reporter CAR-T cells are provided per well of a 24-well plate. In a preferred embodiment, approximately 300,000 to approximately 700,000 cells or approximately 400,000 to approximately 600,000 reporter CAR-T cells are provided per well of a 24-well plate. In one embodiment, in step 1.c), approximately 500,000 reporter CAR-T cells are provided per well of a 24-well plate. In one embodiment, in step 1.c), approximately 10,000 to approximately 100,000 reporter CAR-T cells are provided per well of a 96-well plate. In a preferred embodiment, approximately 30,000 to approximately 70,000 reporter CAR-T cells or approximately 40,000 to approximately 60,000 reporter CAR-T cells are provided per well of a 96-well plate. In one embodiment, in step 1.c), approximately 50,000 reporter CAR-T cells are provided per well of a 96-well plate. In one embodiment, in step 1.c), approximately 3,000 to approximately 30,000 reporter CAR-T cells are provided per well of a 384-well plate. In a preferred embodiment, approximately 5,000 to approximately 15,000 cells or approximately 8,000 to approximately 12,000 reporter CAR-T cells are provided per well of a 384-well plate. In one embodiment, in step 1.c), approximately 10,000 reporter CAR-T cells are provided per well of a 384-well plate. In one embodiment, in step 1.c), approximately 200,000 to approximately 2,000,000 reporter CAR-T cells are provided per ml of cell culture medium. In a preferred embodiment, approximately 600,000 to approximately 1,400,000 reporter CAR-T cells or approximately 800,000 to approximately 1,200,000 reporter CAR-T cells are provided per ml of cell culture medium. In one embodiment, in step 1.c), approximately 1,000,000 reporter CAR-T cells are provided per ml of cell culture medium.
[0197] In one embodiment, target cells, such as tumor cells or tumor samples, are provided in cell culture inserts. In one embodiment, target cells, such as tumor samples, are embedded in Matrigel.
[0198] In certain embodiments, the methods of the present invention can be used to assess the specificity of novel antigen-binding moieties to be included in T cell bispecific (TCB) formats. Methods according to the present invention are particularly suitable for evaluating and selecting novel antigen-binding moieties for TCBs because they measure T cell activation. One drawback of known assays in the art (e.g., affinity-based FACS assays) is that the measured affinity does not always reflect the specificity of the TCB format. TCBs are highly potent molecules, already capable of mediating T cell activation and killing via binding affinities in the micromolar range. Therefore, TCBs containing novel target antigen-binding moieties need to be highly selective to avoid nonspecific reactivity, such as killing of healthy cells or alloreactivity. The methods described herein meet the high demands of this format. Without being bound by theory, the assays of the present invention are based on T cell activation and a comparable mechanism of action. Thus, provided is a method as described herein, wherein high levels of reporter gene expression in the presence of target cells and low levels of reporter gene expression in the absence of target cells indicate high specificity of the antigen-binding moiety, particularly when the antigen-binding moiety is transferred into a T cell bispecific (TCB) antibody format. Furthermore, provided is a method for generating a TCB antibody, wherein the TCB antibody format comprises a first antigen-binding moiety specific for a target antigen and a second antigen-binding moiety capable of specifically binding to a T cell activating receptor, wherein the first antigen-binding moiety is selected according to the methods described herein. In a preferred embodiment, the T cell activating receptor is CD3.
[0199] In one such embodiment, the TCB pattern comprises
[0200] (a) a first antigen-binding moiety, in particular a Fab molecule capable of specifically binding to a target cell antigen;
[0201] (b) a second antigen binding moiety, in particular a Fab molecule capable of specifically binding to CD3.
[0202] In a specific embodiment, the bispecific antibody comprises
[0203] (a) a first antigen-binding moiety, which is a Fab molecule capable of specifically binding to a target cell antigen;
[0204] (b) a second antigen binding moiety, which is a Fab molecule capable of specifically binding to CD3 and comprising heavy chain complementary determining regions (CDRs) of SEQ ID NO: 88, SEQ ID NO: 89 and SEQ ID NO: 90 and light chain CDRs of SEQ ID NO: 91, SEQ ID NO: 92, SEQ ID NO: 93.
[0205] Bispecific antibodies with one antigen binding moiety that is capable of specifically binding to a target cell antigen are useful, particularly in situations where internalization of the target cell antigen is desired following binding of a high-affinity antigen binding moiety. In such situations, the presence of more than one antigen binding moiety specific for a target cell antigen may enhance internalization of the target cell antigen, thereby reducing its availability.
[0206] However, in many other situations it will be advantageous to have bispecific antibodies comprising two or more antigen binding moieties specific for target cell antigens, for example to optimize targeting to a target site.
[0207] Thus, in certain embodiments, the TCB format comprises a third antigen-binding moiety capable of specifically binding to a target cell antigen. In yet another embodiment, the third antigen-binding moiety is a conventional Fab molecule, or a crossover Fab molecule in which either the variable or constant regions of the Fab light chain and the Fab heavy chain are exchanged. In one embodiment, the third antigen-binding moiety is capable of specifically binding to the same target cell antigen as the first antigen-binding moiety. In a specific embodiment, the second antigen-binding moiety is capable of specifically binding to CD3, and the first and third antigen-binding moieties are capable of specifically binding to the target cell antigen. In a specific embodiment, the first and third antigen-binding moieties are identical (i.e., they comprise the same amino acid sequence).
[0208] Yet another aspect of this invention is a nucleic acid and vector encoding one or more CARs for use in accordance with the present invention. The nucleic acid molecule can be under the control of regulatory sequences. For example, a promoter, transcriptional enhancer, and / or a sequence that allows for inducible expression of the CAR can be employed. In the context of the present invention, the nucleic acid molecule is expressed under the control of a constitutive or inducible promoter. Suitable promoters are, for example, CMV promoter (Qin et al., PLoS One 5(5)(2010), e10611), UBC promoter (Qin et al., PLoS One 5(5)(2010), e10611), PGK (Qin et al., PLoS One 5(5)(2010), e10611), EF1A promoter (Qin et al., PLoS One 5(5)(2010), e10611), CAGG promoter (Qin et al., PLoS One 5(5)(2010), e10611), SV40 promoter (Qin et al., PLoS One 5(5)(2010), e10611), COPIA promoter (Qin et al., PLoS One 5(5)(2010), e10611), ACT5C promoter (Qin et al., PLoS One 5(5)(2010), e10611), al., PLoS One 5(5)(2010), e10611), TRE promoter (Qin et al., PLoS One 5(5)(2010), e10611), Oct3 / 4 promoter (Chang et al., Molecular Therapy 9(2004), S367-S367(doi:10.1016 / j.ymthe.2004.06.904)), or Nanog promoter (Wu et al., Cell Res. 15(5)(2005), 317-24). In this document, the term vector refers to a circular or linear nucleic acid molecule that is capable of autonomous replication in a cell into which it is introduced (i.e., in a transduced cell). A skilled artisan in molecular biology is aware of many suitable vectors, the choice of which will depend on the desired function and include plasmids, cosmids, viruses, phages, and other vectors routinely used in genetic engineering. Various plasmids and vectors can be constructed using methods known to those skilled in the art; see, for example, the techniques described in Sambrook et al. (supra) and Ausubel, Current Protocols in Molecular Biology, Green Publishing Associates and Wiley Interscience, NY (1989), (1994). Alternatively, the polynucleotides and vectors of the invention can be reconstituted into liposomes for delivery to target cells.As discussed in more detail below, cloning vectors are used to isolate individual sequences of DNA. Where expression of a particular polypeptide is desired, the sequence of interest can be transferred into an expression vector. Typical cloning vectors include pBluescript SK, pGEM, pUC9, pBR322, pGA18, and pGBT9. Typical expression vectors include pTRE, pCAL-n-EK, pESP-1, and pOP13CAT.
[0209] In the context of the present invention, the vector can be a polycistronic. Such regulatory sequences (control elements) are known to the skilled person and may include promoters, splice cassettes, translation start codons, translation and insertion sites for introducing inserts into the vector. In the context of the present invention, the nucleic acid molecule is operably linked to the expression control sequence, allowing expression in eukaryotic or prokaryotic cells. It is encompassed that the vector is an expression vector comprising a nucleic acid molecule encoding a CAR as defined herein. Operably linked refers to the juxtaposition of the components described therein in a relationship that allows them to function in their intended manner. The operably linked coding sequence of the control sequence is a connection in such a way that expression of the coding sequence is achieved under conditions compatible with the control sequence. In the case where the control sequence is a promoter, it will be apparent to the skilled person that double-stranded nucleic acids are preferably used.
[0210] In the context of the present invention, the vector is an expression vector. An expression vector is a construct that can be used to transform a selected cell and provide expression of a coding sequence in the selected cell. For example, an expression vector can be a cloning vector, a binary vector, or an integrating vector. Expression comprises transcription of the nucleic acid molecule, preferably into translatable mRNA. Regulatory elements that ensure expression in prokaryotes and / or eukaryotic cells are well known to those skilled in the art. In the case of eukaryotic cells, they normally contain a promoter to ensure initiation of transcription and, optionally, a polyA signal to ensure termination of transcription and stabilization of the transcript. Possible regulatory elements that allow expression in prokaryotic host cells include, for example, the pL, lac, trp, or tac promoters in Escherichia coli, while examples of regulatory elements that allow expression in eukaryotic host cells include the AOX1 or GAL1 promoters in yeast or the CMV, SV40, RSV (Rous sarcoma virus) promoter, the CMV enhancer, the SV40 enhancer, or the globin intron in mammalian and other animal cells.
[0211] In addition to the elements responsible for initiating transcription, such regulatory elements may also include transcription termination signals downstream of the polynucleotide, such as the SV40 polyA site or the tk polyA site. Furthermore, depending on the expression system used, a leader sequence encoding a signal peptide capable of directing the polypeptide to a cellular compartment or secreting it into the culture medium may be added to the coding sequence of the nucleic acid sequence and is well known in the art; see, for example, the appended Examples.
[0212] The leader sequence is assembled in a suitable state with the translation initiation and termination sequences, and preferably, the leader sequence is capable of directing the secretion of the translated protein or portion thereof into the periplasmic space or extracellular medium. Optionally, the heterologous sequence can encode a CAR that includes an N-terminal identification peptide that confers desired characteristics, such as stably expressed recombinant products or simplifies their purification; see above. In this context, suitable expression vectors are known in the art, such as the Okayama-Berg cDNA expression vector pcDV1 (Pharmacia), pCDM8, pRc / CMV, pcDNA1, pcDNA3 (In-vitrogene), pEF-DHFR, pEF-ADA or pEF-neo (Raum et al. Cancer Immunol Immunother 50 (2001), 141-150) or pSPORT1 (GIBCOBRL).
[0213] The described nucleic acid molecules or vectors introduced into T cells or their precursor cells can either be integrated into the genome of the cells or can be maintained extrachromosomally.
[0214] Exemplary embodiments
[0215] 1. A method for evaluating the specificity of an antigen binding moiety, comprising the following steps:
[0216] a. Providing an antigen binding module specific for the target antigen;
[0217] b. Generate chimeric antigen receptor (CAR)-expressing reporter T (CAR-T) cells by:
[0218] i. transferring the antigen binding moiety into a CAR carrier system operably coupled to a response element; and
[0219] ii. transferring the CAR vector system into reporter T cells comprising a reporter gene under the control of the response element;
[0220] c. contacting the reporter CAR-T cell with a target cell comprising the target antigen on its surface, particularly wherein the target cell is a cancer cell; and
[0221] d. Assaying T cell activation by measuring expression of the reporter gene to establish the specificity of the antigen binding moiety.
[0222] 2. The method according to embodiment 1, wherein the antigen binding moiety is a Fab fragment, in particular a Fab fragment derived from phage display library screening.
[0223] 3. The method of embodiment 1 or 2, wherein the antigen binding moiety comprises a variable heavy chain domain (VH) and a variable light chain domain (VL) and wherein the VH and VL domains of the antigen binding moiety are transferred to the CAR, in particular wherein the polynucleotide sequences encoding the VH and VL domains of the antigen binding moiety are transferred to the CAR vector system.
[0224] 4. The method of any one of embodiments 1 to 3, wherein the CAR vector system encodes a CAR comprising an antigen binding module, an anchoring transmembrane domain and at least one intracellular signaling and / or co-signaling domain.
[0225] 5. The method of embodiment 4, wherein binding of the target antigen to the reporter CAR-T cell results in activation of the intracellular signaling and / or co-signaling domain.
[0226] 6. The method of any one of embodiments 5 or 6, wherein activation of the intracellular signaling domain results in activation of the response element.
[0227] 7. The method according to any one of embodiments 1 to 6, wherein the response element controls the expression of the reporter gene.
[0228] 8. The method according to any one of embodiments 1 to 7, wherein activation of the response element results in expression of the reporter gene.
[0229] 9. The method according to any one of embodiments 1 to 8, wherein the response element is part of the NFAT pathway, the NF-κB pathway or the AP-1 pathway.
[0230] 10. The method according to any one of embodiments 1 to 9, wherein the reporter gene encodes a photoprotein, in particular a fluorescent protein.
[0231] 11. The method according to any one of embodiments 1 to 10, wherein the reporter gene encodes green fluorescent protein (GFP) or luciferase.
[0232] 12. The method according to any one of embodiments 1 to 11, wherein the target antigen is a cell surface receptor.
[0233] 13. The method according to any one of embodiments 1 to 12, wherein the target antigen is a peptide that binds to a molecule of the human major histocompatibility complex (MHC).
[0234] 14. The method according to embodiment 13, wherein the antigen binding moiety is a T cell receptor-like (TCRL) antigen binding moiety.
[0235] 15. The method according to any one of embodiments 1 to 14, further comprising the steps of:
[0236] e. Compare the level of expression of the reporter gene to a reference.
[0237] 16. The method according to embodiment 15, wherein the reference is the expression of the reporter gene in the absence of the target cell.
[0238] 17. The method of embodiment 16, wherein the expression of the reporter gene is at least 2-fold, 3-fold, 4-fold, 5-fold, 10-fold, 100-fold, 1000-fold, or 10,000-fold higher than the expression of the reporter gene in the absence of the target cell.
[0239] 18. The method according to embodiment 15, further comprising the steps of:
[0240] f. If the level of expression of the reporter gene in the presence of the target cell is higher than a predetermined threshold relative to the expression of the reporter gene in the absence of the target cell, selecting the novel antigen binding moiety.
[0241] 19. The method according to embodiment 18, wherein the threshold value is 2, 3, 4, 5, 10, 100, 1000, or 10000.
[0242] 20. The method according to any one of embodiments 1 to 19, wherein a high level of expression of the reporter gene in the presence of the target cell and a low level of expression of the reporter gene in the absence of the target cell indicates high specificity of the antigen binding moiety.
[0243] 21. The method according to any one of embodiments 1 to 20, wherein high levels of expression of the reporter gene in the presence of the target cell and low levels of expression of the reporter gene in the absence of the target cell indicate high specificity of the T cell bispecific (TCB) antibody comprising the antigen binding moiety.
[0244] 22. The method according to any one of embodiments 1 to 21, wherein the method is an in vitro method.
[0245] 23. A method for producing a TCB antibody, wherein the TCB antibody version comprises a first antigen binding moiety specific for a target antigen and a second antigen binding moiety capable of specifically binding to a T cell activating receptor, wherein the first antigen binding moiety is selected according to the method of any one of embodiments 1 to 22.
[0246] 24. The method of embodiment 23, wherein the T cell activating receptor is CD3.
[0247] 25. A method as herein before described. Example
[0248] The following are examples of methods and compositions of the present invention. It is understood that various other embodiments may be practiced, given the general description provided above.
[0249] Recombinant DNA technology
[0250] Standard methods for DNA manipulation were used, as described in Sambrook et al., Molecular cloning: A laboratory manual; Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, 1989. Molecular biology reagents were used according to the manufacturer's instructions. General information regarding the nucleotide sequences of human immunoglobulin light and heavy chains is given in Kabat, EA et al., (1991) Sequences of Proteins of Immunological Interest, Fifth Ed., NIH Publication No. 91-3242.
[0251] DNA sequencing
[0252] The DNA sequence was determined by double-strand sequencing.
[0253] gene synthesis
[0254] The desired gene segments were either generated by PCR using appropriate templates or synthesized by automated gene synthesis using self-synthesized oligonucleotides and PCR products by Geneart AG (Regensburg, Germany). The gene segments, flanked by single restriction endonuclease cleavage sites, were cloned into standard cloning / sequencing vectors. Plasmid DNA was purified from transformed bacteria and concentrations were determined by UV spectroscopy. The DNA sequences of the subcloned gene segments were confirmed by DNA sequencing. The gene segments were designed with appropriate restriction sites to allow subcloning into the corresponding expression vectors. All constructs were designed with a 5' end DNA sequence encoding a leader peptide that targets the protein for secretion in eukaryotic cells.
[0255] Protein purification
[0256] Proteins were purified from filtered cell culture supernatants using standard protocols. Briefly, antibodies were applied to a Protein A Sepharose column (GE Healthcare) and washed with PBS. Antibody elution was achieved at pH 2.8, followed by immediate sample neutralization. Aggregated protein was separated from monomeric antibody by size exclusion chromatography (Superdex 200, GE Healthcare) in PBS or in 20 mM histidine, 150 mM NaCl, pH 6.0. Monomeric antibody fractions were pooled, concentrated (if necessary) using, for example, a MILLIPORE Amicon Ultra (30 MWCO) centrifugal concentrator, frozen, and stored at -20°C or -80°C. A portion of the sample was provided for subsequent protein analysis and analytical characterization, for example, by SDS-PAGE and size exclusion chromatography (SEC).
[0257] SDS-PAGE
[0258] Use according to the manufacturer's instructions Precast gel system (Invitrogen). In particular, 10% or 4-12% Bis-TRIS precast gel (pH 6.4) and MES (reducing gel, with Antioxidant running buffer additive) or MOPS (non-reducing gel) running buffer.
[0259] Analytical size exclusion chromatography
[0260] Size exclusion chromatography (SEC) was performed by HPLC chromatography to determine the aggregation and oligomeric state of the antibodies. Briefly, the antibodies purified by protein A were applied to a Tosoh TSKgel G3000SW column in 300 mM NaCl, 50 mM KH2PO4 / K2HPO4, pH 7.5 on an Agilent HPLC 1100 system or a Superdex 200 column (GE Healthcare) in 2x PBS on a Dionex HPLC system. The eluted protein was quantified by UV absorbance and peak area integration. BioRad gel filtration standard 151-1901 served as a standard.
[0261] Lentiviral transduction of Jurkat NFAT T cells
[0262] To generate the lentiviral vector, the DNA sequence corresponding to the correct assembly of the CAR was cloned in frame under the constitutively active human cytomegalovirus immediate early promoter (CMV) in a lentiviral polynucleotide vector. The retroviral vector contains the woodchuck hepatitis virus posttranscriptional regulatory element (WPRE), the central polypurine tract (cPPT) element, the pUC origin of replication, and genes encoding antibiotic resistance for propagation and selection in bacteria.
[0263] To generate functional viral particles, 60-70% confluent Hek293T cells (ATCC CRL3216) were used with the CAR-containing vector and the pCMV-VSV-G:pRSV-REV:pCgpV transfer vector at a ratio of 3:1:1:1 to perform a Lipofectamine LTX-based TM After 48 hours, the supernatant was collected, centrifuged at 250 g for 5 minutes to remove cell debris, and filtered through a 0.45 or 0.22 μm polyethersulfone filter. Jurkat NFAT cells (Signosis) were transduced using concentrated viral particles (Lenti-x-Concentrator, Takara). Positively transduced cells were sorted as pools or single clones using a FACSARIA sorter (BD Bioscience). After the cells were expanded to an appropriate density, Jurkat NFAT T cells were used in the experiment.
[0264] Example 1
[0265] Described herein is a Jurkat NFAT T cell reporter assay using CD20-expressing SUDHDL4 tumor cells as target cells and sorted monoclonal clones of anti-CD20-Fab-CD28ATD-CD28CSD-CD3zSSD-expressing Jurkat NFAT T cells as target cells ( Figure 4 As a positive control, some wells of a 96-well plate (Cellstar Greiner-bio-one, catalog number 655185) were incubated with 10 μg / ml CD3 antibody (from ) or coated overnight at 4°C or at 37°C for at least 1 hour. The CD3 antibody-coated wells were washed twice with PBS, completely removing the PBS after the final wash step. Jurkat NFAT wild-type cells or Jurkat NFAT CAR cells engineered to express the antigen-binding receptor anti-CD20-Fab-CD28ATD-CD28CSD-CD3zSSD (hereinafter referred to as reporter cells) were counted and their viability was examined using Cedex HiRes. The cell number was adjusted to 1x10 6viable cells / ml. Therefore, appropriate aliquots of the cell suspension were pelleted at 210 g for 5 minutes at room temperature (RT) and resuspended in fresh RPMI-160 + 10% FCS + 1% Glutamax (growth medium). Target cells expressing the antigen of interest were also counted and their viability checked. The cell number was adjusted to 1 x 10 in growth medium. 6 Viable cells / ml. Target cells and reporter cells were plated in triplicate in a 96-well suspension culture plate (Greiner-bio one) at a final volume of 200 μl at a 10:1, 5:1, 2:1, or 1:1 E:T ratio (a total of 110,000 cells per well). The 96-well plate was then centrifuged at 190 g for 2 minutes at room temperature and the plate was washed with water. seal.
[0266] After incubation for 20 hours at 37°C and 5% CO2 in a humidified atmosphere, the contents of each well were mixed by pipetting up and down 10 times using a multichannel pipette. 100 μl of the cell suspension was transferred to a new white clear-bottom 96-well plate (Greiner-bio-one) and 100 μl of ONE-Glo TM Luciferase assay (Promega). Incubate at room temperature for 15 minutes in the dark on a rotary shaker at 300 rpm before use. The luminescence was measured by Spark10M plate reader, and the detection time was 1 s / well.
[0267] The bar graph shows activation of Jurkat NFAT T cells expressing anti-CD20-Fab-CD28ATD-CD28CSD-CD3zSSD depending on the duration of co-culture with target cells at different E:T ratios. This shows that activation of Jurkat NFAT T cells depends on the duration of co-culture with target cells and the E:T ratio. For all conditions tested, a 20-hour incubation time exhibited the highest luminescence signal. Furthermore, among the different E:T ratios, an E:T ratio of 10:1 produced the highest detectable luminescence signal. Jurkat NFAT wild-type T cells only showed a time-dependent increase in luminescence signal, with the highest luminescence signal detected after 40 hours. The detected luminescence signal was independent of the E:T ratio and was generally significantly lower than the luminescence signal detected for Jurkat NFAT T cells expressing anti-CD20-Fab-CD28ATD-CD28CSD-CD3zSSD at each time point. Generally, the highest luminescence signal was detected when cells were incubated in wells coated with CD3 antibodies. Anti-CD20-Fab-CD28ATD-CD28CSD-CD3zSSD expressing Jurkat NFAT T cells depict higher signals compared to non-transduced Jurkat NFAT control T cells. Each point represents the mean of technical duplicates.
[0268] Example 2
[0269] Described herein is a Jurkat NFAT T cell reporter assay using CD20-expressing SUDHDL4 tumor cells as target cells and sorted monoclonal clones of anti-CD20-Fab-CD28ATD-CD28CSD-CD3zSSD or anti-CD20-crossFab-CD28ATD-CD28CSD-CD3zSSD-expressing Jurkat NFAT T cells as target cells ( Figure 5 As a positive control, wells of a 96-well plate (Cellstar Greiner-bio-one, catalog number 655185) were incubated with 10 μg / ml CD3 antibody (from ) were coated overnight at 4°C. The CD3 antibody-coated wells were washed twice with PBS, completely removing the PBS after the final wash step. Jurkat NFAT wild-type cells or Jurkat NFAT T cells engineered to express anti-CD20-Fab-CD28ATD-CD28CSD-CD3zSSD or anti-CD20-crossFab-CD28ATD-CD28CSD-CD3zSSD (hereinafter referred to as reporter cells) were counted and their viability was examined using Cedex HiRes. The cell number was adjusted to 1x10 6viable cells / ml. Therefore, appropriate aliquots of the cell suspension were pelleted at 210 g for 5 minutes at room temperature (RT) and resuspended in fresh RPMI-160 + 10% FCS + 1% Glutamax (growth medium). Target cells expressing the antigen of interest were also counted and their viability checked. The cell number was adjusted to 1 x 10 in growth medium. 6 Viable cells / ml. Target cells and reporter cells were plated in triplicate in a 96-well suspension culture plate (Greiner-bio one) at a 5:1 E:T ratio (a total of 110,000 cells per well) in a final volume of 200 μl. The 96-well plate was then centrifuged at 190 g for 2 minutes at room temperature and seal.
[0270] After incubation for 20 hours at 37°C and 5% CO2 in a humidified atmosphere, the contents of each well were mixed by pipetting up and down 10 times using a multichannel pipette. 100 μl of the cell suspension was transferred to a new white clear-bottom 96-well plate (Greiner-bio-one) and 100 μl of ONE-Glo TM Luciferase assay (Promega). Incubate at room temperature for 15 minutes in the dark on a rotary shaker at 300 rpm before use. The luminescence was measured by Spark10M plate reader, and the detection time was 1 s / well.
[0271] The bar graph shows activation of Jurkat NFAT T cells expressing anti-CD20-Fab-CD28ATD-CD28CSD-CD3zSSD and Jurkat NFAT T cells expressing anti-CD20-crossFab-CD28ATD-CD28CSD-CD3zSSD after coculture with target cells. No luminescent signal was detected when Jurkat NFAT T cells expressing anti-CD20-Fab-CD28ATD-CD28CSD-CD3zSSD or anti-CD20-crossFab-CD28ATD-CD28CSD-CD3zSSD or Jurkat NFAT control T cells were cultured in the absence of target cells. The highest luminescent signal was detected when anti-CD20-Fab-CD28ATD-CD28CSD-CD3zSSD or anti-CD20-cross Fab-CD28ATD-CD28CSD-CD3zSSD expressing Jurkat NFAT T cells or Jurkat NFAT control T cells were co-cultured with target cells using CD3 antibody-coated plates. Surprisingly, the cross Fab format resulted in strong activation of Jurkat NFAT T cells along with CD3-mediated signaling. Each point represents the mean of technical triplicates. Standard deviations are indicated by error bars.
[0272] Example 3
[0273] Described herein is a Jurkat NFAT T cell reporter assay using CD20-expressing SUDHDL4 tumor cells and a sorted pool of anti-CD20-scFab-CD28ATD-CD28CSD-CD3zSSD-expressing Jurkat NFAT T cells as target cells ( Figure 6 ).
[0274] As a positive control, wells of a 96-well plate (Cellstar Greiner-bio-one, catalog number 655185) were incubated with 10 μg / ml CD3 antibody (from ) were coated overnight at 4°C or for at least 1 hour at 37°C. The CD3 antibody-coated wells were washed twice with PBS, completely removing the PBS after the final wash step. Jurkat NFAT wild-type T cells or Jurkat NFAT T cells engineered to express anti-CD20-scFab-CD28ATD-CD28CSD-CD3zSSD (hereinafter referred to as reporter cells) were counted and their viability was assessed using Cedex HiRes. The cell number was adjusted to 1x10 6 viable cells / ml. Therefore, appropriate aliquots of the cell suspension were pelleted at 210 g for 5 minutes at room temperature (RT) and resuspended in fresh RPMI-160 + 10% FCS + 1% Glutamax (growth medium). Target cells expressing the antigen of interest were also counted and their viability checked. The cell number was adjusted to 1 x 10 in growth medium. 6 Viable cells / ml. Target cells and reporter cells were plated in triplicate in a 96-well suspension culture plate (Greiner-bio one) at a final volume of 200 μl at a 10:1, 5:1, 2:1, or 1:1 E:T ratio (a total of 110,000 cells per well). The 96-well plate was then centrifuged at 190 g for 2 minutes at room temperature and the plate was washed with water. seal.
[0275] After incubation for 20 hours at 37°C and 5% CO2 in a humidified atmosphere, the contents of each well were mixed by pipetting up and down 10 times using a multichannel pipette. 100 μl of the cell suspension was transferred to a new white clear-bottom 96-well plate (Greiner-bio-one) and 100 μl of ONE-Glo TM Luciferase assay (Promega). Incubate at room temperature for 15 minutes in the dark on a rotary shaker at 300 rpm before use. The luminescence was measured by Spark10M plate reader, and the detection time was 1 s / well.
[0276] The bar graph shows the activation of Jurkat NFAT T cells expressing anti-CD20-scFab-CD28ATD-CD28CSD-CD3zSSD after co-culture with SUDHL4 target cells at different E:T ratios for 20 hours. Among the different E:T ratios, 10:1 and 5:1 E:T ratios showed the highest luminescence signal ( Figure 6 Black bars.) Furthermore, anti-CD20-scFab-CD28ATD-CD28CSD-CD3zSSD-expressing Jurkat NFAT T cells co-cultured at a 10:1 E:T ratio in CD3 antibody-coated wells showed a high luminescent signal comparable to that under the same conditions without CD3 stimulation.
[0277] Furthermore, Jurkat NFAT wild-type cells did not show any activation independent of the different E:T ratios, but a clear luminescent signal was detected if co-cultured at an E:T ratio of 10:1 in CD3 antibody-coated wells, demonstrating their functionality.
[0278] Other control experiments showed that target cells alone or anti-CD20-scFab-CD28ATD-CD28CSD-CD3zSSD expressing T cells and CD3 antibody-coated wells with target cells did not show any activation. Each point represents the mean of three technical replicates. The standard deviation is indicated by the error bar.
[0279] Example 4
[0280] Described herein is a Jurkat NFAT T cell reporter assay using CD20-expressing SUDHDL4 tumor cells as target cells and sorted pools of anti-CD20-Fab-CD28ATD-CD28CSD-CD3zSSD-expressing Jurkat NFAT T cells or anti-CD20-scFv-CD28ATD-CD28CSD-CD3zSSD-expressing Jurkat NFAT T cells as target cells ( Figure 7 ).
[0281] As a positive control, wells of a 96-well plate (Cellstar Greiner-bio-one, catalog number 655185) were incubated with 10 μg / ml CD3 antibody (from ) were coated overnight at 4°C or at 37°C for at least 1 hour. The CD3 antibody-coated wells were washed twice with PBS, completely removing the PBS after the final wash step. Jurkat NFAT wild-type T cells or Jurkat NFAT T cells engineered to express anti-CD20-Fab-CD28ATD-CD28CSD-CD3zSSD or anti-CD20-scFv-CD28ATD-CD28CSD-CD3zSSD (hereinafter referred to as reporter cells) were counted and their viability was examined using Cedex HiRes. The cell number was adjusted to 1x10 6 viable cells / ml. Therefore, appropriate aliquots of the cell suspension were pelleted at 210 g for 5 minutes at room temperature (RT) and resuspended in fresh RPMI-160 + 10% FCS + 1% Glutamax (growth medium). Target cells expressing the antigen of interest were also counted and their viability checked. The cell number was adjusted to 1 x 10 in growth medium. 6 Viable cells / ml. Target cells and reporter cells were plated in triplicate in a 96-well suspension culture plate (Greiner-bio one) at a final volume of 200 μl at a 10:1, 5:1, 2:1, or 1:1 E:T ratio (a total of 110,000 cells per well). The 96-well plate was then centrifuged at 190 g for 2 minutes at room temperature and the plate was washed with water. seal.
[0282] After incubation for 20 hours at 37°C and 5% CO2 in a humidified atmosphere, the contents of each well were mixed by pipetting up and down 10 times using a multichannel pipette. 100 μl of the cell suspension was transferred to a new white clear-bottom 96-well plate (Greiner-bio-one) and 100 μl of ONE-Glo TM Luciferase assay (Promega). Incubate at room temperature for 15 minutes in the dark on a rotary shaker at 300 rpm before use. The luminescence was measured by Spark10M plate reader, and the detection time was 1 s / well.
[0283] The bar graph shows activation of Jurkat NFAT T cells expressing anti-CD20-scFv-CD28ATD-CD28CSD-CD3zSSD after 20 hours of coculture with SUDHL4 target cells at a 5:1 E:T ratio. Anti-CD20-scFv-CD28ATD-CD28CSD-CD3zSSD-expressing Jurkat NFAT T cells cocultured with target cells in wells coated with CD3 antibodies exhibited the highest luminescence signal, comparable to the same conditions without CD3 stimulation. Surprisingly, the crossover Fab format resulted in differential activation of Jurkat NFAT T cells, with strong activation observed alongside CD3-mediated signaling. Furthermore, wild-type Jurkat NFAT cells showed no activation, but a significant luminescence signal was detected when cocultured in wells coated with CD3 antibodies at a 10:1 E:T ratio, demonstrating their functionality. Each bar represents the mean of technical triplicates. Error bars indicate standard deviation.
[0284] Example 5
[0285] Two antibody candidates, 5E11 and 33H09, were initially selected through phage display library screening for binding to the WT1 peptide "RMF" complexed with MHC I. A dilution series of both binders in IgG format was examined for binding by flow cytometry. Therefore, T2 cells pulsed with 10 μM of the target peptide "RMF," 10 μM of the off-target peptide "VLD," or left unpulsed were incubated on ice for 30 minutes with a dilution series of the antibodies. After a wash step to remove unbound conjugates, the cells were incubated with a fluorescently labeled secondary antibody (anti-huFc, Jackson ImmunoResearch), followed by another wash step and detection of residual antibody by flow cytometry. Importantly, in this assay, both evaluated candidates (5E11 and 33H09) appeared similar in terms of specificity, with a clear concentration-dependent signal on T2 cells pulsed with the target peptide "RMF," compared to no binding on T2 cells pulsed with the off-target peptide "VLD" or unpulsed T2 cells (Figure 8).
[0286] exist Figure 9 The same two antibody candidates (5E11 and 33H09) plus two additional candidates against the same target peptide / MHC (ESK1 and 11D06) were evaluated in the Jurkat NFAT reporter CAR-T cell assay depicted in FIG.
[0287] This Jurkat NFAT reporter CAR-T cell assay employs a collection of Jurkat NFAT reporter cells that recognize the HLA-A2 / WT1 peptide RMF via four different Fabs embedded in chimeric antigen receptors expressed on the cell surface: 5E11 (SEQ ID NOs 86 and 87), ESK1, 33H09 (SEQ ID NOs 84 and 85), or 11D06 (SEQ ID NOs 82 and 83), respectively.
[0288] Before co-incubation with Jurkat NFAT reporter cells, -5 M pulsed T2 cells with the respective peptide for 2 hours or left unpulsed. Target cells and reporter cells were distributed in triplicate in a 384-well white transparent flat-bottom plate (Greiner-bio-one) at a 5:1E:T ratio (10,000 effector cells per 2000 target cells per well). Jurkat NFAT reporter CAR-T cells and target cells were co-incubated at 37°C for 7 hours, followed by the addition of 6 μl / well ONE-GloTM luciferase substrate (Promega) and direct measurement of luminescence using a TECAN infinite M1000Pro plate reader. Activation of CAR-NFAT signaling (A) measured in triplicate on T2 cells pulsed with RMF or VLD peptides is presented as a bar graph. Figure 9 Comparison of the signal on RMF peptide (target) versus VLD peptide (off-target) and differently pulsed T2 cells incubated with luciferase substrate but without reporter cells helps to assess the specificity of activation by the respective binders.
[0289] Unlike the FACS-based screen depicted in FIG8 , this Jurkat NFAT reporter CAR-T cell assay did clearly discriminate between candidates 5E11 and 33H09 in terms of specific T cell activation on target as opposed to nonspecific activation on off-targets.
[0290] The background signal of the respective Jurkat NFAT reporter cell pools incubated with luciferase substrate as above but without any co-incubation with target cells was lower, as shown in FIG. Figure 10 Depicted in.
[0291] Example 6
[0292] This Jurkat NFAT reporter CAR-T cell assay utilizes pools of Jurkat NFAT reporter cells that recognize two different HLA-A2 / peptide targets. Pools F06, F29, and F30 express candidate Fabs selected for binding to blind peptide / HLA targets, while the pool with Fab 33H09 is specific for the HLA-A2 / WT1 peptide RMF.
[0293] Before co-incubation with Jurkat NFAT reporter cells, -5 T2 cells were pulsed with the respective peptides for 2 hours or left unpulsed. Target and reporter cells were plated in triplicate in a 384-well white, clear-bottom plate (Greiner-bio-one) at a 5:1 E:T ratio (10,000 effector cells per 2,000 target cells per well). Jurkat NFAT reporter cells and target cells were incubated at 37°C for 7 hours, followed by the addition of 6 μl / well of ONE-Glo TM Luciferase substrate (Promega) and luminescence was measured directly using a TECANinfinite M1000Pro plate reader. Activation of CAR-NFAT signaling from triplicate measurements on T2 cells is presented as a bar graph ( Figure 11 ). Comparison of the signals obtained from four different cell pools on the different peptides indicated high specificity of activation of the respective candidates towards their desired target peptide / HLA.
[0294] illustrative sequence
[0295] Table 2: Anti-CD20 Fab amino acid sequences
[0296]
[0297]
[0298] Table 3: Anti-CD20 Fab DNA sequences
[0299]
[0300]
[0301]
[0302]
[0303]
[0304]
[0305] Table 4: Anti-CD20 crossover Fab (VH-CL-ATD) amino acid sequence
[0306]
[0307]
[0308] Table 5: Anti-CD20 crossover Fab (VL-CH1-ATD) amino acid sequence
[0309]
[0310]
[0311] Table 6: Anti-CD20 crossover Fab (VH-CL-ATD) DNA sequences
[0312]
[0313]
[0314]
[0315]
[0316] Table 7: Anti-CD20 Fab (VL-CL-ATD) amino acid sequence
[0317]
[0318]
[0319] Table 8: Anti-CD20 scFab amino acid sequences
[0320]
[0321]
[0322] Table 9: Anti-CD20 scFab DNA sequences
[0323]
[0324]
[0325]
[0326] Table 10: Anti-CD20-ds-scFv amino acid sequence
[0327]
[0328]
[0329] Table 11: Anti-CD20 ds scFv DNA sequences
[0330]
[0331]
[0332]
[0333] Table 12
[0334]
[0335]
[0336] Sequence Listing <110> F.Hoffmann-La Roche Ltd <120> CAR-T cell assay for specificity testing of novel antigen-binding modules <130> P34478 <160> 93 <170> PatentIn version 3.5 <210> 1 <211> 5 <212> PRT <213> Artificial sequence <220> <223> Anti-CD20 (GA101) CDR H1 Kabat <400> 1 Tyr Ser Trp Ile Asn 1 5 <210> 2 <211> 17 <212> PRT <213> Artificial sequence <220> <223> Anti-CD20 (GA101) CDR H2 Kabat <400> 2 Arg Ile Phe Pro Gly Asp Gly Asp Thr Asp Tyr Asn Gly Lys Phe Lys 1 5 10 15 Gly <210> 3 <211> 10 <212> PRT <213> Artificial sequence <220> <223> Anti-CD20 (GA101) CDR H3 Kabat <400> 3 Asn Val Phe Asp Gly Tyr Trp Leu Val Tyr 1 5 10 <210> 4 <211> 16 <212> PRT <213> Artificial sequence <220> <223> Anti-CD20 (GA101) CDR L1 Kabat <400> 4 Arg Ser Ser Lys Ser Leu Leu His Ser Asn Gly Ile Thr Tyr Leu Tyr 1 5 10 15 <210> 5 <211> 7 <212> PRT <213> Artificial sequence <220> <223> Anti-CD20 (GA101) CDR L2 Kabat <400> 5 Gln Met Ser Asn Leu Val Ser 1 5 <210> 6 <211> 9 <212> PRT <213> Artificial sequence <220> <223> Anti-CD20 (GA101) CDR L3 Kabat <400> 6 Ala Gln Asn Leu Glu Leu Pro Tyr Thr 1 5 <210> 7 <211> 407 <212> PRT <213> Artificial sequence <220> <223> Anti-CD20-(GA101)-Fab heavy chain-CD28ATD-CD28CSD-CD3zSSD fusion pETR17097 <400> 7 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Ala Phe Ser Tyr Ser 20 25 30 Trp Ile Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Arg Ile Phe Pro Gly Asp Gly Asp Thr Asp Tyr Asn Gly Lys Phe 50 55 60 Lys Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Asn Val Phe Asp Gly Tyr Trp Leu Val Tyr Trp Gly Gln Gly 100 105 110 Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe 115 120 125 Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu 130 135 140 Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp 145 150 155 160 Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu 165 170 175 Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser 180 185 190 Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro 195 200 205 Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Gly Gly 210 215 220 Gly Gly Ser Phe Trp Val Leu Val Val Val Gly Gly Val Leu Ala Cys 225 230 235 240 Tyr Ser Leu Leu Val Thr Val Ala Phe Ile Ile Phe Trp Val Arg Ser 245 250 255 Lys Arg Ser Arg Leu Leu His Ser Asp Tyr Met Asn Met Thr Pro Arg 260 265 270 Arg Pro Gly Pro Thr Arg Lys His Tyr Gln Pro Tyr Ala Pro Pro Arg 275 280 285 Asp Phe Ala Ala Tyr Arg Ser Arg Val Lys Phe Ser Arg Ser Ala Asp 290 295 300 Ala Pro Ala Tyr Gln Gln Gly Gln Asn Gln Leu Tyr Asn Glu Leu Asn 305 310 315 320 Leu Gly Arg Arg Glu Glu Tyr Asp Val Leu Asp Lys Arg Arg Gly Arg 325 330 335 Asp Pro Glu Met Gly Gly Lys Pro Arg Arg Lys Asn Pro Gln Glu Gly 340 345 350 Leu Tyr Asn Glu Leu Gln Lys Asp Lys Met Ala Glu Ala Tyr Ser Glu 355 360 365 Ile Gly Met Lys Gly Glu Arg Arg Arg Gly Lys Gly His Asp Gly Leu 370 375 380 Tyr Gln Gly Leu Ser Thr Ala Thr Lys Asp Thr Tyr Asp Ala Leu His 385 390 395 400 Met Gln Ala Leu Pro Pro Arg[[ID=1十八]] 405 <210> 8 <211> 222 <212> PRT <213> Artificial Sequence <220> <223> Anti-CD20-(GA101)-Fab Heavy Chain <400> 8 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Ala Phe Ser Tyr Ser 20 25 30 Trp Ile Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Arg Ile Phe Pro Gly Asp Gly Asp Thr Asp Tyr Asn Gly Lys Phe 50 55 60 Lys Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Asn Val Phe Asp Gly Tyr Trp Leu Val Tyr Trp Gly Gln Gly 100 105 110 Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe 115 120 125 Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu 130 135 140 Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp 145 150 155 160 Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu 165 170 175 Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser 180 185 190 Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro 195 200 205 Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys 210 215 220 <210> 9 <211> 219 <212> PRT <213> Artificial sequence <220> <223> Anti-CD20-(GA101)-Fab light chain <400> 9 Asp Ile Val Met Thr Gln Thr Pro Leu Ser Leu Pro Val Thr Pro Gly 1 5 10 15 Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Lys Ser Leu Leu His Ser 20 25 30 Asn Gly Ile Thr Tyr Leu Tyr Trp Tyr Leu Gln Lys Pro Gly Gln Ser 35 40 45 Pro Gln Leu Leu Ile Tyr Gln Met Ser Asn Leu Val Ser Gly Val Pro 50 55 60 Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 65 70 75 80 Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Ala Gln Asn 85 90 95 Leu Glu Leu Pro Tyr Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 100 105 110 Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu 115 120 125 Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe 130 135 140 Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln 145 150 155 160 Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser 165 170 175 Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu 180 185 190 Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser 195 200 205 Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys 210 215 <210> 10 <211> 112 <212> PRT <213> Synthetic Sequence <220> <223> Anti-CD20-(GA101) VL <400> 10 Asp Ile Val Met Thr Gln Thr Pro Leu Ser Leu Pro Val Thr Pro Gly 1 5 10 15 Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Lys Ser Leu Leu His Ser 20 25 30 Asn Gly Ile Thr Tyr Leu Tyr Trp Tyr Leu Gln Lys Pro Gly Gln Ser 35 40 45 Pro Gln Leu Leu Ile Tyr Gln Met Ser Asn Leu Val Ser Gly Val Pro 50 55 60 Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 65 70 75 80 Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Ala Gln Asn 85 90 95 Leu Glu Leu Pro Tyr Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 100 105 110 <210> 11 <211> 107 <212> PRT <213> artificial sequence <220> <223> CL <400> 11 Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu 1 5 10 15 Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe 20 25 30 Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln 35 40 45 Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser 50 55 60 Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu 65 70 75 80 Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser 85 90 95 Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys 100 105 <210> 12 <211> 119 <212> PRT <213> Artificial sequence <220> <223> Anti-CD20-(GA101) VH <400> 12 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Ala Phe Ser Tyr Ser 20 25 30 Trp Ile Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Arg Ile Phe Pro Gly Asp Gly Asp Thr Asp Tyr Asn Gly Lys Phe 50 55 60 Lys Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Asn Val Phe Asp Gly Tyr Trp Leu Val Tyr Trp Gly Gln Gly 100 105 110 Thr Leu Val Thr Val Ser Ser 115 <210> 13 <211> 103 <212> PRT <213> Artificial Sequence <220> <223> CH1 <400> 13 Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys 1 5 10 15 Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr 20 25 30 Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser 35 40 45 Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser 50 55 60 Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr 65 70 75 80 Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys 85 90 95 Lys Val Glu Pro Lys Ser Cys 100 <210> 14 <211> 27 <212> PRT <213> Artificial sequence <220> <223> CD28ATD <400> 14 Phe Trp Val Leu Val Val Val Gly Gly Val Leu Ala Cys Tyr Ser Leu 1 5 10 15 Leu Val Thr Val Ala Phe Ile Ile Phe Trp Val 20 25 <210> 15 <211> 41 <212> PRT <213> Artificial sequence <220> <223> CD28CSD <400> 15 Arg Ser Lys Arg Ser Arg Leu Leu His Ser Asp Tyr Met Asn Met Thr 1 5 10 15 Pro Arg Arg Pro Gly Pro Thr Arg Lys His Tyr Gln Pro Tyr Ala Pro 20 25 30 Pro Arg Asp Phe Ala Ala Tyr Arg Ser 35 40 <210> 16 <211> 112 <212> PRT <213> Artificial sequence <220> <223> CD3zSSD <400> 16 Arg Val Lys Phe Ser Arg Ser Ala Asp Ala Pro Ala Tyr Gln Gln Gly 1 5 10 15 Gln Asn Gln Leu Tyr Asn Glu Leu Asn Leu Gly Arg Arg Glu Glu Tyr 20 25 30 Asp Val Leu Asp Lys Arg Arg Gly Arg Asp Pro Glu Met Gly Gly Lys 35 40 45 Pro Arg Arg Lys Asn Pro Gln Glu Gly Leu Tyr Asn Glu Leu Gln Lys 50 55 60 Asp Lys Met Ala Glu Ala Tyr Ser Glu Ile Gly Met Lys Gly Glu Arg 65 70 75 80 Arg Arg Gly Lys Gly His Asp Gly Leu Tyr Gln Gly Leu Ser Thr Ala 85 90 95 Thr Lys Asp Thr Tyr Asp Ala Leu His Met Gln Ala Leu Pro Pro Arg 100 105 110 <210> 17 <211> 180 <212> PRT <213> Artificial Sequence <220> <223> CD28ATD - CD28CSD - CD3zSSD <400> 17 Phe Trp Val Leu Val Val Val Gly Gly Val Leu Ala Cys Tyr Ser Leu 1 5 10 15[[ID=?]] Leu Val Thr Val Ala Phe Ile Ile Phe Trp Val Arg Ser Lys Arg Ser 20 25 30 It seems there might be an issue with the "ID=?" tag in the original. I've translated it as best as possible while keeping all the tags intact as per the instructions. If you meant something specific for that "ID=?", please clarify.Arg Leu Leu His Ser Asp Tyr Met Asn Met Thr Pro Arg Arg Pro Gly 35 40 45 Pro Thr Arg Lys His Tyr Gln Pro Tyr Ala Pro Pro Arg Asp Phe Ala 50 55 60 Ala Tyr Arg Ser Arg Val Lys Phe Ser Arg Ser Ala Asp Ala Pro Ala 65 70 75 80 Tyr Gln Gln Gly Gln Asn Gln Leu Tyr Asn Glu Leu Asn Leu Gly Arg 85 90 95 Arg Glu Glu Tyr Asp Val Leu Asp Lys Arg Arg Gly Arg Asp Pro Glu 100 105 110 Met Gly Gly Lys Pro Arg Arg Lys Asn Pro Gln Glu Gly Leu Tyr Asn 115 120 125 Glu Leu Gln Lys Asp Lys Met Ala Glu Ala Tyr Ser Glu Ile Gly Met 130 135 140 Lys Gly Glu Arg Arg Arg Gly Lys Gly His Asp Gly Leu Tyr Gln Gly 145 150 155 160 Leu Ser Thr Ala Thr Lys Asp Thr Tyr Asp Ala Leu His Met Gln Ala 165 170 175 Leu Pro Pro Arg 180 <210> 18 <211> 238 <212> PRT <213> Artificial sequence <220> <223> eGFP <400> 18 Val Ser Lys Gly Glu Glu Leu Phe Thr Gly Val Val Pro Ile Leu Val 1 5 10 15 Glu Leu Asp Gly Asp Val Asn Gly His Lys Phe Ser Val Ser Gly Glu 20 25 30 Gly Glu Gly Asp Ala Thr Tyr Gly Lys Leu Thr Leu Lys Phe Ile Cys 35 40 45 Thr Thr Gly Lys Leu Pro Val Pro Trp Pro Thr Leu Val Thr Thr Leu 50 55 60 Thr Tyr Gly Val Gln Cys Phe Ser Arg Tyr Pro Asp His Met Lys Gln 65 70 75 80 His Asp Phe Phe Lys Ser Ala Met Pro Glu Gly Tyr Val Gln Glu Arg 85 90 95 Thr Ile Phe Phe Lys Asp Asp Gly Asn Tyr Lys Thr Arg Ala Glu Val 100 105 110 Lys Phe Glu Gly Asp Thr Leu Val Asn Arg Ile Glu Leu Lys Gly Ile 115 120 125 Asp Phe Lys Glu Asp Gly Asn Ile Leu Gly His Lys Leu Glu Tyr Asn 130 135 140 Tyr Asn Ser His Asn Val Tyr Ile Met Ala Asp Lys Gln Lys Asn Gly 145 150 155 160 Ile Lys Val Asn Phe Lys Ile Arg His Asn Ile Glu Asp Gly Ser Val 165 170 175 Gln Leu Ala Asp His Tyr Gln Gln Asn Thr Pro Ile Gly Asp Gly Pro 180 185 190 Val Leu Leu Pro Asp Asn His Tyr Leu Ser Thr Gln Ser Ala Leu Ser 195 200 205 Lys Asp Pro Asn Glu Lys Arg Asp His Met Val Leu Leu Glu Phe Val 210 215 220 Thr Ala Ala Gly Ile Thr Leu Gly Met Asp Glu Leu Tyr Lys 225 230 235 <210> 19 <211> 20 <212> PRT <213> Synthetic sequence <220> <223> (G4S)4 linker <400> 19 Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly 1 5 10 15 Gly Gly Gly Ser 20 <210> 20 <211> 5 <212> PRT <213> Synthetic sequence <220> <223> G4S linker <400> 20 Gly Gly Gly Gly Ser 1 5 <210> 21 <211> 19 <212> PRT <213> Artificial sequence <220> <223> T2A linker <400> 21 Gly Glu Gly Arg Gly Ser Leu Leu Thr Cys Gly Asp Val Glu Glu Asn 1 5 10 15 Pro Gly Pro <210> 22 <211> 2659 <212> DNA <213> Artificial sequence <220> <223> Anti-CD20-(GA101)-Fab-CD28ATD-CD28CSD-CD3zSSD pETR17097 <400> 22 atgggatgga gctgtatcat cctcttcttg gtagcaacag ctaccggtgt gcattccgat 60 atcgtgatga cccagactcc actctccctg cccgtcaccc ctggagagcc cgccagcatt 120 agctgcaggt ctagcaagag cctcttgcac agcaatggca tcacttattt gtattggtac 180 ctgcaaaagc cagggcagtc tccacagctc ctgatttatc aaatgtccaa ccttgtctct 240 ggcgtccctg accggttctc cggatccggg tcaggcactg atttcacact gaaaatcagc 300 agggtggagg ctgaggatgt tggagtttat tactgcgctc agaatctaga acttccttac 360 accttcggcg gaggaccaa ggtggagatc aaaccgtacg gtggctgcac catctgtctt 420 catcttccg ccatctgatg agcagttgaa atctggaact gcctctgttg tgtgcctgct 480 gaataacttc tatcccagag aggccaaagt acagtggaag gtggataacg ccctccaatc 540 gggtaactcc caggagagtg tcacagagca ggacagcaag gacagcacct acagcctcag 600 cagcaccctg acgctgagca aagcagacta cgagaaacac aaagtctacg cctgcgaagt 660 cacccatcag ggcctgagct cgccccgtcac aaagagcttc aacaggggag agtgttagaa 720 tagaattccc cgaagtaact tagaagctgt aaatcaacga tcaatagcag gtgtggcaca 780 ccagtcatac cttgatcaag cacttctgtt tccccggact gagtatcaat aggctgctcg 840 cgcggctgaa ggagaaaacg ttcgttaccc gaccaactac ttcgagaagc ttagtaccac 900 catgaacgag gcagggtgtt tcgctcagca caaccccagt gtagatcagg ctgatgagtc 960 actgcaaccc ccatgggcga ccatggcagt ggctgcgttg gcggcctgcc catggagaaa 1020 tccatgggac gctctaattc tgacatggtg tgaagtgcct attgagctaa ctggtagtcc 1080 tccggcccct gattgcggct aatcctaact gcggagcaca tgctcacaaa ccagtgggtg 1140 gtgtgtcgta acgggcaact ctgcagcgga accgactact ttgggtgtcc gtgtttcctt 1200 ttatcctat attggctgct tatggtgaca atcaaaaagt tgttaccata tagctattgg 1260 attggccatc cggtgtgcaa cagggcaact gtttacctat ttatggttt tgtaccatta 1320 tcactgaagt ctgtgatcac tctcaaattc attttgaccc tcaacacaat caaacgccac 1380 catgggatgg agctctatca tcctcttctt ggtagcaaca gctaccggtg tgcactccca 1440 ggtgcaattg gtgcagtctg gcgctgaagt taagaagcct gggagttcag tgaaggtctc 1500 ctgcaaggct tcgggatacg ccttcagcta ttcttggatc aattgggtgc ggcaggcgcc 1560 tggacaaggg ctcgagtgga tgggacggat ctttcccggc gatggggata ctgactacaa 1620 tgggaaattc aagggcagag tcacaattac cgccgacaaa tccactagca cagcctatat 1680 ggagctgagc agcctgagat ctgaggacac ggccgtgtat tactgtgcaa gaaatgtctt 1740 tgatggttac tggcttgttt actggggcca gggaaccctg gtcaccgtct ccagcgctag 1800 caccaagggc ccctccgtgt tccccctggc ccccagcagc aagagcacca gcggcggcac 1860 agccgctctg ggctgcctgg tcaaggacta cttccccgag cccgtgaccg tgtcctggaa 1920 cagcggagcc ctgacctccg gcgtgcacac cttccccgcc gtgctgcaga gttctggcct 1980 gtatagcctg agcagcgtgg tcaccgtgcc ttctagcagc ctgggcaccc agacctacat 2040 ctgcaacgtg aaccacaagc ccagcaacac caaggtggac aagaaggtgg agcccaagag 2100 ctgcggaggg ggcggatcct tctgggtgct ggtggtggtg ggcggcgtgc tggcctgcta 2160 cagcctgctg gtgaccgtgg ccttcatcat cttctgggtg aggagcaaga ggagcaggct 2220 gctgcacagc gactacatga acatgacccc caggaggccc ggccccacca ggaagcacta 2280 ccagccctac gcccccccca gggacttcgc cgcctacagg agcagggtga agttcagcag 2340 gagcgccgac gccccgcct accagcaggg ccagaaccag ctgtataacg agctgaacct 2400 gggcaggagg gaggagtacg acgtgctgga caagaggagg ggcagggacc ccgagatggg 2460 cggcaagccc aggaggaga acccccagga gggcctgtat aacgagctgc aggaggaca gatggccgag gcctacagcg agatcggcat gaagggcgag aggaggg gcaagggcca 2580 cgacggcctg taccagggcc tgagcaccgc caccaaggac acctacgacg ccctgcacat gcaggccctg ccccccagg 2659 <210> 23 <211> 336 <212> DNA <213> The snowstorm <220> <223> CD20-(GA101)-Fab-VL <400> 23 60. gatatcgtga tgacccagac tccactctcc ctgcccgtca cccctggaga gcccgccagc attagctgca ggtctagcaa gagcctcttg cacagcaatg gcatcactta tttgtattgg 180. tacctgcaaa agccagggca gtctccacag ctcctgattt atcaaatgtc caaccttgtc tctggcgtcc ctgaccggtt ctccggatcc gggtcaggca ctgatttcac actgaaaatc 240 agcagggtgg aggctgagga tgttggagtt tattactgcg ctcagaatct agaacttcct tacaccttcg gcggagggac caaggtggag atcaaa 336 <210> 24 <211> 324 <212> DNA <213> The snowstorm <220> <223> Fab CL <400> 24 cgtacggtgg ctgcaccatc tgtcttcatc ttcccgccat ctgatgagca gttgaaatct 60 ggaactgcct ctgttgtgtg cctgctgaat aacttctatc ccagagaggc caaagtacag 120 tggaaggtgg ataacgccct ccaatcgggt aactcccagg agagtgtcac agagcaggac 180 agcaaggaca gcacctacag cctcagcagc accctgacgc tgagcaaagc agactacgag 240 aaacacaaag tctacgcctg cgaagtcacc catcagggcc tgagctcgcc cgtcacaaag 300 agcttcaaca ggggagagtg ttag 324 <210> 25 <211> 357 <212> DNA <213> Artificial sequence <220> <223> Anti-CD20-(GA101)-Fab-VH <400> 25 caggtgcaat tggtgcagtc tggcgctgaa gttaagaagc ctgggagttc agtgaaggtc 60 tcctgcaagg cttcgggata cgccttcagc tattcttgga tcaattgggt gcggcaggcg 120 cctggacaag ggctcgagtg gatgggacgg atctttcccg gcgatgggga tactgactac 180 aatgggaaat tcaagggcag agtcacaatt accgccgaca aatccactag cacagcctat 240 atggagctga gcagcctgag atctgaggac acggccgtgt attactgtgc aagaaatgtc 300 tttgatggtt actggcttgt ttactggggc cagggaaccc tggtcaccgt ctccagc 357 <210> 26 <211> 309 <212> DNA <213> Artificial sequence <220> <223> Fab CH1 <400> 26 gctagcacca agggcccctc cgtgttcccc ctggccccca gcagcaagag caccagcggc 60 ggcacagccg ctctgggctg cctggtcaag gactacttcc ccgagcccgt gaccgtgtcc 120 tggaacagcg gagccctgac ctccggcgtg cacaccttcc ccgccgtgct gcagagttct 180 ggcctgtata gcctgagcag cgtggtcacc gtgccttcta gcagcctggg cacccagacc 240 tacatctgca acgtgaacca caagcccagc aacaccaagg tggacaagaa ggtggagccc 300 aagagctgc 309 <210> 27 <211> 647 <212> DNA <213> Artificial sequence <220> <223> IRES EV71 internal ribosome entry site <400> 27 cccgaagtaa cttagaagct gtaaatcaac gatcaatagc aggtgtggca caccagtcat 60 accttgatca agcacttctg tttccccgga ctgagtatca ataggctgct cgcgcggctg 120 aaggagaaaa cgttcgttac ccgaccaact acttcgagaa gcttagtacc accatgaacg 180 aggcagggtg tttcgctcag cacaacccca gtgtagatca ggctgatgag tcactgcaac 240 ccccatgggc gaccatggca gtggctgcgt tggcggcctg cccatggaga aatccatggg 300 acgctctaat tctgacatgg tgtgaagtgc ctattgagct aactggtagt cctccggccc 360 ctgattgcgg ctaatcctaa ctgcggagca catgctcaca aaccagtggg tggtgtgtcg 420 taacgggcaa ctctgcagcg gaaccgacta ctttgggtgt ccgtgtttcc ttttattcct 480 atattggctg cttatggtga caatcaaaaa gttgttacca tatagctatt ggattggcca 540 tccggtgtgc aacagggcaa ctgtttacct atttattggt tttgtaccat tatcactgaa 600 gtctgtgatc actctcaaat tcattttgac cctcaacaca atcaaac 6^47 <210> 28 <211> 15 <212> DNA <213> Artificial Sequence <220> <223> G4S linker <400> 28 ggagggggcg gatcc 15 <210> 29 <211> 81 <212> DNA <213> Artificial sequence <220> <223> CD28ATD <400> 29 ttttgggtgc tggtggtggt tggtggagtc ctggcttgct atagcttgct agtaacagtg 60 gcctttatta ttttctgggt g 81 <210> 30 <211> 123 <212> DNA <213> Artificial sequence <220> <223> CD28CSD <400> 30 aggagtaaga ggagcaggct cctgcacagt gactacatga acatgactcc ccgccgcccc 60 gggcccaccc gcaagcatta ccagccctat gccccaccac gcgacttcgc agcctatcgc 120 tcc 123 <210> 31 <211> 336 <212> DNA <213> Artificial sequence <220> <223> CD3zSSD <400> 31 agagtgaagt tcagcaggag cgcagacgcc cccgcgtacc agcagggcca gaaccagctc 60 tataacgagc tcaatctagg acgaagagag gagtacgatg ttttggacaa gagacgtggc 120 cgggaccctg agatgggggg aaagccgaga aggaagaacc ctcaggaagg cctgtacaat 180 gaactgcaga aagataagat ggcggaggcc tacagtgaga ttgggatgaa aggcgagcgc 240 cggaggggca aggggcacga tggcctttac cagggtctca gtacagccac caaggacacc 300 tacgacgccc ttcacatgca ggccctgccc cctcgc 336 <210> 32 <211> 540 <212> DNA <213> Artificial sequence <220> <223> CD28ATD-CD28CSD-CD3zSSD <400> 32 ttctgggtgc tggtggtggt gggcggcgtg ctggcctgct acagcctgct ggtgaccgtg 60 gccttcatca tcttctgggt gaggagcaag aggagcaggc tgctgcacag cgactacatg 120 aacatgaccc ccaggaggcc cggccccacc aggaagcact accagcccta cgcccccccc 180 agggacttcg ccgcctacag gagcagggtg aagttcagca ggagcgccga cgcccccgcc 240 taccagcagg gccagaacca gctgtataac gagctgaacc tgggcaggag ggaggagtac 300 gacgtgctgg acaagaggag gggcagggac cccgagatgg gcggcaagcc caggaggaag 360 aacccccagg agggcctgta taacgagctg cagaaggaca agatggccga ggcctacagc 420 gagatcggca tgaagggcga gaggaggagg ggcaagggcc acgacggcct gtaccagggc 480 ctgagcaccg ccaccaagga cacctacgac gccctgcaca tgcaggccct gccccccagg 540 <210> 33 <211> 63 <212> DNA <213> Artificial sequence <220> <223> T2A linker <400> 33 tccggagagg gcagaggaag tcttctaaca tgcggtgacg tggaggagaa tcccggccct 60 agg 63 <210> 34 <211> 717 <212> DNA <213> Artificial sequence <220> <223> eGFP <400> 34 gtgagcaagg gcgaggagct gttcaccggg gtggtgccca tcctggtcga gctggacggc 60 gacgtaaacg gccacaagtt cagcgtgtcc ggcgagggcg agggcgatgc cacctacggc 120 aagctgaccc tgaagttcat ctgcaccacc ggcaagctgc ccgtgccctg gcccaccctc 180 gtgaccaccc tgacctacgg cgtgcagtgc ttcagccgct accccgacca catgaagcag 240 cacgacttct tcaagtccgc catgcccgaa ggctacgtcc aggagcgcac catcttcttc 300 aaggacgacg gcaactacaa gacccgcgcc gaggtgaagt tcgagggcga caccctggtg 360 aaccgcatcg agctgaaggg catcgacttc aaggaggacg gcaacatcct ggggcacaag 420 ctggagtaca actacaacag ccacaacgtc tatatcatgg ccgacaagca gaagaacggc 480 atcaaggtga acttcaagat ccgccacaac atcgaggacg gcagcgtgca gctcgccgac 540 cactaccagc agaacacccc catcggcgac ggccccgtgc tgctgcccga caaccactac 600 ctgagcaccc agtccgccct gagcaaagac cccaacgaga agcgcgatca catggtcctg 660 ctggagttcg tgaccgccgc cgggatcact ctcggcatgg acgagctgta caagtga 717 <210> 35 <211> 3438 <212> DNA <213> Artificial Sequence <220> <223> Anti-CD20-(GA101)-Fab-CD28ATD-CD28CSD-CD3zSSD-eGFP pETR17097 <400> 35 atgggatgga gctgtatcat cctcttcttg gtagcaacag ctaccggtgt gcattccgat 60 atcgtgatga cccagactcc actctccctg cccgtcaccc ctggagagcc cgccagcatt agctgcaggt ctagcaagag cctcttgcac agcaatggca tcacttattt gtattggtac 240. ctgcaaaagc cagggcagtc tccacagctc ctgatttatc aaatgtccaa ccttgtctct ggcgtccctg accggttctc cggatccggg tcaggcactg atttcacact gaaaatcagc agggtggagg ctgaggatgt tggagtttat tactgcgctc agaatctaga acttccttac 360 accttcggcg gaggacca ggtggagatc aaacgtacgg tggctgcacc atctgtcttc atcttcccgc catctgatga gcagttgaaa tctggaactg cctctgttgt gtgcctgctg 480 aataacttct atcccagaga ggccaaagta cagtggaagg tggataacgc cctccaatcg ggtaactccc aggagagtgt cacagagcag cacagcaagg acagcaccta cagcctcagc agcaccctga cgctgagcaa agcacctc gagaaacaca aagtctacgc ctgcgaagtc acccatcagg gcctgagctc gcccgtcaca aagagcttca acaggggaga gtgttagaat agaattcccc gaagtaactt agaagctgta aatcaacgat caatagcagg tgtggcacac cagtcatacc ttgatcaagc acttctgttt ccccggactg agtatcaata ggctgctcgc 840 gcggctgaag gagaaaacgt tcgttacccg accaactact tcgagaagct tagtaccacc 900 atgaacgagg cagggtgttt cgctcagcac aaccccagtg tagatcaggc tgatgagtca 960 ctgcaacccc catgggcgac catggcagtg gctgcgttgg cggcctgccc atggagaaat 1020 ccatgggacg ctctaattct gacatggtgt gaagtgccta ttgagctaac tggtagtcct 1080 ccggcccctg attgcggcta atcctaactg cggagcacat gctcacaaac cagtgggtgg 1140 tgtgtcgtaa cgggcaactc tgcagcggaa ccgactactt tgggtgtccg tgtttccttt 1200 tattcctata ttggctgctt atggtgacaa tcaaaaagtt gttaccatat agctattgga 1260 ttggccatcc ggtgtgcaac agggcaactg tttacctatt tattggtttt gtaccattat 1320 cactgaagtc tgtgatcact ctcaaattca ttttgaccct caacacaatc aaacgccacc 1380 atgggatgga gctgtatcat cctcttcttg gtagcaacag ctaccggtgt gcactcccag 1440 gtgcaattgg tgcagtctgg cgctgaagtt aagaagcctg ggagttcagt gaaggtctcc 1500 tgcaaggctt cgggatacgc cttcagctat tcttggatca attgggtgcg gcaggcgcct 1560 ggacaagggc tcgagtggat gggacggatc tttcccggcg atggggatac tgactacaat 1620 gggaaattca agggcagagt caaattacc gccgacaaat ccactagcac agcctatatg 1680 gagctgagca gcctgagatc tgaggacacg gccgtgtatt actgtgcaag aaatgtcttt 1740 gatggttact ggcttgttta ctggggccag ggaaccctgg tcaccgtctc cagcgctagc 1800 accaagggcc cctccgtgtt ccccctggcc cccagcagca agagcaccag cggcggcaca 1860 gccgctctgg gctgcctggt caaggactac ttccccgagc ccgtgaccgt gtcctggaac 1920 agcggagccc tgacctccgg cgtgcacacc ttccccgccg tgctgcagag ttctggcctg 1980 tatagcctga gcagcgtggt caccgtgcct tctagcagcc tgggcaccca gacctacatc 2040 tgcaacgtga accacaagcc cagcaacacc aaggtggaca agaaggtgga gcccaagagc 2100 tgcggagggg gcggatcctt ctgggtgctg gtggtggtgg gcggcgtgct ggcctgctac 2160 agcctgctgg tgaccgtggc cttcatcatc ttctgggtga ggagcaagag gagcaggctg 2220 ctgcacagcg actacatgaa catgaccccc aggaggcccg gccccaccag gaagcactac 2280 cagccctacg ccccccccag ggacttcgcc gcctacagga gcagggtgaa gttcagcagg 2340 agcgccgacg cccccgccta ccagcagggc cagaaccagc tgtataacga gctgaacctg 2400 ggcaggaggg aggagtacga cgtgctggac aagaggaggg gcagggaccc cgagatgggc 2460 ggcaagccca ggaggaagaa cccccaggag ggcctgtata acgagctgca gaaggacaag 2520 atggccgagg cctacagcga gatcggcatg aagggcgaga ggaggagggg caagggccac 2580 gacggcctgt accagggcct gagcaccgcc accaaggaca cctacgacgc cctgcacatg 2640 caggccctgc cccccaggtc cggagagggc agaggaagtc ttctaacatg cggtgacgtg 2700 gaggagaatc ccggccctag ggtgagcaag ggcgaggagc tgttcaccgg ggtggtgccc 2760 atcctggtcg agctggacgg cgacgtaaac ggccacaagt tcagcgtgtc cggcgagggc 2820 gagggcgatg ccacctacgg caagctgacc ctgaagttca tctgcaccac cggcaagctg 2880 cccgtgccct ggcccaccct cgtgaccacc ctgacctacg gcgtgcagtg cttcagccgc 2940 taccccgacc acatgaagca gcacgacttc ttcaagtccg ccatgcccga aggctacgtc 3000 caggagcgca ccatcttctt caaggacgac ggcaactaca agacccgcgc cgaggtgaag 3060 ttcgagggcg acaccctggt gaaccgcatc gagctgaagg gcatcgactt caaggaggac 3120 ggcaacatcc tggggcacaa gctggagtac aactacaaca gccacaacgt ctatatcatg 3180 gccgacaagc agaagaacgg catcaaggtg aacttcaaga tccgccacaa catcgaggac 3240 ggcagcgtgc agctcgccga ccactaccag cagaacaccc ccatcggcga cggccccgtg 3300 ctgctgcccg acaaccacta cctgagcacc cagtccgccc tgagcaaaga ccccaacgag 3360 aagcgcgatc acatggtcct gctggagttc gtgaccgccg ccgggatcac tctcggcatg 3420 gacgagctgt acaagtga 3438 <210> 36 <211> 411 <212> PRT <213> Artificial Sequence <220> <223> Anti-CD20-(GA101)-crossFab VH-CL light chain-ATD-CD28 ATD-CD28 CSD-CD3z SSD fusion pETR17098 <400> 36 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Ala Phe Ser Tyr Ser 20 25 30 Trp Ile Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Arg Ile Phe Pro Gly Asp Gly Asp Thr Asp Tyr Asn Gly Lys Phe 50 55 60 Lys Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Asn Val Phe Asp Gly Tyr Trp Leu Val Tyr Trp Gly Gln Gly 100 105 110 Thr Leu Val Thr Val Ser Ser Ala Ser Val Ala Ala Pro Ser Val Phe 115 120 125 Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val 130 135 140 Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp 145 150 155 160 Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr 165 170 175 Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr 180 185 190 Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val 195 200 205 Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly 210 215 220 Glu Cys Gly Gly Gly Gly Ser Phe Trp Val Leu Val Val Val Gly Gly 225 230 235 240 Val Leu Ala Cys Tyr Ser Leu Leu Val Thr Val Ala Phe Ile Ile Phe 245 250 255 Trp Val Arg Ser Lys Arg Ser Arg Leu Leu His Ser Asp Tyr Met Asn 260 265 270 Met Thr Pro Arg Arg Pro Gly Pro Thr Arg Lys His Tyr Gln Pro Tyr 275 280 285 Ala Pro Pro Arg Asp Phe Ala Ala Tyr Arg Ser Arg Val Lys Phe Ser 290 295 300 Arg Ser Ala Asp Ala Pro Ala Tyr Gln Gln Gly Gln Asn Gln Leu Tyr 305 310 315 320 Asn Glu Leu Asn Leu Gly Arg Arg Glu Glu Tyr Asp Val Leu Asp Lys 325 330 335 Arg Arg Gly Arg Asp Pro Glu Met Gly Gly Lys Pro Arg Arg Lys Asn 340 345 350 Pro Gln Glu Gly Leu Tyr Asn Glu Leu Gln Lys Asp Lys Met Ala Glu 355 360 365 Ala Tyr Ser Glu Ile Gly Met Lys Gly Glu Arg Arg Arg Gly Lys Gly 370 375 380 His Asp Gly Leu Tyr Gln Gly Leu Ser Thr Ala Thr Lys Asp Thr Tyr 385 390 395 400 Asp Ala Leu His Met Gln Ala Leu Pro Pro Arg 405 410 <210> 37 <211> 226 <212> PRT <213> Synthetic Sequence <220> <223> Anti-CD20-(GA101)-crossFab VH-CL light chain pETR17098 <400> 37 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Ala Phe Ser Tyr Ser 20 25 30 Trp Ile Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Arg Ile Phe Pro Gly Asp Gly Asp Thr Asp Tyr Asn Gly Lys Phe 50 55 60 Lys Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Asn Val Phe Asp Gly Tyr Trp Leu Val Tyr Trp Gly Gln Gly 100 105 110 Thr Leu Val Thr Val Ser Ser Ala Ser Val Ala Ala Pro Ser Val Phe 115 120 125 Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val 130 135 140 Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp 145 150 155 160 Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr 165 170 175 Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr 180 185 190 Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val 195 200 205 Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly 210 215 220 Glu Cys 225 <210> 38 <211> 217 <212> PRT <213> Artificial sequence <220> <223> Anti-CD20-(GA101)-crossFab VL-CH1 heavy chain-pETR17098 <400> 38 Asp Ile Val Met Thr Gln Thr Pro Leu Ser Leu Pro Val Thr Pro Gly 1 5 10 15 Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Lys Ser Leu Leu His Ser 20 25 30 Asn Gly Ile Thr Tyr Leu Tyr Trp Tyr Leu Gln Lys Pro Gly Gln Ser 35 40 45 Pro Gln Leu Leu Ile Tyr Gln Met Ser Asn Leu Val Ser Gly Val Pro 50 55 60 Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 65 70 75 80 Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Ala Gln Asn 85 90 95 Leu Glu Leu Pro Tyr Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 100 105 110 Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser 115 120 125 Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys 130 135 140 Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu 145 150 155 160 Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu 165 170 175 Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr 180 185 190 Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val 195 200 205 Asp Lys Lys Val Glu Pro Lys Ser Cys 210 215 <210> 39 <211> 107 <212> PRT <213> artificial sequence <220> <223> crossFab CL <400> 39 Ala Ser Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu 1 5 10 15 Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe 20 25 30 Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln 35 40 45 Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser 50 55 60 Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu 65 70 75 80 Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser 85 90 95 Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys 100 105 <210> 40 <211> 105 <212> PRT <213> artificial sequence <220> <223> crossFab CH1 <400> 40 Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser 1 5 10 15 Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys 20 25 30 Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu 35 40 45 Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu 50 55 60 Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr 65 70 75 80 Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val 85 90 95 Asp Lys Lys Val Glu Pro Lys Ser Cys 100 105 <210> 41 <211> 402 <212> PRT <213> Artificial Sequence <220> <223> Anti-CD20-(GA101)-crossFab VL-CH1 heavy chain-ATD-CD28 ATD-CD28 CSD-CD3z SSD fusion <400> 41 Asp Ile Val Met Thr Gln Thr Pro Leu Ser Leu Pro Val Thr Pro Gly 1 5 10 15 Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Lys Ser Leu Leu His Ser 20 25 30 Asn Gly Ile Thr Tyr Leu Tyr Trp Tyr Leu Gln Lys Pro Gly Gln Ser 35 40 45 Pro Gln Leu Leu Ile Tyr Gln Met Ser Asn Leu Val Ser Gly Val Pro 50 55 60 Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 65 70 75 80 Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Ala Gln Asn 85 90 95 Leu Glu Leu Pro Tyr Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 100 105 110 Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser 115 120 125 Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys 130 135 140 Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu 145 150 155 160 Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu 165 170 175 Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr 180 185 190 Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val 195 200 205 Asp Lys Lys Val Glu Pro Lys Ser Cys Gly Gly Gly Gly Ser Phe Trp 210 215 220 Val Leu Val Val Val Gly Gly Val Leu Ala Cys Tyr Ser Leu Leu Val 225 230 235 240 Thr Val Ala Phe Ile Ile Phe Trp Val Arg Ser Lys Arg Ser Arg Leu 245 250 255 Leu His Ser Asp Tyr Met Asn Met Thr Pro Arg Arg Pro Gly Pro Thr 260 265 270 Arg Lys His Tyr Gln Pro Tyr Ala Pro Pro Arg Asp Phe Ala Ala Tyr 275 280 285 Arg Ser Arg Val Lys Phe Ser Arg Ser Ala Asp Ala Pro Ala Tyr Gln 290 295 300 Gln Gly Gln Asn Gln Leu Tyr Asn Glu Leu Asn Leu Gly Arg Arg Glu 305 310 315 320 Glu Tyr Asp Val Leu Asp Lys Arg Arg Gly Arg Asp Pro Glu Met Gly 325 330 335 Gly Lys Pro Arg Arg Lys Asn Pro Gln Glu Gly Leu Tyr Asn Glu Leu 340 345 350 Gln Lys Asp Lys Met Ala Glu Ala Tyr Ser Glu Ile Gly Met Lys Gly 355 360 365 Glu Arg Arg Arg Gly Lys Gly His Asp Gly Leu Tyr Gln Gly Leu Ser 370 375 380 Thr Ala Thr Lys Asp Thr Tyr Asp Ala Leu His Met Gln Ala Leu Pro 385 390 395 400 Pro Arg <210> 42 <211> 217 <212> PRT <213> Synthetic sequence <220> <223> Anti-CD20-(GA101)-crossFab VL-CH1 heavy chain <400> 42 Asp Ile Val Met Thr Gln Thr Pro Leu Ser Leu Pro Val Thr Pro Gly 1 5 10 15 Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Lys Ser Leu Leu His Ser 20 25 30 Asn Gly Ile Thr Tyr Leu Tyr Trp Tyr Leu Gln Lys Pro Gly Gln Ser 35 40 45 Pro Gln Leu Leu Ile Tyr Gln Met Ser Asn Leu Val Ser Gly Val Pro 50 55 60 Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 65 70 75 80 Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Ala Gln Asn 85 90 95 Leu Glu Leu Pro Tyr Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 100 105 110 Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser 115 120 125 Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys 130 135 140 Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu 145 150 155 160 Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu 165 170 175 Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr 180 185 190 Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val 195 200 205 Asp Lys Lys Val Glu Pro Lys Ser Cys 210 215 <210> 43 <211> 226 <212> PRT <213> Artificial sequence <220> <223> Anti-CD20-(GA101)-crossFab VH-CL light chain <400> 43 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Ala Phe Ser Tyr Ser 20 25 30 Trp Ile Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Arg Ile Phe Pro Gly Asp Gly Asp Thr Asp Tyr Asn Gly Lys Phe 50 55 60 Lys Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Asn Val Phe Asp Gly Tyr Trp Leu Val Tyr Trp Gly Gln Gly 100 105 110 Thr Leu Val Thr Val Ser Ser Ala Ser Val Ala Ala Pro Ser Val Phe 115 120 125 Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val 130 135 140 Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp 145 150 155 160 Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr 165 170 175 Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr 180 185 190 Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val 195 200 205 Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly 210 215 220 GluCys 225 <210> 44 <211> 107 <212> PRT <213> artificial sequence <220> <223> crossFab CL <400> 44 Ala Ser Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu 1 5 10 15 Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe 20 25 30 Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln 35 40 45 Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser 50 55 60 Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu 65 70 75 80 Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser 85 90 95 Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys 100 105 <210> 45 <211> 105 <212> PRT <213> Artificial Sequence <220> <223> crossFab CH1 <400> 45 Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser 1 5 10 15 Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys 20 25 30 Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu 35 40 45 Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu 50 55 60 Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr 65 70 75 80 Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val 85 90 95 Asp Lys Lys Val Glu Pro Lys Ser Cys 100 105 <210> 46 <211> 2664 <212> DNA <213> Artificial sequence <220> <223> Anti-CD20-(GA101)-crossFabVH-CL CD28ATD-CD28CSD-CD3zSSD pETR17098 <400> 46 atgggatgga gctgtatcat cctcttcttg gtagcaacag ctaccggtgt gcattcccag 60 gtgcaattgg tgcagtctgg cgctgaagtt aagaagcctg ggagttcagt gaaggtctcc 120 tgcaaggctt ccggatacgc cttcagctat tcttggatca attgggtgcg gcaggcgcct 180 ggacaagggc tcgagtggat gggacggatc tttcccggcg atggggatac tgactacaat 240 gggaaattca agggcagagt cacaattacc gccgacaaat ccactagcac agcctatatg 300 gagctgagca gcctgagatc tgaggacacg gccgtgtatt actgtgcaag aaatgtcttt 360 gatggttact ggcttgttta ctggggccag ggaaccctgg tcaccgtctc ctcagctagc 420 gtggccgctc cctccgtgtt catcttccca ccttccgacg agcagctgaa gtccggcacc 480 gcttctgtcg tgtgcctgct gaacaacttc tacccccgcg aggccaaggt gcagtggaag 540 gtggacaacg ccctgcagtc cggcaacagc caggaatccg tgaccgagca ggactccaag 600 gacagcacct actccctgtc ctccaccctg accctgtcca aggccgacta cgagaagcac 660 aaggtgtacg cctgcgaagt gacccaccag ggcctgtcta gccccgtgac caagtctttc 720 aaccggggcg agtgctgata aggaattccc cgaagtaact tagaagctgt aaatcaacga 780 tcaatagcag gtgtggcaca ccagtcatac cttgatcaag cacttctgtt tccccggact 840 gagtatcaat aggctgctcg cgcggctgaa ggagaaaacg ttcgttaccc gaccaactac 900 ttcgagaagc ttagtaccac catgaacgag gcagggtgtt tcgctcagca caaccccagt 960 gtagatcagg ctgatgagtc actgcaaccc ccatgggcga ccatggcagt ggctgcgttg 1020 gcggcctgcc catggagaaa tccatgggac gctctaattc tgacatggtg tgaagtgcct 1080 attgagctaa ctggtagtcc tccggcccct gattgcggct aatcctaact gcggagcaca 1140 tgctcacaaa ccagtgggtg gtgtgtcgta acgggcaact ctgcagcgga accgactact 1200 ttgggtgtcc gtgtttcctt ttatcctat attggctgct tatggtgaca atcaaaaagt 1260 tgttaccata tagctattgg attggccatc cggtgtgcaa cagggcaact gtttacctat 1320 ttattggttt tgtaccatta tcactgaagt ctgtgatcac tctcaaattc attttgaccc 1380 tcaacacaat caaacgccac catgggatgg agctgtatca tcctcttctt ggtagcaaca 1440 gctaccggtg tgcactccga catcgtgatg acccagactc cactctccct gcccgtcacc 1500 cctggagagc ccgccagcat tagctgcagg tctagcaaga gcctcttgca cagcaatggc 1560 atcacttatt tgtattggta cctgcaaaag ccagggcagt ctccacagct cctgatttat 1620 caaatgtcca accttgtctc tggcgtccct gatcggttct ccggttccgg gtcaggcact 1680 gatttcacac tgaaaatcag cagggtggag gctgaggatg ttggagttta ttactgcgct 1740 cagaatctag aacttcctta caccttcggc ggagggacca aggtggagat caaatccagc 1800 gctagcacca agggcccctc cgtgttcccc ctggccccca gcagcaagag caccagcggc 1860 ggcacagccg ctctgggctg cctggtcaag gactacttcc ccgagcccgt gaccgtgtcc 1920 tggaacagcg gagccctgac ctccggcgtg cacaccttcc ccgccgtgct gcagagttct 1980 ggcctgtata gcctgagcag cgtggtcacc gtgccttcta gcagcctggg caccagacc 2040 tacatctgca acgtgaacca caagcccagc aacaccaagg tggacaagaa ggtggagccc 2100 aagagctgcg gagggggcgg atccttctgg gtgctggtgg tggtgggcgg cgtgctggcc 2160 tgctacagcc tgctggtgac cgtggccttc atcatcttct gggtgaggag caagaggagc 2220 aggctgctgc acagcgacta catgaacatg accccccagga ggcccggccc caccaggaag 2280 cactaccagc cctacgcccc ccccagggac ttcgccgccct acggagcag ggtgaagttc 2340 agcaggagcg ccgacgcccc cgcctaccag cagggccaga accagctgta taacgagctg 2400 aacctgggca ggagggag gtacgacgtg ctggacaaga ggaggggcag ggaccccgag 2460 atgggcggca agcccaggag gaagacccc caggagggcc tgtataacga gctgcagaag 2520 gacaagatgg ccgaggccta cagcgagatc ggcatgaagg gcgagaggag gagggcaag 2580 ggccacgacg gcctgtacca gggcctgagc accgccacca aggacaccta cgacgccctg 2640 cacatgcagg ccctgccccc cagg 2664 <210> 47 <211> 324 <212> DNA <213> Artificial sequence <220> <223> crossFab CL <400> 47 gctagcgtgg ccgctccctc cgtgttcatc ttcccacctt ccgacgagca gctgaagtcc 60 ggcaccgctt ctgtcgtgtg cctgctgaac aacttctacc cccgcgaggc caaggtgcag 120 tggaaggtgg acaacgccct gcagtccggc aacagccagg aatccgtgac cgagcaggac 180 tccaaggaca gcacctactc cctgtcctcc accctgaccc tgtccaaggc cgactacgag 240 aagcacaagg tgtacgcctg cgaagtgacc caccagggcc tgtctagccc cgtgaccaag 300 tctttcaacc ggggcgagtg ctga 324 <210> 48 <211> 315 <212> DNA <213> Artificial sequence <220> <223> crossFab CH1 <400> 48 tccagcgcta gcaccaaggg cccctccgtg ttccccctgg cccccagcag caagagcacc 60 agcggcggca cagccgctct gggctgcctg gtcaaggact acttccccga gcccgtgacc 120 gtgtcctgga acagcggagc cctgacctcc ggcgtgcaca ccttccccgc cgtgctgcag 180 agttctggcc tgtatagcct gagcagcgtg gtcaccgtgc cttctagcag cctgggcacc 240 cagacctaca tctgcaacgt gaaccacaag cccagcaaca ccaaggtgga caagaaggtg 300 gagcccaaga gctgc 315 <210> 49 <211> 3444 <2x12> DNA <213> Artificial sequence <220> <223> Anti-CD20-(GA101)-crossFabVH-CL CD28ATD-CD28CSD-CD3zSSD-eGFP pETR17098 <400> 49 atgggatgga gctgtatcat cctcttcttg gtagcaacag ctaccggtgt gcattcccag 60 gtgcaattgg tgcagtctgg cgctgaagtt aagaagcctg ggagttcagt gaaggtctcc 120 tgcaaggctt ccggatacgc cttcagctat tcttggatca attgggtgcg gcaggcgcct 180 ggacaagggc tcgagtggat gggacggatc tttcccggcg atggggatac tgactacaat 240 gggaaattca agggcagagt cacaattacc gccgacaaat ccactagcac agcctatatg 300 gagctgagca gcctgagatc tgaggacacg gccgtgtatt actgtgcaag aaatgtcttt 360 gatggttact ggcttgttta ctggggccag ggaaccctgg tcaccgtctc ctcagctagc 420 It should be noted that in the translation, the "2x12" in might be a misrepresentation in the original. It's translated as "DNA" as it seems to be related to a DNA sequence context, but the "2x12" part is rather unclear. If there is more context available, a more accurate translation could be provided.gtggccgctc cctccgtgtt catcttccca ccttccgacg agcagctgaa gtccggcacc 480 gcttctgtcg tgtgcctgct gaacaacttc taccccgcg aggccaaggt gcagtggaag 540 gtggacaacg ccctgcagtc cggcaacagc caggaatccg tgaccgagca ggactccaag 600 gacagcacct actccctgtc ctccaccctg accctgtcca aggccgacta cgagaagcac 660 aaggtgtacg cctgcgaagt gacccaccag ggcctgtcta gccccgtgac caagtctttc 720 aaccggggcg agtgctgata aggaattccc cgaagtaact tagaagctgt aaatcaacga 780 tcaatagcag gtgtggcaca ccagtcatac cttgatcaag cacttctgtt tccccggact 840 gagtatcaat aggctgctcg cgcggctgaa ggagaaaacg ttcgttaccc gaccaactac 900 ttcgagaagc ttagtaccac catgaacgag gcagggtgtt tcgctcagca caaccccagt 960 gtagatcagg ctgatgagtc actgcaaccc ccatgggcga ccatggcagt ggctgcgttg 1020 gcggcctgcc catggagaaa tccatgggac gctctaattc tgacatggtg tgaagtgcct 1080 attgagctaa ctggtagtcc tccggcccct gattgcggct aatcctaact gcggagcaca 1140 tgctcacaaa ccagtgggtg gtgtgtcgta acgggcaact ctgcagcgga accgactact 1200 ttgggtgtcc gtgtttcctt ttattcctat attggctgct tatggtgaca atcaaaaagt 1260 tgttaccata tagctattgg attggccatc cggtgtgcaa cagggcaact gtttacctat 1320 ttattggttt tgtaccatta tcactgaagt ctgtgatcac tctcaaattc attttgaccc 1380 tcaacacaat caaacgccac catgggatgg agctgtatca tcctcttctt ggtagcaaca 1440 gctaccggtg tgcactccga catcgtgatg acccagactc cactctccct gcccgtcacc 1500 cctggagagc ccgccagcat tagctgcagg tctagcaaga gcctcttgca cagcaatggc 1560 atcacttatt tgtattggta cctgcaaaag ccagggcagt ctccacagct cctgatttat 1620 caaatgtcca accttgtctc tggcgtccct gatcggttct ccggttccgg gtcaggcact 1680 gatttcacac tgaaaatcag cagggtggag gctgaggatg ttggagttta ttactgcgct 1740 cagaatctag aacttcctta caccttcggc ggagggacca aggtggagat caaatccagc 1800 gctagcacca agggcccctc cgtgttcccc ctggccccca gcagcaagag caccagcggc 1860 ggcacagccg ctctgggctg cctggtcaag gactacttcc ccgagcccgt gaccgtgtcc 1920 tggaacagcg gagccctgac ctccggcgtg cacaccttcc ccgccgtgct gcagagttct 1980 ggcctgtata gcctgagcag cgtggtcacc gtgccttcta gcagcctggg caccagacc 2040 tacatctgca acgtgaacca caagcccagc aacaccaagg tggacaagaa ggtggagccc 2100 aagagctgcg gagggggcgg atccttctgg gtgctggtgg tggtgggcgg cgtgctggcc 2160 tgctacagcc tgctggtgac cgtggccttc atcatcttct gggtgaggag caagaggagc 2220 aggctgctgc acagcgacta catgaacatg accccccagga ggcccggccc caccaggaag 2280 cactaccagc cctacgcccc ccccagggac ttcgccgccct acggagcag ggtgaagttc 2340 agcaggagcg ccgacgcccc cgcctaccag cagggccaga accagctgta taacgagctg 2400 aacctgggca ggagggag gtacgacgtg ctggacaaga ggaggggcag ggaccccgag 2460 atgggcggca agcccaggag gaagacccc caggagggcc tgtataacga gctgcagaag 2520 gacaagatgg ccgaggccta cagcgagatc ggcatgaagg gcgagaggag gagggcaag 2580 ggccacgacg gcctgtacca gggcctgagc accgccacca aggacaccta cgacgccctg 2640 cacatgcagg ccctgccccc caggtccgga gagggcagag gaagtcttct aacatgcggt 2700 gacgtggagg agaatcccgg ccctagggtg agcaagggcg aggagctgtt caccggggtg 2760 gtgcccatcc tggtcgagct ggacggcgac gtaaacggcc acaagttcag cgtgtccggc 2820 gagggcgagg gcgatgccac ctacggcaag ctgaccctga agttcatctg caccaccggc 2880 aagctgcccg tgccctggcc caccctcgtg accaccctga cctacggcgt gcagtgcttc 2940 agccgctacc ccgaccacat gaagcagcac gacttcttca agtccgccat gcccgaaggc 3000 tacgtccagg agcgcaccat cttcttcaag gacgacggca actacaagac ccgcgccgag 3060 gtgaagttcg agggcgacac cctggtgaac cgcatcgagc tgaagggcat cgacttcaag 3120 gaggacggca acatcctggg gcacaagctg gagtacaact acaacagcca caacgtctat 3180 atcatggccg acaagcagaa gaacggcatc aaggtgaact tcaagatccg ccacaacatc 3240 gaggacggca gcgtgcagct cgccgaccac taccagcaga acacccccat cggcgacggc 3300 cccgtgctgc tgcccgacaa ccactacctg agcacccagt ccgccctgag caaagacccc 3360 aacgagaagc gcgatcacat ggtcctgctg gagttcgtga ccgccgccgg gatcactctc 3420 ggcatggacg agctgtacaa gtga 3444 <210> 50 <211> 404 <212> PRT <213> Artificial Sequence <220> <223> Anti-CD20-(GA101)-Fab VL-CL Light Chain-CD28ATD-CD28CSD-CD3zSSD Fusion <400> 50 Asp Ile Val Met Thr Gln Thr Pro Leu Ser Leu Pro Val Thr Pro Gly 1 5 10 15 Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Lys Ser Leu Leu His Ser 20 25 30 Asn Gly Ile Thr Tyr Leu Tyr Trp Tyr Leu Gln Lys Pro Gly Gln Ser 35 40 45 Pro Gln Leu Leu Ile Tyr Gln Met Ser Asn Leu Val Ser Gly Val Pro 50 55 60 Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 65 70 75 80<00020^28>Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Ala Gln Asn 85 90 95 Leu Glu Leu Pro Tyr Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 100 105 110 Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu 115 120 125 Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe 130 135 140 Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln 145 150 155 160 Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser 165 170 175 Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu 180 185 190 Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser 195 200 205 Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys Gly Gly Gly Gly Ser 210 215 220 Phe Trp Val Leu Val Val Val Gly Gly Val Leu Ala Cys Tyr Ser Leu 225 230 235 240 Leu Val Thr Val Ala Phe Ile Ile Phe Trp Val Arg Ser Lys Arg Ser 245 250 255 Arg Leu Leu His Ser Asp Tyr Met Asn Met Thr Pro Arg Arg Pro Gly 260 265 270 Pro Thr Arg Lys His Tyr Gln Pro Tyr Ala Pro Pro Arg Asp Phe Ala 275 280 285 Ala Tyr Arg Ser Arg Val Lys Phe Ser Arg Ser Ala Asp Ala Pro Ala 290 295 300 Tyr Gln Gln Gly Gln Asn Gln Leu Tyr Asn Glu Leu Asn Leu Gly Arg 305 310 315 320 Arg Glu Glu Tyr Asp Val Leu Asp Lys Arg Arg Gly Arg Asp Pro Glu 325 330 335 Met Gly Gly Lys Pro Arg Arg Lys Asn Pro Gln Glu Gly Leu Tyr Asn 340 345 350 Glu Leu Gln Lys Asp Lys Met Ala Glu Ala Tyr Ser Glu Ile Gly Met 355 360 365 Lys Gly Glu Arg Arg Arg Gly Lys Gly His Asp Gly Leu Tyr Gln Gly 370 375 380 Leu Ser Thr Ala Thr Lys Asp Thr Tyr Asp Ala Leu His Met Gln Ala 385 390 395 400 Leu Pro Pro Arg <210> 51 <211> 658 <212> PRT <213> Artificial sequence <220> <223> Anti-CD20-(GA101)-scFab-CD28ATD-CD28CSD-CD3zSSD fusion pETR17101 <400> 51 Asp Ile Val Met Thr Gln Thr Pro Leu Ser Leu Pro Val Thr Pro Gly 1 5 10 15 Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Lys Ser Leu Leu His Ser 20 25 30 Asn Gly Ile Thr Tyr Leu Tyr Trp Tyr Leu Gln Lys Pro Gly Gln Ser 35 40 45 Pro Gln Leu Leu Ile Tyr Gln Met Ser Asn Leu Val Ser Gly Val Pro 50 55 60 Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 65 70 75 80 Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Ala Gln Asn 85 90 95 Leu Glu Leu Pro Tyr Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 100 105 110 Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu 115 120 125 Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe 130 135 140 Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln 145 150 155 160 Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser 165 170 175 Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu 180 185 190 Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser 195 200 205 Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys Gly Gly Gly Gly Ser 210 215 220 Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly 225 230 235 240 Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gln Val Gln Leu Val 245 250 255 Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser 260 265 270 Cys Lys Ala Ser Gly Tyr Ala Phe Ser Tyr Ser Trp Ile Asn Trp Val 275 280 285 Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Arg Ile Phe Pro 290 295 300 Gly Asp Gly Asp Thr Asp Tyr Asn Gly Lys Phe Lys Gly Arg Val Thr 305 310 315 320 Ile Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser 325 330 335 Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asn Val Phe 340 345 350 Asp Gly Tyr Trp Leu Val Tyr Trp Gly Gln Gly Thr Leu Val Thr Val 355 360 365 Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser 370 375 380 Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys 385 390 395 400 Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu 405 410 415 Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu 420 425 430 Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr 435 440 445 Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val 450 455 460 Asp Lys Lys Val Glu Pro Lys Ser Cys Gly Gly Gly Gly Ser Phe Trp 465 470 475 480 Val Leu Val Val Val Gly Gly Val Leu Ala Cys Tyr Ser Leu Leu Val 485 490 495 Thr Val Ala Phe Ile Ile Phe Trp Val Arg Ser Lys Arg Ser Arg Leu 500 505 510 Leu His Ser Asp Tyr Met Asn Met Thr Pro Arg Arg Pro Gly Pro Thr 515 520 525 Arg Lys His Tyr Gln Pro Tyr Ala Pro Pro Arg Asp Phe Ala Ala Tyr 530 535 540 Arg Ser Arg Val Lys Phe Ser Arg Ser Ala Asp Ala Pro Ala Tyr Gln 545 550 555 560 Gln Gly Gln Asn Gln Leu Tyr Asn Glu Leu Asn Leu Gly Arg Arg Glu 565 570 575 Glu Tyr Asp Val Leu Asp Lys Arg Arg Gly Arg Asp Pro Glu Met Gly 580 585 590 Gly Lys Pro Arg Arg Lys Asn Pro Gln Glu Gly Leu Tyr Asn Glu Leu 595 600 605 Gln Lys Asp Lys Met Ala Glu Ala Tyr Ser Glu Ile Gly Met Lys Gly 610 615 620 Glu Arg Arg Arg Gly Lys Gly His Asp Gly Leu Tyr Gln Gly Leu Ser 625 630 635 640 Thr Ala Thr Lys Asp Thr Tyr Asp Ala Leu His Met Gln Ala Leu Pro 645 650 655 Pro Arg <210> 52 <211> 473 <212> PRT <213> Artificial sequence <220> <223> Anti-CD20-(GA101)-scFab <400> 52 Asp Ile Val Met Thr Gln Thr Pro Leu Ser Leu Pro Val Thr Pro Gly 1 5 10 15 Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Lys Ser Leu Leu His Ser 20 25 30 Asn Gly Ile Thr Tyr Leu Tyr Trp Tyr Leu Gln Lys Pro Gly Gln Ser 35 40 45 Pro Gln Leu Leu Ile Tyr Gln Met Ser Asn Leu Val Ser Gly Val Pro 50 55 60 Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 65 70 75 80 Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Ala Gln Asn 85 90 95 Leu Glu Leu Pro Tyr Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 100 105 110 Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu 115 120 125 Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe 130 135 140 Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln 145 150 155 160 Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser 165 170 175 Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu 180 185 190 Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser 195 200 205 Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys Gly Gly Gly Gly Ser 210 215 220 Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly 225 230 235 240 Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gln Val Gln Leu Val 245 250 255 Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser 260 265 270 Cys Lys Ala Ser Gly Tyr Ala Phe Ser Tyr Ser Trp Ile Asn Trp Val 275 280 285 Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Arg Ile Phe Pro 290 295 300 Gly Asp Gly Asp Thr Asp Tyr Asn Gly Lys Phe Lys Gly Arg Val Thr 305 310 315 320 Ile Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser 325 330 335 Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asn Val Phe 340 345 350 Asp Gly Tyr Trp Leu Val Tyr Trp Gly Gln Gly Thr Leu Val Thr Val 355 360 365 Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser 370 375 380 Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys 385 390 395 400 Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu 405 410 415 Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu 420 425 430 Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr 435 440 445 Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val 450 455 460 Asp Lys Lys Val Glu Pro Lys Ser Cys 465 470 <210> 53 <211> 106 <212> PRT <213> artificial sequence <220> <223> scFab-CL <400> 53 Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu 1 5 10 15 Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe 20 25 30 Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln 35 40 45 Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser 50 55 60 Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu 65 70 75 80 Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser 85 90 95 Pro Val Thr Lys Ser Phe Asn Arg Gly Glu 100 105 <210> 54 <211> 32 <212> PRT <213> Artificial sequence <220> <223> (G4S)6G2 linker <400> 54 Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly 1 5 10 15 Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly 20 25 30 <210> 55 <211> 2031 <212> DNA <213> Artificial sequence <220> <223> Anti-CD20-(GA101)-scFab-CD28ATD-CD28CSD-CD3zSSD fusion pETR170101 <400> 55 atgggatgga gctgtatcat cctcttcttg gtagcaacag ctacgggtgt gcattccgac 60 atcgtgatga cccagactcc actctccctg cccgtcaccc ctggagagcc cgccagcatt 120 agctgcaggt ctagcaagag cctcttgcac agcaatggca tcacttattt gtattggtac 180 ctgcaaaagc cagggcagtc tccacagctc ctgatttatc aaatgtccaa ccttgtctct 240 ggcgtccctg atcggttctc cggttccggg tcaggcactg atttcacact gaaaatcagc 300 agggtggagg ctgaggatgt tggagtttat tactgcgctc agaatctaga acttccttac 360 accttcggcg gagggaccaa ggtggagatc aaacgtacgg tggctgcacc atctgtcttc 420 atcttcccgc catctgatga gcagttgaaa tctggaactg cctctgttgt gtgcctgctg 480 aataacttct atcccagaga ggccaaagta cagtggaagg tggataacgc cctccaatcg 540 ggtaactccc aggagagtgt cacagagcag gacagcaagg acagcaccta cagcctcagc 600 agcaccctga cgctgagcaa agcagactac gagaaacaca aagtctacgc ctgcgaagtc 660 acccatcagg gcctgagctc gcccgtcaca aagagcttca acaggggaga gtgtggcggc 720 ggaggatctg gtggcggagg tagtggtggt ggtggatctg gcggaggcgg ctccggcgga 780 ggtggaagcg gaggtggtgg ttccggagga caggtgcaat tggtgcagtc tggcgctgaa 840 gttaagaagc ctgggagttc agtgaaggtc tcctgcaagg cttcgggata cgccttcagc 900 tattcttgga tcaattgggt gcggcaggcg cctggacaag ggctcgagtg gatgggacgg 960 atctttcccg gcgatgggga tactgactac aatgggaaat tcaagggcag agtcacaatt 1020 accgccgaca aatccactag cacagcctat atggagctga gcagcctgag atctgaggac 1080 acggccgtgt attactgtgc aagaaatgtc tttgatggtt actggcttgt ttactggggc 1140 cagggaaccc tggtcaccgt ctcctcagct agcaccaagg gcccctccgt gttccccctg 1200 gcccccagca gcaagagcac cagcggcggc acagccgctc tgggctgcct ggtcaaggac 1260 tacttccccg agcccgtgac cgtgtcctgg aacagcggag ccctgacctc cggcgtgcac 1320 accttccccg ccgtgctgca gagttctggc ctgtatagcc tgagcagcgt ggtcaccgtg 1380 ccttctagca gcctgggcac ccagacctac atctgcaacg tgaaccacaa gcccagcaac 1440 accaaggtgg acaagaaggt ggagcccaag agctgcggag ggggcggatc cttctgggtg 1500 ctggtggtgg tgggcggcgt gctggcctgc tacagcctgc tggtgaccgt ggccttcatc 1560 atcttctggg tgaggagcaa gaggagcagg ctgctgcaca gcgactacat gaacatgacc 1620 cccaggaggc ccggccccac caggaagcac taccagccct acgccccccc cagggacttc 1680 gccgcctaca ggagcagggt gaagttcagc aggagcgccg acgcccccgc ctaccagcag 1740 ggccagaacc agctgtataa cgagctgaac ctgggcagga gggaggagta cgacgtgctg 1800 gacaagagga ggggcaggga ccccgagatg ggcggcaagc ccaggaggaa gaacccccag 1860 gagggcctgt ataacgagct gcagaaggac aagatggccg aggcctacag cgagatcggc 1920 atgaagggcg agaggaggag gggcaagggc cacgacggcc tgtaccaggg cctgagcacc 1980 gccaccaagg acacctacga cgccctgcac atgcaggccc tgccccccag g 2031 <210> 56 <211> 336 <212> DNA <213> Artificial Sequence <220> <223> scFab-VL <400> 56 gacatcgtga tgacccagac tccactctcc ctgcccgtca cccctggaga gcccgccagc 60 attagctgca ggtctagcaa gagcctcttg cacagcaatg gcatcactta tttgtattgg 120 tacctgcaaa agccagggca gtctccacag ctcctgattt atcaaatgtc caaccttgtc 180 tctggcgtcc ctgatcggtt ctccggttcc gggtcaggca ctgatttcac actgaaaatc 240 agcagggtgg aggctgagga tgttggagtt tattactgcg ctcagaatct agaacttcct 300 tacaccttcg gcggagggac caaggtggag atcaaa 336 <210> 57 <211> 321 <212> DNA <213> Artificial sequence <220> <223> scFab-CL <400> 57 cgtacggtgg ctgcaccatc tgtcttcatc ttcccgccat ctgatgagca gttgaaatct 60 ggaactgcct ctgttgtgtg cctgctgaat aacttctatc ccagagaggc caaagtacag 120 tggaaggtgg ataacgccct ccaatcgggt aactcccagg agagtgtcac agagcaggac 180 agcaaggaca gcacctacag cctcagcagc accctgacgc tgagcaaagc agactacgag 240 aaacacaaag tctacgcctg cgaagtcacc catcagggcc tgagctcgcc cgtcacaaag 300 agcttcaaca ggggagagtg t 321 <210> 58 <211> 357 <212> DNA <213> Artificial sequence <220> <223> Anti-CD20-(GA101)-scFab-VH <400> 58 caggtgcaat tggtgcagtc tggcgctgaa gttaagaagc ctgggagttc agtgaaggtc 60 tcctgcaagg cttcgggata cgccttcagc tattcttgga tcaattgggt gcggcaggcg 120 cctggacaag ggctcgagtg gatgggacgg atctttcccg gcgatgggga tactgactac 180 aatgggaaat tcaagggcag agtcacaatt accgccgaca aatccactag cacagcctat 240 atggagctga gcagcctgag atctgaggac acggccgtgt attactgtgc aagaaatgtc 300 tttgatggtt actggcttgt ttactggggc cagggaaccc tggtcaccgt ctcctca 357 <210> 59 <211> 2806 <212> DNA <213> Artificial sequence <220> <223> Anti-CD20-(GA101)-scFab-CD28ATD-CD28CSD-CD3zSSD-eGFP fusion pETR170101 <400> 59 atggagctgt atcatcctct tcttggtagc aacagctacg ggtgtgcatt ccgacatcgt 60 gatgacccag actccactct ccctgcccgt cacccctgga gagcccgcca gcattagctg 120 caggtctagc aagagcctct tgcacagcaa tggcatcact tatttgtatt ggtacctgca 180 aaagccaggg cagtctccac agctcctgat ttatcaaatg tccaaccttg tctctggcgt 240 ccctgatcgg ttctccggtt ccgggtcagg cactgatttc acactgaaaa tcagcagggt 300 ggaggctgag gatgttggag tttatactg cgctcagaat ctagaacttc cttacacctt 360 cggcggaggg accaaggtgg agatcaaacg tacggtggct gcaccatctg tcttcatctt 420 cccgccatct gatgagcagt tgaaatctgg aactgcctct gttgtgtgcc tgctgaataa 480 540 ctcccaggag agtgtcacag agcaggacag caaggacagc acctacagcc tcagcagcac 600 cctgacgctg agcaaagcag actacgagaa acaaaagtc tacgcctgcg aagtcaccca 660 tcagggcctg agctcgcccg tcaaaagag cttcaacagg ggagagtgtg gcggcggagg 720 atctggtggc ggaggtagtg gtggtggtgg atctggcgga ggcggctccg gccgaggtgg 780 aagcggaggt ggtggttccg gaggacaggt gcaattggtg cagtctggcg ctgaagttaa 840 gaagcctggg agttcagtga aggtctcctg caaggcttcg ggatacgcct tcagctattc 900 ttggatcaat tgggtgcggc aggcgcctgg acaagggctc gagtggatgg gacggatctt 960 tcccggcgat ggggatactg actacaatgg gaaattcaag ggcagagtca caattaccgc 1020 cgacaaatcc actagcacag cctatatgga gctgagcagc ctgagatctg aggacacggc 1080 cgtgtattac tgtgcaagaa atgtctttga tggttactgg cttgtttact ggggccaggg 1140 aaccctggtc accgtctcct cagctagcac caagggcccc tccgtgttcc ccctggcccc 1200 cagcagcaag agcaccagcg gcggcacagc cgctctgggc tgcctggtca aggactactt 1260 ccccgagccc gtgaccgtgt cctggaacag cggagccctg acctccggcg tgcacacctt 1320 ccccgccgtg ctgcagagtt ctggcctgta tagcctgagc agcgtggtca ccgtgccttc 1380 tagcagcctg ggcacccaga cctacatctg caacgtgaac cacaagccca gcaacaccaa 1440 ggtggacaag aaggtggagc ccaagagctg cggagggggc ggatccttct gggtgctggt 1500 ggtggtgggc ggcgtgctgg cctgctacag cctgctggtg accgtggcct tcatcatctt 1560 ctgggtgagg agcaagagga gcaggctgct gcacagcgac tacatgaaca tgacccccag 1620 gaggcccggc cccaccagga agcactacca gccctacgcc ccccccaggg acttcgccgc 1680 ctacaggagc agggtgaagt tcagcaggag cgccgacgcc cccgcctacc agcagggcca 1740 gaaccagctg tataacgagc tgaacctggg caggagggag gagtacgacg tgctggacaa 1800 gaggaggggc agggaccccg agatgggcgg caagcccagg aggaagaacc cccaggaggg 1860 cctgtataac gagctgcaga aggacaagat ggccgaggcc tacagcgaga tcggcatgaa 1920 gggcgagagg aggaggggca agggccacga cggcctgtac cagggcctga gcaccgccac 1980 caaggacacc tacgacgccc tgcacatgca ggccctgccc cccaggtccg gagagggcag 2040 aggaagtctt ctaacatgcg gtgacgtgga ggagaatccc ggccctaggg tgagcaaggg 2100 cgaggagctg ttcaccgggg tggtgcccat cctggtcgag ctggacggcg acgtaaacgg 2160 ccacaagttc agcgtgtccg gcgagggcga gggcgatgcc acctacggca agctgaccct 2220 gaagttcatc tgcaccaccg gcaagctgcc cgtgccctgg cccaccctcg tgaccaccct 2280 2340. gtgcagtgc tcagccgcta ccccgaccac atgaagcagc acgacttctt caagtccgcc atgcccgaag gctacgtcca ggagcgcacc atcttcttca aggacgacgg caactacaag acccgcgccg aggtgaagtt cgagggcgac accctggtga accgcatcga gctgaagggc atcgacttca aggaggacgg caacatcctg gggcacaagc tggagtacaa ctacaacagc cacaacgtct atatcatggc cgacaagcag aagaacggca tcaaggtgaa cttcaagatc cgccacaaca tcgaggacgg cagcgtgcag ctcgccgacc actaccagca gaacacccc atcggcgacg gcccgtgct gctgcccgac aaccactacc tgagcaccca gtccgccctg agcaaagacc ccaacgagaa gcgcgatcac atggtcctgc tggagttcgt gaccgccgcc gggatcactc tcggcatgga cgagctgtac aagtga <210> 60 <211> 436 <212> PRT <213> The snowstorm <220> <223> The CD20-(GA101)-ds-scFv-CD28ATD-CD28CSD-CD3zSSD fragment pETR17162 <400> 60 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Ala Phe Ser Tyr Ser 20 25 30 Trp Ile Asn Trp Val Arg Gln Ala Pro Gly Gln Cys Leu Glu Trp Met 35 40 45 Gly Arg Ile Phe Pro Gly Asp Gly Asp Thr Asp Tyr Asn Gly Lys Phe 50 55 60 Lys Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Asn Val Phe Asp Gly Tyr Trp Leu Val Tyr Trp Gly Gln Gly 100 105 110 Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly 115 120 125 Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Ile Val Met Thr 130 135 140 Gln Thr Pro Leu Ser Leu Pro Val Thr Pro Gly Glu Pro Ala Ser Ile 145 150 155 160 Ser Cys Arg Ser Ser Lys Ser Leu Leu His Ser Asn Gly Ile Thr Tyr 165 170 175 Leu Tyr Trp Tyr Leu Gln Lys Pro Gly Gln Ser Pro Gln Leu Leu Ile 180 185 190 Tyr Gln Met Ser Asn Leu Val Ser Gly Val Pro Asp Arg Phe Ser Gly 195 200 205 Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala 210 215 220 Glu Asp Val Gly Val Tyr Tyr Cys Ala Gln Asn Leu Glu Leu Pro Tyr 225 230 235 240 Thr Phe Gly Cys Gly Thr Lys Val Glu Ile Lys Gly Gly Gly Gly Ser 245 250 255 Phe Trp Val Leu Val Val Val Gly Gly Val Leu Ala Cys Tyr Ser Leu 260 265 270 Leu Val Thr Val Ala Phe Ile Ile Phe Trp Val Arg Ser Lys Arg Ser 275 280 285 Arg Leu Leu His Ser Asp Tyr Met Asn Met Thr Pro Arg Arg Pro Gly 290 295 300 Pro Thr Arg Lys His Tyr Gln Pro Tyr Ala Pro Pro Arg Asp Phe Ala 305 310 315 320 Ala Tyr Arg Ser Arg Val Lys Phe Ser Arg Ser Ala Asp Ala Pro Ala 325 330 335 Tyr Gln Gln Gly Gln Asn Gln Leu Tyr Asn Glu Leu Asn Leu Gly Arg 340 345 350 Arg Glu Glu Tyr Asp Val Leu Asp Lys Arg Arg Gly Arg Asp Pro Glu 355 360 365 Met Gly Gly Lys Pro Arg Arg Lys Asn Pro Gln Glu Gly Leu Tyr Asn 370 375 380 Glu Leu Gln Lys Asp Lys Met Ala Glu Ala Tyr Ser Glu Ile Gly Met 385 390 395 400 Lys Gly Glu Arg Arg Arg Gly Lys Gly His Asp Gly Leu Tyr Gln Gly 405 410 415 Leu Ser Thr Ala Thr Lys Asp Thr Tyr Asp Ala Leu His Met Gln Ala 420 425 430 Leu Pro Pro Arg 435 <210> 61 <211> 251 <212> PRT <213> Artificial Sequence <220> <223> Anti-CD20-(GA101)-ds-scFv <400> 61 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Ala Phe Ser Tyr Ser 20 25 30 Trp Ile Asn Trp Val Arg Gln Ala Pro Gly Gln Cys Leu Glu Trp Met 35 40 45 Gly Arg Ile Phe Pro Gly Asp Gly Asp Thr Asp Tyr Asn Gly Lys Phe 50 55 60 Lys Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Asn Val Phe Asp Gly Tyr Trp Leu Val Tyr Trp Gly Gln Gly 100 105 110 Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly 115 120 125 Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Ile Val Met Thr 130 135 140 Gln Thr Pro Leu Ser Leu Pro Val Thr Pro Gly Glu Pro Ala Ser Ile 145 150 155 160 Ser Cys Arg Ser Ser Lys Ser Leu Leu His Ser Asn Gly Ile Thr Tyr 165 170 175 Leu Tyr Trp Tyr Leu Gln Lys Pro Gly Gln Ser Pro Gln Leu Leu Ile 180 185 190 Tyr Gln Met Ser Asn Leu Val Ser Gly Val Pro Asp Arg Phe Ser Gly 195 200 205 Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala 210 215 220 Glu Asp Val Gly Val Tyr Tyr Cys Ala Gln Asn Leu Glu Leu Pro Tyr 225 230 235 240 Thr Phe Gly Cys Gly Thr Lys Val Glu Ile Lys 245 250 <210> 62 <211> 119 <212> PRT <213> artificial sequence <220> <223> Anti-CD20-(GA101)-ds-Fab VH <400> 62 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Ala Phe Ser Tyr Ser 20 25 30 Trp Ile Asn Trp Val Arg Gln Ala Pro Gly Gln Cys Leu Glu Trp Met 35 40 45 Gly Arg Ile Phe Pro Gly Asp Gly Asp Thr Asp Tyr Asn Gly Lys Phe 50 55 60 Lys Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Asn Val Phe Asp Gly Tyr Trp Leu Val Tyr Trp Gly Gln Gly 100 105 110 Thr Leu Val Thr Val Ser Ser 115 <210> 63 <211> 112 <212> PRT <213> Synthetic sequence <220> <223> Anti-CD20-(GA101)-ds-Fab VL <400> 63 Asp Ile Val Met Thr Gln Thr Pro Leu Ser Leu Pro Val Thr Pro Gly 1 5 10 15 Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Lys Ser Leu Leu His Ser 20 25 30 Asn Gly Ile Thr Tyr Leu Tyr Trp Tyr Leu Gln Lys Pro Gly Gln Ser 35 40 45 Pro Gln Leu Leu Ile Tyr Gln Met Ser Asn Leu Val Ser Gly Val Pro 50 55 60 Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 65 70 75 80 Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Ala Gln Asn 85 90 95 Leu Glu Leu Pro Tyr Thr Phe Gly Cys Gly Thr Lys Val Glu Ile Lys 100 105 110 <210> 64 <211> 1364 <212> DNA <213> Artificial Sequence <220> <223> Anti-CD20-(GA101)-ds-Fab-CD28ATD-CD28CSD-CD3zSSD Fusion pETR17162 <400> 64 atgggatgga gctgtatcat cctcttcttg gtagcaacag ctaccggtgt gcattcccag 60 gtgcaattgg tgcagtctgg cgctgaagtt aagaagcctg ggagttcagt gaaggtctcc 120 tgcaaggctt ccggttacgc cttcagctat tcttggatca attgggtgcg gcaggcgcct 180 ggacaatgtc tcgagtggat gggacggatc tttcccggcg atggggatac tgactacaat 240 gggaaattca agggcagagt cacaattacc gccgacaaat ccactagcac agcctatatg 300 gagctgagca gcctgagatc tgaggacacg gccgtgtatt actgtgcaag aaatgtcttt 360 gatggttact ggcttgttta ctggggccag ggaaccctgg tcaccgtctc ctcaggaggg 420 ggcggaagtg gtggcggggg aagcggcggg ggtggcagcg gagggggcgg atctgacatc 480 gtgatgaccc agactccact ctccctgccc gtcacccctg gagagcccgc cagcattagc 540 tgcaggtcta gcaagagcct cttgcacagc aatggcatca cttatttgta ttggtacctg 600 caaaagccag ggcagtctcc acagctcctg atttatcaaa tgtccaacct tgtctctggc 660 gtccctgacc gcttctccgg ttccgggtca ggcactgatt tcacactgaa aatcagcagg 720 gtggaggctg aggatgttgg agtttattac tgcgctcaga atctagaact tccttacacc 780 ttcggctgtg ggaccaaggt ggagatcaag gagggggcgg atccttctgg gtgctggtgg 840 tggtgggcgg cgtgctggcc tgctacagcc tgctggtgac cgtggccttc atcatcttct 900 gggtgaggag caagaggagc aggctgctgc acagcgacta catgaacatg acccccagga 960 ggcccggccc caccaggaag cactaccagc cctacgcccc ccccagggac ttcgccgcct 1020 acaggagcag ggtgaagttc agcaggagcg ccgacgcccc cgcctaccag cagggccaga 1080 accagctgta taacgagctg aacctgggca ggagggagga gtacgacgtg ctggacaaga 1140 ggaggggcag ggaccccgag atgggcggca agcccaggag gaagaacccc caggagggcc 1200 tgtataacga gctgcagaag gacaagatgg ccgaggccta cagcgagatc ggcatgaagg 1260 gcgagaggag gaggggcaag ggccacgacg gcctgtacca gggcctgagc accgccacca 1320 aggacaccta cgacgccctg cacatgcagg ccctgccccc cagg 1364 <210> 65 <211> 357 <212> DNA <213> Artificial Sequence <220> <223> Anti-CD20-(GA101)-ds-Fab VH <400> 65 caggtgcaat tggtgcagtc tggcgctgaa gttaagaagc ctgggagttc agtgaaggtc 60 tcctgcaagg cttccggtta cgccttcagc tattcttgga tcaattgggt gcggcaggcg 120 cctggacaat gtctcgagtg gatgggacgg atctttcccg gcgatgggga tactgactac 180 aatgggaaat tcaagggcag agtcacaatt accgccgaca aatccactag cacagcctat 240 atggagctga gcagcctgag atctgaggac acggccgtgt attactgtgc aagaaatgtc 300 tttgatggtt actggcttgt ttactggggc cagggaaccc tggtcaccgt ctcctca 357 <210> 66 <211> 336 <212> DNA <213> Synthetic sequence <220> <223> Anti-CD20-(GA101)-ds-Fab VL <400> 66 gacatcgtga tgacccagac tccactctcc ctgcccgtca cccctggaga gcccgccagc 60 attagctgca ggtctagcaa gagcctcttg cacagcaatg gcatcactta tttgtattgg 120 tacctgcaaa agccagggca gtctccacag ctcctgattt atcaaatgtc caaccttgtc 180 tctggcgtcc ctgaccgctt ctccggttcc gggtcaggca ctgatttcac actgaaaatc 240 agcagggtgg aggctgagga tgttggagtt tattactgcg ctcagaatct agaacttcct 300 tacaccttcg gctgtgggac caaggtggag atcaaa 336 <210> 67 <211> 2151 <212> DNA <213> Synthetic sequence <220> <223> Anti-CD20-(GA101)-ds-scFv-CD28ATD-CD28CSD-CD3zSSD-eGFP fusion pETR17162 <400> 67 gccaccatgg gatggagctg tatcatcctc ttcttggtag caacagctac cggtgtgcat 60 tcccaggtgc aattggtgca gtctggcgct gaagttaaga agcctgggag ttcagtgaag 120 gtctcctgca aggcttccgg ttacgccttc agctattctt ggatcaattg ggtgcggcag 180 gcgcctggac aatgtctcga gtggatggga cggatctttc ccggcgatgg ggatactgac 240 tacaatggga aattcaaggg cagagtcaca attaccgccg acaaatccac tagcacagcc 300 tatatggagc tgagcagcct gagatctgag gacacggccg tgtattactg tgcaagaaat 360 gtctttgatg gttactggct tgtttactgg ggccagggaa ccctggtcac cgtctcctca 420 ggagggggcg gaagtggtgg cgggggaagc ggcgggggtg gcagcggagg gggcggatct 480 gacatcgtga tgacccagac tccactctcc ctgcccgtca cccctggaga gcccgccagc 540 attagctgca ggtctagcaa gagcctcttg cacagcaatg gcatcactta tttgtattgg 600 tacctgcaaa agccagggca gtctccacag ctcctgattt atcaaatgtc caaccttgtc 660 tctggcgtcc ctgaccgctt ctccggttcc gggtcaggca ctgatttcac actgaaaatc 720 agcagggtgg aggctgagga tgttggagtt tattactgcg ctcagaatct agaacttcct 780 tacaccttcg gctgtgggac caaggtggag atcaaaggag ggggcggatc cttctgggtg 840 ctggtggtgg tgggcggcgt gctggcctgc tacagcctgc tggtgaccgt ggccttcatc 900 atcttctggg tgaggagcaa gaggagcagg ctgctgcaca gcgactacat gaacatgacc 960 cccaggaggc ccggccccac caggaagcac taccagccct acgccccccc cagggacttc 1020 gccgcctaca ggagcagggt gaagttcagc aggagcgccg acgcccccgc ctaccagcag 1080 ggccagaacc agctgtataa cgagctgaac ctgggcagga gggaggagta cgacgtgctg 1140 gacaagagga ggggcaggga ccccgagatg ggcggcaagc ccaggaggaa gaacccccag 1200 gagggcctgt ataacgagct gcagaaggac aagatggccg aggcctacag cgagatcggc 1260 atgaagggcg agaggaggag gggcaagggc cacgacggcc tgtaccaggg cctgagcacc 1320 gccaccaagg acacctacga cgccctgcac atgcaggccc tgccccccag gtccggagag 1380 ggcagaggaa gtcttctaac atgcggtgac gtggaggaga atcccggccc tagggtgagc 1440 aagggcgagg agctgttcac cggggtggtg cccatcctgg tcgagctgga cggcgacgta 1500 aacggccaca agttcagcgt gtccggcgag ggcgagggcg atgccaccta cggcaagctg 1560 accctgaagt tcatctgcac caccggcaag ctgcccgtgc cctggcccac cctcgtgacc 1620 accctgacct acggcgtgca gtgcttcagc cgctaccccg accacatgaa gcagcacgac 1680 ttcttcaagt ccgccatgcc cgaaggctac gtccaggagc gcaccatctt cttcaaggac 1740 gacggcaact acaagacccg cgccgaggtg aagttcgagg gcgacaccct ggtgaaccgc 1800 atcgagctga agggcatcga cttcaaggag gacggcaaca tcctggggca caagctggag 1860 tacaactaca acagccacaa cgtctatatc atggccgaca agcagaagaa cggcatcaag 1920 gtgaacttca agatccgcca caacatcgag gacggcagcg tgcagctcgc cgaccactac 1980 cagcagaaca cccccatcgg cgacggcccc gtgctgctgc ccgacaacca ctacctgagc 2040 acccagtccg ccctgagcaa agaccccaac gagaagcgcg atcacatggt cctgctggag 2100 ttcgtgaccg ccgccgggat cactctcggc atggacgagc tgtacaagtg a 2151 <210> 68 <211> 164 <212> PRT <213> Human (Homo sapiens) <400> 68 Met Lys Trp Lys Ala Leu Phe Thr Ala Ala Ile Leu Gln Ala Gln Leu 1 5 10 15 Pro Ile Thr Glu Ala Gln Ser Phe Gly Leu Leu Asp Pro Lys Leu Cys 20 25 30 Tyr Leu Leu Asp Gly Ile Leu Phe Ile Tyr Gly Val Ile Leu Thr Ala 35 40 45 Leu Phe Leu Arg Val Lys Phe Ser Arg Ser Ala Asp Ala Pro Ala Tyr 50 55 60 Gln Gln Gly Gln Asn Gln Leu Tyr Asn Glu Leu Asn Leu Gly Arg Arg 65 70 75 80 Glu Glu Tyr Asp Val Leu Asp Lys Arg Arg Gly Arg Asp Pro Glu Met 85 90 95 Gly Gly Lys Pro Gln Arg Arg Lys Asn Pro Gln Glu Gly Leu Tyr Asn 100 105 110 Glu Leu Gln Lys Asp Lys Met Ala Glu Ala Tyr Ser Glu Ile Gly Met 115 120 125 Lys Gly Glu Arg Arg Arg Gly Lys Gly His Asp Gly Leu Tyr Gln Gly 130 135 140 Leu Ser Thr Ala Thr Lys Asp Thr Tyr Asp Ala Leu His Met Gln Ala 145 150 155 160 Leu Pro Pro Arg <210> 69 <211> 492 <212> DNA <213> Homo sapiens <400> 69 atgaagtgga aggcgctttt caccgcggcc atcctgcagg cacagttgcc gattacagag 60 gcacagagct ttggcctgct ggatcccaaa ctctgctacc tgctggatgg aatcctcttc 120 atctatggtg tcattctcac tgccttgttc ctgagagtga agttcagcag gagcgcagag 180 ccccccgcgt accagcaggg ccagaaccag ctctataacg agctcaatct aggacgaaga 240 gaggagtacg atgttttgga caagagacgt ggccgggacc ctgagatggg gggaaagccg 300 agaaggaaga accctcagga aggcctgtac aatgaactgc agaaagataa gatggcggag 360 gcctacagtg agattgggat gaaaggcgag cgccggaggg gcaaggggca cgatggcctt 420 taccagggtc tcagtacagc caccaaggac acctacgacg cccttcacat gcaggccctg 480 ccccctcgct aa 492 <210> 70 <211> 164 <212> PRT <213> mice (Mus musculus) <400> 70 Met Lys Trp Lys Val Ser Val Leu Ala Cys Ile Leu His Val Arg Phe 1 5 10 15 Pro Gly Ala Glu Ala Gln Ser Phe Gly Leu Leu Asp Pro Lys Leu Cys 20 25 30 Tyr Leu Leu Asp Gly Ile Leu Phe Ile Tyr Gly Val Ile Ile Thr Ala 35 40 45 Leu Tyr Leu Arg Ala Lys Phe Ser Arg Ser Ala Glu Thr Ala Ala Asn 50 55 60 Leu Gln Asp Pro Asn Gln Leu Tyr Asn Glu Leu Asn Leu Gly Arg Arg 65 70 75 80 Glu Glu Tyr Asp Val Leu Glu Lys Lys Arg Ala Arg Asp Pro Glu Met 85 90 95 Gly Gly Lys Gln Gln Arg Arg Arg Asn Pro Gln Glu Gly Val Tyr Asn 100 105 110 Ala Leu Gln Lys Asp Lys Met Ala Glu Ala Tyr Ser Glu Ile Gly Thr 115 120 125 Lys Gly Glu Arg Arg Arg Gly Lys Gly His Asp Gly Leu Tyr Gln Gly 130 135 140 Leu Ser Thr Ala Thr Lys Asp Thr Tyr Asp Ala Leu His Met Gln Thr 145 150 155 160 Leu Ala Pro Arg <210> 71 <211> 495 <212> DNA <213> Mouse (Mus musculus) <400> 71 atgaagtgga aagtgtctgt tctcgcctgc atcctccacg tgcggttccc aggagcagag 60 gcacagagct ttggtctgct ggatcccaaa ctctgctact tgctagatgg aatcctcttc 120 atctacggag tcatcatcac agccctgtac ctgagagcaa aattcagcag gagtgcagag 180 actgctgcca acctgcagga ccccaaccag ctctacaatg agctcaatct agggcgaaga 240 gaggaatatg acgtcttgga gaagaagcgg gctcgggatc cagagatggg aggcaaacag 300 cagaggagga ggaaccccca ggaaggcgta tacaatgcac tgcagaaaga caagatggca 360 gaagcctaca gtgagatcgg cacaaaaggc gagaggcgga gaggcaaggg gcacgatggc 420 ctttaccagg gtctcagcac tgccaccaag gacacctatg atgccctgca tatgcagacc 480 ctggcccctc gctaa 495 <210> 72 <211> 660 <212> DNA <213> Human (Homo sapiens) <400> 72 atgctgcgcc tgctgctggc gctgaacctg tttccgagca ttcaggtgac cggcaacaaa 60 attctggtga aacagagccc gatgctggtg gcgtatgata acgcggtgaa cctgagctgc 120 aaatatagct ataacctgtt tagccgcgaa tttcgcgcga gcctgcataa aggcctggat 180 agcgcggtgg aagtgtgcgt ggtgtatggc aactatagcc agcagctgca ggtgtatagc 240 aaaaccggct ttaactgcga tggcaaactg ggcaacgaaa gcgtgacctt ttatctgcag 300 aacctgtatg tgaaccagac cgatatttat ttttgcaaaa ttgaagtgat gtatccgccg 360 ccgtatctgg ataacgaaaa aagcaacggc accattattc atgtgaaagg caaacatctg 420 tgcccgagcc cgctgtttcc gggcccgagc aaaccgtttt gggtgctggt ggtggtgggc 480 ggcgtgctgg cgtgctatag cctgctggtg accgtggcgt ttattatttt ttgggtgcgc 540 agcaaacgca gccgcctgct gcatagcgat tatatgaaca tgaccccgcg ccgcccgggc 600 ccgacccgca aacattatca gccgtatgcg ccgccgcgcg attttgcggc gtatcgcagc 660 <210> 73 <211> 220 <212> PRT <213> Homo sapiens <400> 73 Met Leu Arg Leu Leu Leu Ala Leu Asn Leu Phe Pro Ser Ile Gln Val 1 5 10 15 Thr Gly Asn Lys Ile Leu Val Lys Gln Ser Pro Met Leu Val Ala Tyr 20 25 30 Asp Asn Ala Val Asn Leu Ser Cys Lys Tyr Ser Tyr Asn Leu Phe Ser 35 40 45 Arg Glu Phe Arg Ala Ser Leu His Lys Gly Leu Asp Ser Ala Val Glu 50 55 60 Val Cys Val Val Tyr Gly Asn Tyr Ser Gln Gln Leu Gln Val Tyr Ser 65 70 75 80 Lys Thr Gly Phe Asn Cys Asp Gly Lys Leu Gly Asn Glu Ser Val Thr 85 90 95 Phe Tyr Leu Gln Asn Leu Tyr Val Asn Gln Thr Asp Ile Tyr Phe Cys 100 105 110 Lys Ile Glu Val Met Tyr Pro Pro Pro Tyr Leu Asp Asn Glu Lys Ser 115 120 125 Asn Gly Thr Ile Ile His Val Lys Gly Lys His Leu Cys Pro Ser Pro 130 135 140 Leu Phe Pro Gly Pro Ser Lys Pro Phe Trp Val Leu Val Val Gly 145 150 155 160 Gly Val Leu Ala Cys Tyr Ser Leu Leu Val Thr Val Ala Phe Ile Ile 165 170 175 Phe Trp Val Arg Ser Lys Arg Ser Arg Leu Leu His Ser Asp Tyr Met 180 185 190 Asn Met Thr Pro Arg Arg Pro Gly Pro Thr Arg Lys His Tyr Gln Pro 195 200 205 Tyr Ala Pro Pro Arg Asp Phe Ala Ala Tyr Arg Ser 210 215 220 <210> 74 <211> 654 <212> DNA <213> Musculus (Musculus) <400> 74 atgaccctgc gcctgctgtt tctggcgctg aactttta gcgtgcaggt gaccgaaaac 60 aaaattctgg tgaacagag cccgctgctg gtggtggata gcaacgaagt gagcctgagc 120 tgccgctata gctataacct gctggcgaaa gatttcgcg cgagcctgta tAAggcgtg 180 aacagcgatg tggaagtgtg cgtgggcaac ggcaacttta cctatcagcc gcagtttcgc 240 agcaacgcgg aatttaactg cgatggcgat tttgataacg aaaccgtgac ctttcgcctg 300 tggaacctgc atgtgaacca taccgatatt tatttttgca aaattgaatt tatgtatccg 360 ccgccgtatc tggataacga acgcagcaac ggcaccatta ttcatattaa agaaaaacat 420 ctgtgccata cccagagcag cccgaaactg ttttgggcgc tggtggtggt ggcgggcgtg 480 ctgttttgct atggcctgct ggtgaccgtg gcgctgtgcg tgatttggac caacagccgc 540 cgcaaccgcc tgctgcagag cgattatatg aacatgaccc cgcgccgccc gggcctgacc 600 cgcaaaccgt atcagccgta tgcgccggcg cgcgattttg cggcgtatcg cccg 654 <210> 75 <211> 218 <212> PRT <213> Mouse (Mus musculus) <400> 75 Met Thr Leu Arg Leu Leu Phe Leu Ala Leu Asn Phe Phe Ser Val Gln 1 5 10 15 Val Thr Glu Asn Lys Ile Leu Val Lys Gln Ser Pro Leu Leu Val Val 20 25 30 Asp Ser Asn Glu Val Ser Leu Ser Cys Arg Tyr Ser Tyr Asn Leu Leu 35 40 45 Ala Lys Glu Phe Arg Ala Ser Leu Tyr Lys Gly Val Asn Ser Asp Val 50 55 60 Glu Val Cys Val Gly Asn Gly Asn Phe Thr Tyr Gln Pro Gln Phe Arg 65 70 75 80 Ser Asn Ala Glu Phe Asn Cys Asp Gly Asp Phe Asp Asn Glu Thr Val 85 90 95 Thr Phe Arg Leu Trp Asn Leu His Val Asn His Thr Asp Ile Tyr Phe 100 105 110 Cys Lys Ile Glu Phe Met Tyr Pro Pro Pro Tyr Leu Asp Asn Glu Arg 115 120 125 Ser Asn Gly Thr Ile Ile His Ile Lys Glu Lys His Leu Cys His Thr 130 135 140 Gln Ser Ser Pro Lys Leu Phe Trp Ala Leu Val Val Val Ala Gly Val 145 150 155 160 Leu Phe Cys Tyr Gly Leu Leu Val Thr Val Ala Leu Cys Val Ile Trp 165 170 175 Thr Asn Ser Arg Arg Asn Arg Leu Leu Gln Ser Asp Tyr Met Asn Met 180 185 190 Thr Pro Arg Arg Pro Gly Leu Thr Arg Lys Pro Tyr Gln Pro Tyr Ala 195 200 205 Pro Ala Arg Asp Phe Ala Ala Tyr Arg Pro 210 215 <210> 76 <211> 4 <212> PRT <213> Artificial sequence <220> <223> CD28 YMNM <400> 76 Tyr Met Asn Met 1 <210> 77 <211> 4 <212> PRT <213> Artificial sequence <220> <223> CD28 PYAP <400> 77 Pro Tyr Ala Pro 1 <210> 78 <211> twenty one <212> PRT <213> Artificial sequence <220> <223> signal peptide <400> 78 Ala Thr Met Gly Trp Ser Cys Ile Ile Leu Phe Leu Val Ala Thr Ala 1 5 10 15 Thr Gly Val His Ser 20 <210> 79 <211> 57 <212> DNA <213> Artificial sequence <220> <223> Signal peptide DNA sequence <400> 79 atgggatgga gctgtatcat cctcttcttg gtagcaacag ctaccggtgt gcactcc 57 <210> 80 <211> 116 <212> PRT <213> Artificial Sequence <220> <223> Anti-WT1 (33F05) VH <400> 80 Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Asn Ser Tyr 20 25 30 Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile 35 40 45 Gly Tyr Ile Tyr Tyr Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys 50 55 60 Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu 65 70 75 80 Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95 Arg Ser Tyr Tyr Glu Ala Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val 100 105 110 Thr Val Ser Ser 115 <210> 81 <211> 107 <212> PRT <213> Artificial sequence <220> <223> Anti-WT1 (33F05) VL <4Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr 20 25 30 Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe 50 55 60 Gln Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Ser Ile Glu Leu Trp Trp Gly Gly Phe Asp Tyr Trp Gly Gln 100 105 110 Gly Thr Thr Val Thr Val Ser Ser 115 120 <210> 83 <211> 106 <212> PRT <213> Synthetic sequence <220> <223> Anti-WT1 (11D06) VL <400> 83 Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Trp 20 25 30 Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45 Tyr Asp Ala Ser Ser Leu Glu Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Gly Ser Leu Gln Pro 65 70 75 80 Asp Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Glu Asp Tyr Thr Thr 85 90 95 Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 100 105 <210> 84 <211> 119 <212> PRT <213> Synthetic Sequence <220> <223> Anti-WT1 (33H09) VH <400> 84 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr 20 25 30 Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe 50 55 60 Gln Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Gly Ser Tyr Asp Leu Phe Ser Leu Asp Tyr Trp Gly Gln Gly 100 105 110 Thr Thr Val Thr Val Ser Ser 115 <210> 85 <211> 106 <212> PRT <213> artificial sequence <220> <223> WT1 (33H09) VL <400> 85 Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Trp 20 25 30 Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45 Tyr Asp Ala Ser Ser Leu Glu Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Asp Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Tyr Asp Gly Ile Thr 85 90 95 Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 100 105 <210> 86 <211> 119 <212> PRT <213> Artificial Sequence <220> <223> Anti-WT1 (5E11) VH <400> 86 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr 20 25 30 Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe 50 55 60 Gln Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Ser Ser Tyr Asp Leu Tyr Ser Phe Asp Tyr Trp Gly Gln Gly 100 105 110 Thr Thr Val Thr Val Ser Ser 115 <210> 87 <211> 108 <212> PRT <213> artificial sequence <220> <223> WT1 (5E11) VL <400> 87 Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Trp 20 25 30 Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45 Tyr Asp Ala Ser Ser Leu Glu Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Asp Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Ser Phe Pro Pro Met 85 90 95 Ile Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 100 105 <210> 88 <211> 5 <212> PRT <213> Artificial sequence <220> <223> Anti-CD3 HCDR1 Kabat <400> 88 Thr Tyr Ala Met Asn 1 5 <210> 89 <211> 19 <212> PRT <213> Artificial sequence <220> <223> Anti-CD3 HCDR2 Kabat <400> 89 Arg Ile Arg Ser Lys Tyr Asn Asn Tyr Ala Thr Tyr Tyr Ala Asp Ser 1 5 10 15 Val Lys Gly <210> 90 <211> 14 <212> PRT <213> Artificial sequence <220> <223> Anti-CD3 HCDR3 Kabat <400> 90 His Gly Asn Phe Gly Asn Ser Tyr Val Ser Trp Phe Ala Tyr 1 5 10 <210> 91 <211> 14 <212> PRT <213> Artificial sequence <220> <223> Anti-CD3 LCDR1 Kabat <400> 91 Gly Ser Ser Thr Gly Ala Val Thr Thr Ser Asn Tyr Ala Asn 1 5 10 <210> 92 <211> 7 <212> PRT <213> Artificial sequence <220> <223> Anti-CD3 LCDR2 Kabat <400> 92 Gly Thr Asn Lys Arg Ala Pro 1 5 <210> 93 <211> 9 <212> PRT <213> Artificial sequence <220> <223> Anti-CD3 LCDR3 Kabat <400> 93 Ala Leu Trp Tyr Ser Asn Leu Trp Val 1 5
Claims
1. A method for evaluating the specificity of an antigen binding moiety, comprising the following steps: a) providing an antigen binding moiety specific for a target antigen, wherein the target antigen is a peptide that binds to a molecule of the human major histocompatibility complex (MHC), wherein the antigen binding moiety is a Fab fragment; b) Generation of chimeric antigen receptor (CAR)-expressing reporter T cells by: i. transferring the antigen binding moiety into a CAR vector system operably coupled to a response element; and ii. transfecting the CAR vector system into reporter T cells containing a reporter gene under the control of the response element; c) contacting the CAR-expressing reporter T cell with a target cell comprising the target antigen on its surface; and d) determining T cell activation by measuring expression of the reporter gene to establish the specificity of the antigen binding moiety.
2. The method of claim 1, wherein the target cell is a cancer cell.
3. The method of claim 1, wherein the Fab fragment is a Fab fragment derived from phage display library screening.
4. The method of claim 1, wherein the antigen binding moiety comprises a variable heavy chain domain (VH) and a variable light chain domain (VL) and wherein the polynucleotide sequences encoding the VH and VL domains of the antigen binding moiety are transferred to the CAR vector system.
5. The method of claim 1, wherein the CAR vector system encodes a CAR comprising a Fab or crossover Fab fragment, an anchoring transmembrane domain and at least one intracellular signaling and / or co-signaling domain.
6. The method of claim 5, wherein binding of the target antigen to the CAR-expressing reporter T cell results in activation of the intracellular signaling and / or co-signaling domain.
7. The method of claim 5, wherein activation of the intracellular signaling domain results in activation of the response element.
8. The method according to claim 1, wherein activation of the response element results in expression of the reporter gene.
9. The method according to claim 1, wherein the reporter gene encodes a photoprotein.
10. The method according to claim 9, wherein the luminescent protein is a fluorescent protein.
11. The method according to claim 1, wherein the target antigen is a cell surface receptor.
12. The method according to claim 1, wherein the antigen binding moiety is a T cell receptor-like (TCRL) antigen binding moiety.
13. The method according to claim 1, wherein the method is an in vitro method.
14. The method according to any one of claims 1 to 13, wherein a high level of expression of the reporter gene in the presence of the target cell and a low level of expression of the reporter gene in the absence of the target cell indicates a high specificity of the antigen binding moiety.
15. The method according to any one of claims 1 to 13, wherein a high level of expression of the reporter gene in the presence of the target cell and a low level of expression of the reporter gene in the absence of the target cell indicates high specificity of the T cell bispecific (TCB) antibody comprising the antigen binding moiety.
16. A method for generating a TCB antibody, wherein the TCB antibody form comprises a first antigen binding moiety specific for a target antigen and a second antigen binding moiety capable of specifically binding to a T cell activating receptor, wherein the first antigen binding moiety is selected according to the method of claim 14.
17. The method of claim 16, wherein the T cell activating receptor is CD3.
